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ABSTRACT 
 
Despite the scientific, technological and surgical improvements of the past 50 years organ 
dysfunction following elective paediatric cardiac surgery utilising cardiopulmonary bypass 
continues to account for increased complications, often leading to a protracted course in 
hospital with a longer stay in intensive care and the potential for irreversible organ damage 
long  term.  Furthermore,  paediatric  cardiac  surgeons  are  routinely  undertaking  more 
complex operations with a shift from palliation to early correction. This has resulted in 
younger children being subjected to longer periods on the bypass machine with increased 
effects on vital organs.  
 
This thesis describes two clinical studies designed to further assess and characterise peri-
operative cardiac, renal and pulmonary function in children undergoing elective cardiac 
repair  at  a  tertiary  referral  centre  in  Scotland,  UK.  In  the  first  instance  a  prospective, 
observational study was undertaken in forty-five children to examine the use of tissue 
Doppler imaging in the assessment of peri-operative cardiac function, its relationship to 
myocardial injury and clinical outcome. Tissue Doppler parameters were obtained using a 
Vivid 7 ultrasound scanner with a 7-MHz probe pre-operatively, on admission to paediatric 
intensive care and on day one. Myocardial injury was assessed using Troponin-I on the 
first post-operative day by a commercially available chemiluminescent immunoassay. 
 
In twenty children within this group peri-operative renal function was also investigated 
using  standard  estimates  of  glomerular  filtration  rate,  namely  creatinine  clearance 
measured  by  the  kinetic  Jaffe  method  during  the  first  and  second  twelve  hour  post-
operative periods, in comparison to serum creatinine and the novel biomarker cystatin C. 
Routine plasma retained pre-operatively and on days 0, 1, 2 and 3 post-operatively was 
used to measure serum cystatin C and creatinine using a particle-enhanced nephelometric End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 2 of 192 
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immunoassay and the Roche Creatinine Plus enzymatic assay respectively. The association 
between cystatin C and recorded perfusion parameters including bypass duration, pump 
flow, haematocrit, oxygen delivery and Troponin-I was investigated. 
 
Peri-operative pulmonary function was evaluated through a phase IV, randomised, double-
blind, placebo controlled trial. In total, twenty four children were randomised to receive 
oral  sildenafil  or  equivalent  volume  placebo  four  times  the  day  before  surgery.  Blood 
samples  were  collected  peri-operatively  to  measure  serum  cyclic  guanosine 
monophosphate  with  a  commercially  available  competitive  enzyme  immunoassay. 
Haemodynamic data and echocardiography were acquired at two and twenty four hours 
post-operatively  including  pulmonary  vascular  resistance  index  and  bi-ventricular 
contractility. Post-operative oxygenation was also determined at the same time by oxygen 
delivery and oxygenation index. 
 
In Chapter 2, peri-operative cardiac function as assessed by tissue Doppler imaging was 
examined.  The  results  of  this  study  demonstrated  that  pre-operatively,  bi-ventricular 
systolic  function  in  the  study  group  was  reduced  compared  with  normal  controls, 
displaying  a  significant  step-wise  decrease  with  increasing  complexity  of  lesion.  This 
picture persisted post-operatively predominantly in the right ventricle and was significantly 
associated with the extent of myocardial injury. Impaired peri-operative left ventricular 
function correlated with clinical outcomes. 
 
In Chapter 3, peri-operative renal function as assessed by cystatin C and its association 
with parameters of perfusion was examined. The results of this study demonstrated that in 
comparison  to  serum  creatinine,  cystatin  C  had  a  superior  correlation  with  glomerular 
filtration rate in the early post-operative period. An elevated level of this biomarker was End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 3 of 192 
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significantly  associated  with  bypass  duration,  minimum  pump  flow  and  post-operative 
myocardial injury. Haematocrit was not directly linked to renal dysfunction in this study 
although  evidence  of  a  critical  dysoxic  threshold  within  the  kidney  was  suggested 
indirectly through oxygen delivery calculations. 
 
In Chapter 4, peri-operative pulmonary function and vascular reactivity in association with 
the pre-operative administration of oral sildenafil (0.5mg/kg, six hourly) was examined. 
The results of this trial demonstrated that compared to placebo, pre-operative sildenafil 
resulted in modest elevations of serum cyclic guanosine monophosphate, limited effects on 
pulmonary vascular resistance index, significant reductions in peri-operative bi-ventricular 
contractility,  significant  reductions  in  post-operative  oxygen  delivery  and  a  trend  for 
increasing ventilatory support. 
 
In summary, the current thesis has demonstrated that in children undergoing corrective 
cardiac surgery peri-operative bi-ventricular function can be accurately assessed by tissue 
Doppler imaging which to date has had limited use in this patient group. With regards to 
renal function, cystatin C was shown to be a better estimate of glomerular filtration rate 
and  a  more  sensitive  marker  of  early  renal  dysfunction  in  children  after  surgery. 
Furthermore,  cystatin  C  identified  a  transient  post-operative  renal  impairment,  the 
magnitude of which was associated with duration of bypass, pump flow and myocardial 
injury.  In  relation  to  pulmonary  function,  this  research  identified  that  pre-operative 
administration of oral sildenafil to children undergoing cardiac surgery produced limited 
effects  on  pulmonary  vascular  resistance  but  was  associated with  reduced  ventricular 
contractility and post-operative oxygenation raising significant concerns over its routine 
clinical use.  
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• FiO2  :  inspired oxygen concentration 
• DO2  :  oxygen delivery 
• PVRI  :  pulmonary vascular resistance index 
• WU.m
2  :  woods units per metre squared body surface area 
• PHT  :  pulmonary hypertension 
• PED  :  pulmonary endothelial dysfunction 
• PVR  :  pulmonary vascular resistance 
• NO  :   nitric oxide 
• PDE5  :   phosphodiesterase-5 
• iNO  :  inhaled nitric oxide 
• MHRA  :  medicines and healthcare products regulation agency 
• MAP  :  mean arterial pressure 
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• PA  :   pulmonary artery 
• BSA  :   body surface area 
• OI   :  oxygenation index 
• PDE6  :  phosphodiesterase-6 
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CHAPTER 1: INTRODUCTION 
 
“A physician at the bedside of a child dying of an intracardiac malformation as recently as 
1952 could only pray for a recovery! Today with the heart-lung machine, correction is 
routine.  To  bypass  the  heart,  one  needs  a  basic  understanding
  of  physiology  of  the 
circulation, a method of preventing the
 blood from clotting, a mechanism to pump blood, 
and finally,
 a method to ventilate the blood.” 
Lillehei (1993) 
 
1.1  The history of cardiopulmonary bypass 
Cardiopulmonary bypass (CPB) is the process by which a patient is sustained by diverting 
the circulation through synthetic devices designed to replace the heart and lungs. Over the 
past 50 years it has evolved from an extremely hazardous procedure into a safe, systematic 
process  that  is  practiced  daily  in  thousands  of  centres  worldwide.  The  developmental 
advances in CPB can be broadly divided chronologically into: (1) a conceptual period, pre-
1950 (2) a technological period, 1950-1970 and (3) a refinement period, 1970 to present. 
 
1.1.1  Conceptual period (Pre- 1950) 
The  goal  of  CPB  has  always  been  to  deliver  nutritive  solutions  to  the  body,  namely 
oxygen, with sufficient drive as to maintain physiological homeostasis. As early as 1812 
Julien-Jean Cesar le Gallois demonstrated that blood flow through a circuit located outside 
the body (extracorporeal circulation) was feasible and put forward the original idea for 
resuscitating decapitated heads through the use of blood transfusions. 
1 Brown-Sequard in 
1858 arterialised desaturated blood by whipping it and then perfused the head of a dog 
with  moderate  success. 
2  In  1869  Ludwig  and  Schmidt  produced  the  first  report  on 
artificial oxygenation when they enriched blood with oxygen by shaking it with gas in a 
balloon. 
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flow during extracorporeal circulation.  The earliest uses of ‘bubble’ and ‘film’ oxygenator 
devices  that  combined  blood  with  oxygen  were  respectively  reported  in  1882  by  von 
Schroeder and by von Frey and Gruber in 1885. 
4, 5 In 1915, Hooker reported a type of film 
oxygenator  that  utilised  a  rotating  disc  assembly  within  an  inverted  bell  jar.  Hooker’s 
device became the forerunner for the disc oxygenator later developed to be used in many 
of the early perfusions in humans in the 1950s. 
6 
 
Other  key  medical  developments  occurring  alongside  advances  in  blood-gas  exchange 
systems that strongly influenced progress towards extracorporeal flow came in 1916 when 
Jay McLean, a medical student working in the laboratory of W. H. Howell at the Johns 
Hopkins University at Baltimore, discovered ‘heparin’ and its anticoagulating properties. 
7 
Some 20yrs later Chargaff and Olson discovered ‘protamine’ and its antagonistic actions to 
heparin while exploring a means of extending heparin’s anticoagulating effects. 
8 
 
In an attempt to mimic the normal circulation, Dale and Schuster in 1928 created a valved 
pumping device that delivered a pulsatile wave. This prototype became the predominant 
device used for extracorporeal perfusions. 
9 In 1934, DeBakey modified the twin roller 
pump previously described for blood transfusions to create a roller pump that worked on 
the principle of occluding collapsible tubing along a rigid metal plate. This pump became 
the  standard  by  which  all  positive  displacement  pumps  used  today  for  extracorporeal 
circulation have been modelled. 
10 
 
The culmination of these developments came in 1937 when Dr John H Gibbon, Jr. reported 
the first successful total CPB of an animal (cat) with the use of heparin, a Dale-Schuster-
type pump and vertical rotating cylinder oxygenator. 
11 
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1.1.2  Technological period (1950 – 1970) 
Despite Gibbon’s success the ability of blood-gas exchange devices to replace the entire 
human circulation was not achieved for some 15 years. On April 5 1951, Dennis and 
colleagues  performed  the  first  total  CPB  in  a  6-year-old  patient  with  an  atrial  septal 
defect.
12  Although  their  heart-lung  machine  functioned  well,  the  patient  could  not  be 
separated from CPB and died on the table. After World War II Gibbon and his wife Mary, 
whom many considered to be the first cardiac perfusionist, continued to refine their work 
on CPB and on May 6 1953 at the Thomas Jefferson Hospital in Philadelphia successfully 
closed an atrial septal defect in an 18 year old college girl. The time on the heart-lung 
machine was 26 minutes. 
13 Unfortunately, Gibbon was unable to repeat this success and 
with the death of his next 4 patients gave up his pursuit of open heart surgery with the 
heart-lung  machine.  Other  surgeons  however  utilised  techniques  that  Gibbon  had 
developed to successfully treat children with congenital heart disease. It is for this reason 
that Gibbon is considered by most as the ‘father of cardiopulmonary bypass’.
 13, 14 
 
Kirklin  et  al.  at  the  Mayo  Clinic  in  Rochester  Minnesota  further  developed  Gibbon’s 
oxygenator  into  the  Mayo-Gibbon  pump-oxygenator  apparatus  which  became 
commercially available and led to a pioneering series of successful human intra-cardiac 
operations in March 1955. 
15, 16 Around the same time, Kay and Cross and their colleagues 
in 1956 modified the previously described Bjork oxygenator for clinical use. 
17, 18 Despite 
satisfactory  results  from  both  devices  worldwide,  by  the  mid  to  late  1950s  numerous 
problems associated with the film-type blood-gas exchange systems were being reported. 
Their  complex,  bulky,  non-disposable  nature,  the  large  quantity  of  blood  and  saline 
required  to  prime  the  machine  and  their  inefficient  gas  exchange  led  to  their  eventual 
removal from clinical practice. 
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In 1950, Clark and colleagues expanded on von Schroeder’s concept and demonstrated that 
oxygen bubbled through a sintered-glass placed directly into a column of venous blood, 
created foam whereby gas exchange occurred. 
21 In 1956 Dewall and Lillehei devised a 
bubble oxygenator that was simple and made from readily available hospital equipment. 
22 
In the same year Rygg and Kyvsgaard devised an oxygenator that combined the same three 
basic components (bubbling chamber, settling chamber and arterial reservoir) into a single 
disposable polyethylene bag. 
23 Bubble-type blood-gas exchange systems were inherently 
simpler,  highly  efficient,  disposable,  required  smaller  (potentially  blood  free)  priming 
volumes and were easier to assemble. 
19 As a result, within a short time of being introduced 
bubble oxygenators were commercially available and became a major driving force behind 
the expansion of CPB and open-heart surgery. Despite their success, concerns emerged 
regarding the increasing rates of blood haemolysis, coagulation disorders, activation of 
white blood cells, acidosis and progressive organ failure seen when CPB lasted more than 
four hours. 
19 This was thought to be due to the direct contact of blood with air surfaces 
and  the  plastic  and  metal  components  of  the  pump  oxygenator  circuit. 
19,  24  These 
disadvantages were initially accepted and counteracted by the relatively short duration of 
open-heart surgery and through the use of profound hypothermia. By cooling the body, 
with the aid of a heat-exchanger, to a core temperature of 10-12
oC CPB could be turned off 
for up to one hour while prolonged intra-cardiac surgery was performed. 
25, 26 
 
Meanwhile, attention turned to the idea of a protective membrane existing between the 
blood and air to reduce trauma inherent with direct-contact oxygenators (bubble and film). 
Kolff and Berk in 1944, whilst developing an artificial kidney, observed that blood passing 
through the cellophane membrane of their haemodialysis machine became oxygenated by 
the aerated dialysates through the process of passive diffusion. 
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was incapable of exchanging gas other than at very low flows, Kloff and Berks’ finding 
sparked  the  search  for  a  suitable  inert  material  that  could  best  mimic  the  endogenous 
alveolar capillary membrane. 
27 In 1957, Clowes and colleagues were the first to report the 
clinical use of a ‘membrane’ oxygenator. The surface area of the teflon membrane they 
used  however  was  excessive  (25m
2)  and  led  to  blood  protein  denaturation  and 
coagulopathies. 
28  In  1963,  Kolobow  and  Bowman  designed  a  silicone  membrane 
oxygenator whose biocompatibility was especially attractive for long-term CPB. The first 
practical membrane oxygenators appeared in the mid to late 1960s as the Bramson lung 
and  Lande-Edwards  oxygenators. 
29,  30  Despite  their  theoretical  advantage  membrane 
oxygenators were not widely utilised during the 1960s and 70s mainly due to their higher 
production costs and the lack of clinical evidence that proved their superiority to direct-
contact oxygenators. They remained less efficient, cumbersome and more prone to plasma 
leakages and thrombotic occlusions than their direct-contact counterparts. 
19 
 
1.1.3  Refinement period (1970 – present) 
1.1.3.1  Oxygenators 
Research  in  the  design  of  membrane  oxygenators  continued  and  refinements  to  the 
geometrical arrangement of the gas exchange compartment occurred. The importance of 
reducing  blood  film  thickness  and  disrupting  laminar  flow  characteristics  within  the 
oxygenator to optimise gas exchange became apparent. 
19 Various design modifications 
including screens, spacers and sheets were utilised to promote ‘secondary flow’ which 
improved gas exchange and resulted in a 10-fold reduction in the membrane surface area 
required  for  clinical  perfusion. 
19,  31  With  the  use  of  secondary  flows  in  membrane 
oxygenators, the membrane itself, once again became the limiting factor to gas exchange. 
Modern  membrane  gas  exchangers  are  almost  exclusively  constructed  of  microporous 
polypropylene arranged as a bundle of hollow fibre capillaries. 
32-34 Bodell and colleagues End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 19 of 192 
 
Tony Vassalos   2010 
first put the conceptual use of tubular capillary fibres for gas exchange forward in 1963. 
35 
The  concomitant  use  of  secondary  flow  and  hollow-fibre  technologies  resulted  in  the 
highly efficient gas exchange devices used clinically during the early 1980s. 
19, 32-34 By the 
late 1980s a variant of the above design termed inverse-flow or ‘blood outside’ design 
where blood flowed in the external chamber originally designed for gas, while gas flowed 
within the hollow fibres predominated. This new configuration resulted in a much larger 
gas  exchange  area,  lower  shear  forces  of  blood  and  an  overall  improvement  in  gas 
exchange performance such that membrane areas were 2 to 2.5 times smaller than the 
conventional design. 
32-34 These combined advantages of high gas exchange efficiency, low 
blood trauma, compactness, simplicity and low cost meant that microporous membrane 
devices began to replace efficient bubble oxygenators in the cardiac operating theatres in 
the 1980s. 
32-34 Today such devices have surface areas of 2 to 3m
2 and are used exclusively 
in 95% of centres; transferring up to 400ml of oxygen while removing more than 300mls 
of carbon dioxide in a single pass. 
32-34, 36 
 
The  success  of  hollow  fibre  oxygenators  has  led  to  the  innovative  concept  of 
‘intracorporeal oxygenation’ termed the intravascular oxygenator or IVOX. 
37 In IVOX a 
bundle of silicone coated hollow fibres is inserted into the inferior vena cava of a patient 
and oxygen is pumped through. 
37, 38 Secondary flow occurs as blood migrates through the 
fibres  on  its  way  back  to  the  heart.  Further  enhancements  where  a  balloon  pump  is 
incorporated within these fibres to optimise secondary flow has been suggested and termed 
‘intravascular membrane oxygenator’ or IMO. 
37-38 At present IVOX / IMO devices can 
only offer partial respiratory support and have failed to gain widespread acceptance due to 
a lack of clinical benefit. 
37-39 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 20 of 192 
 
Tony Vassalos   2010 
 
1.1.3.2  Reservoirs 
Venous blood reservoirs form an essential component of the paediatric bypass circuit in 
providing a safety chamber to sequester excess blood during CPB. Two types of reservoirs 
have  traditionally  been  used  relating  to  open  (hard  shell)  and  closed  (collapsible  bag) 
systems. 
32, 34, 36, 40 Open systems which vent air to the atmosphere usually incorporate a 
cardiotomy  reservoir,  defoaming  compartment  and  are  made  of  rigid  plastic.  Although 
offering  a  low  inlet  resistance  and  passive  removal  of  venous  air  the  direct  blood-air 
interface results in a greater inflammatory response as well as the possibility of air being 
pumped  into  the  patient  if  the  reservoir  becomes  completely  empty. 
41  The  soft-shell, 
collapsible, closed system on the other hand requires a separate cardiotomy reservoir and 
active removal of any air entrained into the venous system during CPB. 
36,  40 However, 
despite the inherent safety of the closed system the ease of use of the open system together 
with the option of vacuum assisted venous drainage has prevailed in 88% of centres in 
North America. 
32 
 
1.1.3.3  Pumps 
Since  the  advent  of  CPB  by  Gibbon  in  the  1950s  simplistic,  low  cost,  positive 
displacement roller pumps have predominantly performed the role of the artificial heart. In 
the 1970s however a team of engineers collaborated in the design of a new blood pump 
that  relied  on  centrifugal  forces. 
32,  42  In  the  absence  of  any  occlusive  mechanism 
centrifugal pumps offered a theoretical reduction in the blood trauma normally seen with 
roller pumps. Despite this theoretical advantage centrifugal pumps have not yet gained 
favour  in  the  majority  of  paediatric  cardiac  centres  in  Europe  and  Asia  and  usage  is 
somewhat  confined  to  the  United  States  where  they  are  used  exclusively  in  2-14%  of 
centres. 
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1.1.3.4  CPB circuit modification 
The process of CPB necessitates the exposure of blood to the artificial surfaces of the 
tubing, oxygenator, reservoirs and filters in addition to other non-physiological conditions 
which  are  all  implicated  in  blood  activation  ultimately  expressed  as  a  systemic 
inflammatory response. 
32, 36, 40, 43 In relation to body surface area, compared to adults, the 
surface area of the CPB circuit used in infants is substantially higher and is directly related 
to the magnitude of inflammatory response. 
44 As a result numerous attempts have been 
made to improve the biocompatibility of the circuit through the application of biologically 
active or inert substances onto the surfaces and reduction in circuit size. Heparin-bonded 
CPB circuits have been available for clinical use since the late 1980s and extensive studies 
have demonstrated consistent reductions in plasma levels of complement fragment C3a, 
TNF-α, IL-6, IL-8, E- and P-selectins leading to improved clinical outcomes. 
45-47 Despite 
this it has taken some 20 years for the use of modified circuits to become routine and they 
currently represent 74% of circuits used in paediatric centres across North America. 
32 
 
1.2  The management of perfusion during cardiopulmonary bypass 
Despite the technological advances of the past 50 years there is still no generally accepted 
definition of optimal perfusion during CPB. This is even more difficult when one considers 
variations in the period of survival monitored and the extent to which organ dysfunction is 
investigated. As a result there is considerable variation in how CPB is conducted between 
centres to optimise the fundamental balance between oxygen supply and demand, limit 
activation of inflammatory cascades, maintain vital organ function and ensure a safe, rapid 
and long-lasting recovery. 
32-34, 36, 40 Furthermore, important anatomical and physiological 
differences exist between infants and adults which have to be considered in the setting of 
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1.2.1  Paediatric anatomical and physiological considerations 
In contrast to adults, infants have a high body surface area to weight ratio which when 
combined with their immature thermal auto-regulation makes them particularly vulnerable 
to rapid fluctuations in body temperature. 
36 Temperature regulation and the speed with 
which it occurs is an important consideration of perfusion and has been linked to post-
operative organ dysfunction. 
48-52  
 
Compared to adults the immature heart has a smaller percentage of contractile proteins, a 
lower oxidative capacity, decreased sympathetic innervation, altered calcium handling and 
decreased compliance. 
36,  53 As a result children have a relatively fixed stroke volume 
making  their  heart  rate  and  rhythm  the  main  determinants  of  cardiac  output. 
53 
Additionally, the myocardium of the newborn has an increased glucose dependence when 
compared  with  the  adult  with  episodes  of  hypoglycaemia  potentiating  heart  failure. 
54 
Native differences are further complicated in the context of congenital heart disease (CHD) 
where  a  broad  spectrum  of  cyanotic  and  acyanotic  lesions  exists,  each  with  specific 
pathophysiological  changes  that  can  result  in  hypoxia,  heart  failure,  altered  pulmonary 
blood flow and low cardiac output. 
33, 36 
 
Children  with  CHD  in  contrast  to  adults  often  have  pre-existing  abnormalities  in 
respiratory  mechanics  prior  to  surgery.  Lesion  specific  alterations  to  pulmonary  blood 
flow, pulmonary hypertension and volume / pressure loading of the heart are associated 
with  decreased  lung  compliance,  atelectasis,  pulmonary  oedema,  increased  airway 
resistance and pulmonary endothelial dysfunction related increases in pulmonary vascular 
resistance manifest as episodes of pulmonary hypertension post-operatively. 
55-57 Exposure 
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with  an  acute  lung  injury,  the  severity  of  which  is  directly  related  to  the  duration  on 
bypass. 
55-58 
 
Renal  function  in  neonates  and  infants  is  associated  with  differences  in  electrolyte 
transport, decreased medullary concentrating ability, impaired tubular function, impaired 
excretion  of  free  water  and  a  lower  glomerular  filtration  rate  than  adults  even  when 
corrected for body surface area. 
59-61 Despite these differences, however, most children 
undergo CPB without developing post-operative renal failure.  That being said children 
exposed to a period of CPB have a much greater fluid retention post-operatively compared 
to adults which if not adequately diuresed can result in prolonged ventilatory support. 
36 
The investigation of renal function in children is complicated by the superimposition of 
renal  dysfunction  on  a  background  on  continuing  renal  development.  Moreover,  the 
changing muscle mass of the infant influences circulating creatinine levels with resultant 
inaccuracies in the measurement of creatinine clearance. 
62, 63 
 
Many factors are known to affect cerebral blood flow during CPB including temperature, 
cerebral metabolic rate, arterial carbon dioxide partial pressure, pump flow and perfusion 
pressure. 
64 Retrospective studies have identified decreasing age as an incremental risk 
factor  in  the  development  of  post-operative  neuropsychological  dysfunction. 
51,  65  In 
particular it has been shown that during periods of deep hypothermia, sometimes used 
during repair of CHD, cerebral autoregulation and cerebral flow / metabolism coupling are 
lost with cerebral blood flow becoming dependent on perfusion pressure. 
36, 51, 64  
 
The coagulation system in newborns is deficient with reduced levels of factors XII, XI, 
vitamin K-dependent factors and coagulation inhibitors (antithrombin III, protein C and 
protein S) commonly seen. 
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heart disease who are known to have platelet dysfunction in addition to decreased levels of 
factors II, V, VII, VIII, and IX. 
67 
 
1.2.2  Physiological cardiopulmonary bypass variables 
Modalities used during CPB in adults to a moderate degree are often used in children to a 
much  greater  extent  resulting  in  an  increased  physiological  insult  which  is  often 
remarkably well tolerated. Marked temperature changes (deep hypothermia with or without 
circulatory arrest), profound haemodilution (2-3 times blood volume), large foreign surface 
area exposure, low perfusion pressures, wide variations in pump flow rates, wide-ranging 
pH  management  and  altered  glucose  regulation  are  commonplace  during  paediatric 
perfusion. 
36, 40 
 
1.2.2.1  Perfusion pressure and flow 
The fundamental aim of CPB is to maintain tissue perfusion of all vital organs whilst 
cardiac and pulmonary function is suspended. The optimal mean arterial pressure during 
CPB  that  would  guarantee  satisfactory  tissue  perfusion  is  not  currently  known.  As  a 
consequence  the  lower  limit  used  varies  widely  in  the  adult  population  from  50  to 
80mmHg and is essentially based on data relating to cerebral autoregulation. 
68 In children 
lower perfusion pressures are normally seen ranging from 20 to 50mmHg in association 
with a greater degree of hypothermia. 
36 It is generally accepted that at normothermia in 
children a pump flow rate of 100ml/kg/min or 2.2-2.5L/min/m
2 together with a mixed 
venous  saturation  >75%  and  arterial  oxygen  saturation  >30mmHg  are  suggestive  of 
adequate perfusion. 
40 However, as with mean arterial pressure the minimal safe flow rate 
during CPB has not yet been established. 
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1.2.2.2  Hypothermia 
A degree of hypothermia is used during CPB in virtually all cases of corrective paediatric 
heart surgery to provide organ protection, particularly the brain, by reducing metabolic rate 
and oxygen requirements during periods of altered flow. 
34, 40, 69 Cerebral metabolic rate 
drops  exponentially  as  temperature  is  reduced  with  minimal  adverse  effects  on 
psychomotor testing seen with circulatory arrest times of up to 41 minutes at 18
oC. 
52, 70 
Typically the degree of hypothermia used varies directly with the complexity of the repair 
and  ranges  from  mild  (32  -35
oC),  through  moderate  (25-32
oC)  to  deep  (15-20
oC) 
hypothermia with or without circulatory arrest. However in recent years, with improving 
surgical  and  perfusion  techniques,  the  use  of  deep  hypothermia  with  circulatory  arrest 
during corrective paediatric heart surgery has become more selective with some groups 
favouring low-flow CPB. 
33, 52, 70 
 
1.2.2.3  pH management 
Arterial blood gas management may be more important in children due to the higher levels 
of hypothermia used during cardiac surgical repair. Cooling increases CO2 solubility and 
results in a lower arterial CO2 partial pressure and associated mild alkalosis (0.015pH 
units/
oC). 
71 Cerebral blood flow is directly affected by arterial CO2 partial pressure and 
becomes  pressure-dependent  at  high  levels  through  a  loss  of  autoregulation. 
40  This  is 
thought to be an age-dependent process with children <1yr of age demonstrating a blunted 
response to elevated CO2 levels. 
36, 72 During periods of hypothermia acid-base balance is 
currently managed by 2 main strategies. The majority of centres use ‘alpha-stat strategy’ 
whereby CO2 is not added to the circuit and pH is therefore not corrected to temperature. 
33 
Others  in  contrast  use  the  ‘pH-stat  strategy’  in  which  CO2  is  added  to  the  system  to 
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recent reviews have been unable to show any clear benefit on clinical outcomes with either 
strategy leading to the use of a combined technique in some centres. 
33, 36, 72-74  
 
1.2.2.4  Haemodilution 
The concept of haemodilution was popularised in the 1950s in the belief that it would 
reduce blood and blood product usage in addition to optimising micro-circulation through 
reduced blood viscosity. 
34,  75,  76 Compared to adults the relative priming volume of the 
bypass circuit in children is significantly greater than their blood volume and often results 
in a 3 fold haemodilution. 
36, 75, 77 The priming fluid used in children can therefore directly 
impact  on  fluid  and  electrolyte  balance  with  glucose  containing  solutions  generally 
avoided. 
40 Furthermore, paediatric patients have an impaired ability to excrete the excess 
fluid  load  which  tends  to  accumulate  extravascularly  in  the  tissues. 
40,  59-61,  75  In  time 
several  issues  emerged  related  to  haemodilution  namely  reduced  perfusion  pressure, 
increased  cerebral  blood  flow,  renal  dysfunction  and  decreased  oxygen  delivery  all  of 
which  contributed  to  the  increased  morbidity  and  mortality  seen  with  decreasing 
haematocrit and stimulated the debate as to the optimal pre-CPB haematocrit level. 
34, 75-77 
A  large  contribution  to  this  area  in  infants  was  provided  by  the  Boston  group  who 
investigated the effects of haematocrit in children undergoing cardiac surgery on post-
operative psychomotor development through a succession of randomised clinical trials and 
advocated a haematocrit level of at least 25% before, during and after CPB. 
75, 76 
 
1.2.2.5  Myocardial protection 
The cornerstone of myocardial protection in paediatric CPB is hypothermia particularly in 
children  with  cyanotic  CHD  and  increased  non-coronary  collateral  flow  to  the  heart 
resulting in cardioplegia washout and rewarming of the myocardium. 
36 Hypothermia also 
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circulation  in  such  patients.  The  optimum  electrolyte  composition  of  cardioplegia  for 
paediatric patients is not currently known but potassium, calcium, magnesium, sodium and 
buffers are thought to preserve myocardial function. 
36 Although variations in electrolyte 
composition exist, blood cardioplegia is currently used by the majority of cardiac centres 
with a mean temperature of 8
oC and a haematocrit of 15%. 
33 
 
1.2.3  The inflammatory response to cardiopulmonary bypass 
The  process  of  CPB  is  a  non-physiological  form  of  circulation  that  elicits  a  profound 
inflammatory response within the body through the activation of plasma protein systems 
(coagulation,  contact,  fibrinolytic,  complement)  involved  in  cellular  immunity  and 
protection. 
78-81 This reaction is further enhanced by the activation of blood cells during 
CPB  including  platelets,  neutrophils,  monocytes,  endothelial  cells  and  lymphocytes 
culminating in the release of powerful vasoactive substances. 
79-81 Clinically this systemic 
inflammatory response syndrome (SIRS) manifests within the first 24 hrs post-operatively 
as  tissue  oedema,  thromboembolism,  coagulopathy  and  temporary  organ  dysfunction 
particularly in the heart, lungs, brain and kidneys. 
79, 80 The severity of SIRS ranges from 
being almost undetectable (mild pyrexia, leucocytosis, tachycardia) to the development of 
multiple organ dysfunction syndrome (MODS) requiring intensive supportive therapy. 
80, 82 
Furthermore, these sequelae of CPB can occur in the face of an apparently effective and 
complete cardiac repair with satisfactory haemodynamic performance. 
81 Children through 
their  immature  organ  systems,  higher  metabolic  demands,  greater  haemodilution  and 
comparatively larger CPB circuits appear to be more susceptible and therefore at risk of 
injury. 
83 
 
Several  non-biological  variables  are  known  to  affect  the  magnitude  of  this  response 
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contact with blood. 
79 Mediators released during CPB include pro-inflammatory cytokines 
TNF-α, interleukins (IL-1, IL-2, IL-4, IL-6, IL-8 and IL-10), complement (C3a, C5a, C5b-
9) and endotoxin whose mechanisms of action are thought to involve neutrophil activation 
and nitric oxide induction. 
78-84 The management of the SIRS response to CPB is a difficult 
problem,  due  to  the  complex  interplay  of  inflammatory  cascades,  but  includes 
haemofiltration,  adenosine,  steroids,  aprotinin,  leukocyte  depletion  and  heparin-bonded 
circuits. 
78-84 As a result it is unlikely that a single therapy will successfully inhibit the 
inflammatory response to CPB and current efforts are mainly centred on symptomatically 
treating the multi-organ system dysfunction produced.  
 
1.2.3.1  Ultrafiltration 
Haemodilution, immature renal function and endothelial dysfunction relating to CPB are 
all implicated in the accumulation of extravascular fluid and associated end-organ injury 
commonly seen in children following cardiac surgery. Ultrafiltration of venous blood to 
reduce fluid overload, increase haematocrit and remove inflammatory mediators was first 
introduced as a concept in 1976 by Romanoli et al. 
85 Since then the technique has been 
developed to be used before CPB during priming, intermittently and continuously during 
CPB and modified ultrafiltration post CPB to remove patient fluid and haemoconcentrate. 
86  Multiple  studies  have  demonstrated  the  effectiveness  of  modified  ultrafiltration  in 
increasing  haematocrit,  improving  haemodynamics,  reducing  tissue  oedema,  removing 
inflammatory markers and optimising end organ function following paediatric CPB. 
32, 36, 
40,  87,  88 It is therefore not surprising that currently 98% of centres are routinely using 
ultrafiltration as a whole with 75% utilising the modified approach. 
32  
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1.3  Safety 
If one examines heart-lung bypass machines at their advent in the early 1950s and compare 
their safety features to those of modern day devices it is evident that there have been 
limited  advances  in  safety  and  overall  automation  of  the  process  of  extracorporeal 
circulation. Original designs were complex (often custom built) containing several safety 
features such as oxygenator blood level sensors, level floats and pressure sensors with 
elaborate  feedback  mechanisms. 
89  As  the  process  of  extracorporeal  circulation  moved 
from the lab to clinical practice an increasing need emerged for simpler, cheaper machines 
as seen during the 1970s and early 80s when many CPB circuits were only composed of an 
oxygenator / heat exchanger, roller pump and tubing. 
89 
 
However,  as  the  risk  of  air  and  particulate  embolism  became  more  apparent  added 
attention was given to monitoring anti-coagulation and safety devices such as blood level 
sensors, bubble detectors and filters were added. In time newer designs have incorporated 
feedback loops, from these safety devices, that automatically shut off roller pumps if any 
air is detected within the circuit. 
89 This is of particular importance in children with CHD 
where intra-cardiac surgery and intra- and extra-cardiac shunts are a common occurrence. 
36 Arterial line filters (20-40µm) in addition to significantly reducing both gaseous and 
particulate emboli have been shown to improve post-operative neurological function in 
adults and should be a feature of all circuits. 
32, 34, 36, 40, 90  
 
Further developments with in-line sensing systems enable perfusionists to continuously 
measure  arterial  and  venous  pH,  PO2,  PCO2,  mixed  venous  saturation,  haemoglobin  / 
haematocrit  and  temperature. 
34,  36  With  the  evolution  of  computers  within  the  theatre 
environment data acquisition, storage and analysis became readily available. However, the 
ultimate jump to a fully automated system has to date not been met with much success. In End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 30 of 192 
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recent years, pump control systems that utilise microcomputers and proportional-integral 
control algorithms to maintain constant intravascular volumes have been developed for 
CPB and applied on 15 children undergoing cardiac surgery. 
91 
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1.5  Aims of the thesis 
The objective of this research was to utilise novel investigations and treatment strategies to 
assess  and  further  characterise  peri-operative  cardiac,  renal  and  pulmonary  function  in 
children  undergoing,  present-day  standard,  elective  cardiac  surgery  utilising 
cardiopulmonary bypass in the hope that this would ultimately increase clinical knowledge 
and improve outcomes. In this regard two clinical studies were undertaken: 
 
1)  A prospective observational study to assess cardiac and renal function by exploring: 
-  characteristic  changes  in  peri-operative  tissue  Doppler  imaging  parameters,  their 
relationship to myocardial injury and clinical outcome 
-  the use of cystatin C as a means of quantifying renal performance early after cardiac 
surgery and its association with perfusion parameters and peri-operative myocardial 
injury 
 
2)  A randomised, double-bind, placebo-controlled trial that: 
-  investigated the use of pre-operative oral sildenafil on haemodynamics, contractility, 
oxygenation and serum cyclic guanosine monophosphate levels in children at risk of 
acute post-operative pulmonary hypertension.  
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CHAPTER 2: CARDIAC FUNCTION 
 
2.1  Abstract 
 
2.1.1  Background 
The purpose of this study was to utilise tissue Doppler imaging (TDI) to assess changes in 
ventricular function following repair of congenital heart defects. The relationship between 
TDI indices, myocardial injury and clinical outcome was explored. 
 
2.1.2  Methods 
Forty-five children were studied; thirty-five undergoing elective repair (AVSD n=11, VSD 
n=16,  ASD  n=8)  and  ten  normal  controls.  TDI  was  performed  pre-operatively,  on 
admission to PICU and day 1. Regional myocardial Doppler signals were acquired from 
the RV free-wall (RV), LV free-wall (LV) and basal septum (S). TDI indices were derived 
by off-line analysis including: (1) Peak systolic velocities [cm/sec]: SaRV, SaLV, SaS  (2) 
Isovolumic  velocities  [cm/sec]:  IVVLV,  IVVRV,  IVVS  and  (3)  Isovolumic  acceleration 
[cm/sec
2]:  IVALV, IVARV, IVAS. Troponin-I was measured in study patients at 15 hours 
(day-1) post-operatively. 
 
2.1.3  Results  
Pre-operatively,  bi-ventricular  systolic  TDI  velocities  in  the  study  group  were  reduced 
compared  with  normal  controls  and  displayed  a  significant  step-wise  decrease  with 
increasing complexity of lesion. Post-operatively, RV velocities were significantly reduced 
and this persisted to day-1 (SaRV PreOp vs. PICU and day-1: 7.7±2.2 vs. 3.4±1.0, p<0.0001 
and  3.55±1.29,  p<0.0001).  By  contrast  LV  velocities  initially  declined  but  recovered 
towards baseline by day-1 (SaLV PreOp vs. PICU and day-1: 5.31±1.50 vs. 3.51±1.23, 
p<0.0001 and 4.70±1.37, p=0.36). Isovolumic parameters in all regions were persistently End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 42 of 192 
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reduced throughout the post-operative period. Increased Troponin-I release correlated with 
longer x-clamp times (r=0.82, p<0.0001), bypass duration (r=0.83, p<0.0001) and reduced 
RV velocities (r=0.42, p=0.028).  Reduced pre- and post-operative LV velocities were 
associated with longer ventilation (PreOp: r=0.54, p=0.002; PostOp: r=0.42, p=0.026) and 
PICU times (PreOp: r=0.53, p=0.002; PostOp: r=0.48, p=0.01).  
 
2.1.4  Conclusion 
This study identified a relationship between the extent of peri-operative myocardial injury 
and the degree of post-operative RV contractile impairment as measured by tissue Doppler 
imaging. LV TDI velocities correlated with post-operative outcomes. TDI provided an 
assessment  of  bi-ventricular  function  that  could  allow  optimised  timing  of  surgical 
correction and post-operative therapies. 
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2.2  Introduction 
Advances in surgical technique and ITU management have contributed to the improved 
survival  of  children  undergoing  repair  of  congenital  heart  disease.  Despite  this,  peri-
operative myocardial injury and ventricular dysfunction continue to be major contributors 
to morbidity and mortality.
 1 
 
Tissue Doppler imaging (TDI), an echocardiography based technique, measures Doppler 
shift frequencies produced by the contraction and relaxation of longitudinal muscle fibres 
that run from the plane of the atrio-ventricular annuli to the heart apex. 
2 The resulting 
Doppler  spectrum  and  measured  myocardial  velocities  have  allowed  quantification  of 
systolic and diastolic function in many clinical and experimental studies. 
3, 4 More recently 
myocardial acceleration and peak velocity measured during the period of isovolumetric 
contraction have been proposed and validated as systolic contractile indices independent of 
changing loading conditions. 
5, 6, 7 
 
In children undergoing congenital heart surgery TDI may offer many potential advantages 
over  conventional  echocardiography  and  other  ventricular  imaging  modalities.  Of 
particular interest is the ability to quantify right ventricular (RV) function independent of 
its complex, non-geometric shape. 
8 Published data on normal TDI parameter values in 
children  with  normal  anatomical  hearts  is  available. 
9  To  date  however,  there  is  little 
information on the pattern of change in TDI parameters that follows cardiac surgery in 
children. 
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The objective of this study was to investigate the variations in systolic TDI parameters of 
myocardial velocity and acceleration that occur before and after congenital heart surgery 
and explore the association between TDI change, myocardial injury and clinical outcome.  
 
2.3   Methods 
Both local and regional research ethical committees approved the study. Informed consent 
was obtained prior to study enrolment. In total, thirty-five subjects with a range of atrial 
and ventricular defects undergoing surgical repair and ten control subjects with structurally 
normal  hearts  were  studied.  Neonates  and  patients  with  cyanotic  heart  disease  were 
excluded.  All  patients  underwent  elective  surgery  using  standard  techniques  of 
cardiopulmonary  bypass  with  blood  cardioplegia.  The  study  group  comprised  eight 
patients with ASD (5 primum, 3 secundum), sixteen patients with VSD and eleven patients 
with complete AVSD (Table 1).  This population thus provided a study cohort with a range 
of  ages,  complexity  of  condition  and  varying  duration  of  cardiopulmonary  bypass  and 
cross-clamp times. 
 
Tissue Doppler imaging was performed using a Vivid 7 ultrasound scanner (GE Vingmed, 
Horten,  Norway)  with  a  7-MHz  probe  by  the  same,  experienced  paediatric 
echocardiographer (SL). Measurements were obtained at the following time points: (1) 
Pre-operatively,  in  operating  room  under  general  anaesthesia  (PreOp);  (2)  1hr  post-
operatively  following  return  to  paediatric  ICU  (PICU);  and  (3)  15hrs  post-operatively 
(Day-1).  The  heart  was  imaged  from  a  transthoracic  4-chamber  view.  Colour-coded 
myocardial velocities were recorded from the basal septum and the lateral free walls of 
both ventricles immediately below (0.5cm) the insertion of the mural leaflet of the left and 
right AV valves as previously described. 
10 Filters and gains were adjusted to allow a clear 
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ECG at a sweep speed of 100mm/sec. A cine loop of at least three consecutive cardiac 
cycles was recorded and stored digitally for later off-line analysis. Intra-observer and intra-
individual variation was assessed randomly in 10 patients. 
 
An arterial blood sample for cardiac Troponin-I (cTnl) was taken 15 hours post-operatively 
(day-1).  cTnI  concentration  was  measured  using  a  commercially  available 
chemiluminescent immunoassay (Beckman Coulter AccuTnI, UK) with the upper limit of 
normal being 0.04µg/litre. 
 
2.3.1  Table 1. Characteristic data of patient groups 
 
 
Demographics  Control  ASD  VSD  AVSD 
N  10  8
●  16  11 
Male  4  3  11  5 
Age (months)   23.6 ± 20.9
*  37.8 ± 15.2
*   8.0 ± 5.5  6.1 ± 6.0 
Weight (kg)    13.2 ± 2.6
*  6.4 ± 2.5  5.1 ± 0.8 
XC (mins)  44.0 ± 30.1  50.1 ± 15.9  108.8 ± 19.8
** 
CPB (mins)  73.8 ± 38.3  83.56 ± 20.9  155.2 ± 24.9
** 
Ventilation time (hrs)  18.3 ± 21.9
  61.1 ± 57.5
  107.6 ± 57.4
*** 
PICU stay (days)  1.38 ± 0.7
  3.89 ± 2.7
  6.00 ± 2.6
*** 
cTnI (day-1, µg/L)    3.82 ± 3.7  3.83 ± 2.2  12.9 ± 4.3
*** 
 
Data expressed as mean ± SD. 
Control,  structurally  normal  heart;  ASD,  atrial  septal  defect;  VSD,  ventricular  septal 
defect;  AVSD,  atrio-ventricular  septal  defect;  XC,  cross-clamp;  CPB,  cardiopulmonary 
bypass; PICU, paediatric intensive care unit; cTnI, cardiac troponin-I  
●5 primum, 3 secundum; *Control and ASD groups were significantly older (ASD; and 
heavier)  than  VSD  and  AVSD  groups  (p<0.01);  **Cross-clamp  and  cardiopulmonary 
bypass duration were significantly longer for AVSD group compared to VSD and ASD 
groups (p<0.0001);
 ***Ventilation time, PICU stay and cTnI were significantly higher in 
AVSD group compared to VSD and ASD groups (p<0.001).  End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 46 of 192 
 
Tony Vassalos   2010 
2.3.2  TDI Analysis 
Stored  TDI  data  was  displayed  (Figure.  1)  and  analysed  using  commercially  available 
software (Echopac, GE Vingmed). Each TDI parameter was derived by analysis of the TDI 
annular signal and represented the functional description of corresponding ventricle i.e. 
tricuspid  valve  for  right  ventricle,  mitral  valve  for  left  ventricle  and  basal  septum  for 
septum. Peak myocardial velocity (Sa) was measured by electronic callipers as the wave 
height  during  systole.  Peak  myocardial  isovolumic  velocity  (IVV)  was  defined  as  the 
maximum velocity during isovolumetric contraction (Q wave to onset of systolic ejection). 
Isovolumic acceleration (IVA) was calculated by dividing the peak isovolumic velocity by 
the time interval from baseline to peak isovolumic velocity  (Figure 1). 
5 All measurements 
were  derived  from  3  consecutive  cardiac  cycles  with  the  average  recorded.  Of  note, 
diastolic TDI parameters were invariably more difficult to interpret due to the merging of 
peak early and late (E and A waves depicted below) annular velocities. Intra-observer and 
intra-individual variation in systolic TDI parameter analysis was found to be less than 5%. 
 
2.3.2.1  Figure  1.  Normal  TDI  waveform  depicting  measured  and  acquired 
parameters 
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2.4  Statistical Analysis 
Data are expressed as means ± standard deviations. Demographic and outcome data (age, 
bypass and cross-clamp times, cardiac troponin-I, ventilation time, and PICU stay), TDI 
comparisons with controls and the change in TDI parameters with time were all analysed 
by ANOVA with post-hoc Bonferroni correction. Correlations were performed between 
quantitative variables to assess the degree of linear association using Pearson method. All 
analyses were done using Minitab (Version 14) with a significance level of 5%. 
 
2.5  Results 
Within  the  study  group  there  was  no  mortality;  all  patients  were  discharged  without 
significant complication. Study and control patient demographics are summarised in Table 
1. Control and ASD patients were significantly older than VSD and AVSD patients. There 
was an incremental increase in operative duration, troponin release and ventilation/PICU 
times with increasing cardiac complexity. 
 
Post-operative Troponin-I was elevated compared to the normal range. cTnI (µg/L, all 
patients; 6.6 ± 5.3) was significantly higher following AVSD repair compared with VSD 
and ASD groups (Table 1). There was a strong positive correlation between cTnl release 
and both cross-clamp (r=0.82, p<0.0001) and bypass duration (r=0.83, p<0.0001). 
 
2.5.1  TDI Parameters 
Pre-operatively in both control and study patients, all TDI parameters were greater in the 
RV compared with LV and septum, with the highest values in the control group (Table 2). 
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complexity of cardiac lesion. By contrast the isovolumetric parameters, particularly in the 
septum, tended to remain more consistent across the cardiac lesion spectrum.  
 
LV, RV and septal peak systolic velocities were all significantly reduced in the immediate 
post-operative  period  (PICU)  but  demonstrated  a  modest  trend  to  recovery  by  day-1, 
particularly in the LV (Figure 2a). By contrast both isovolumetric parameters, IVA (Figure 
2b) and IVV (Figure 2c) decreased in the early period and continued to decline at day-1.  
 
2.5.1.1  Table 2. Controls versus pre-operative TDI parameters by diagnosis 
 
 
 
 
TDI data expressed as mean ± SD; (TDI velocity versus control: p<0.05
▲, p<0.0001
◆) 
Sa,  peak  systolic  myocardial  velocity;  IVV,  peak  velocity  during  isovolumetric 
contraction; IVA, isovolumetric acceleration; LV, left ventricle; Sep, basal septum; RV, 
right  ventricle;  Control,  anatomically  normal  heart;  ASD,  atrial  septal  defect;  VSD, 
ventricular septal defect; AVSD, atrio-ventricular septal defect 
 
 
 
 
 
  Sa (cm/sec)   IVV (cm/sec)   IVA (cm/sec
2) 
  LV  Sep  RV  LV  Sep  RV  LV  Sep  RV 
Control  7.75±1.70  7.43±0.46  12.65±0.99  6.20±1.56  7.03±0.74  11.86±4.93  300.8±62.4  291.8±110.8  470.8±189.3 
ASD  6.63±1.47  5.21±0.68
◆  8.64±1.89
◆  6.37±1.20  7.61±0.57  9.80±0.83  230.2±153.9  216.4±44.5  263.0±93.0
▲ 
VSD  5.46±1.30
◆  4.92±0.98
◆  7.73±2.29
◆  6.86±3.97  7.32±2.45  9.04±3.68  220.9±132.9  233.6±113.7  274.5±116.4
▲ 
AVSD  4.19±0.93
◆  4.52±1.41
◆  6.93±2.32
◆  6.17±2.35  6.94±3.00  9.58±2.27  142.2±88.4
▲  218.6±79.6  317.6±111.6
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2.5.1.2  Figure 2a. Change in peak systolic myocardial velocity 
 
 
2.5.1.3  Figure 2b. Change in isovolumic acceleration 
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2.5.1.4  Figure 2c. Change in isovolumic velocity 
 
 
 
2.5.2  Correlation of TDI parameters with myocardial injury and outcome 
Reduced pre-operative LV systolic velocity correlated with greater cTnI release and longer 
ventilation (r=0.54, p=0.002) and PICU times (r=0.53, p=0.02). Post-operatively reduced RV 
(Figure 3a) and septal systolic and isovolumic velocities were associated with greater cTnI 
release. By comparison there was no correlation between post-operative LV TDI parameters 
and troponin-I release (SaLV r=0.06, p=0.84; IVALV r=0.15, p=0.75). 
 
Post-operatively, longer ventilation and ITU times were associated with reduced LV and 
septal parameters (Figures 3b-c). There were no significant correlations between RV TDI 
parameters and ventilation time (SaRV r=0.12, p=0.65; IVARV r=0.30, p=0.30).  End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 51 of 192 
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2.5.2.1  Figure 3a. RV systolic velocity (PICU) vs. cTnI 
 
 
 
2.5.2.2  Figure 3b. LV systolic velocity (PICU) vs. Ventilation Time 
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2.5.2.3  Figure 3c. Septal systolic velocity (PICU) vs. Ventilation time 
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2.6  Discussion 
The principal findings in this study were; (1) In patients with congenital heart lesions pre-
operative  bi-ventricular  systolic  tissue  Doppler  parameters  were  reduced  compared  to 
normal controls (2) Following cardiac surgery there was a reversible reduction in TDI 
velocities  with  sustained  decline  in  isovolumic  indices  (3)  Reduced  post-operative  RV 
velocities were associated with a greater extent of myocardial injury defined by Troponin-I 
release and (4) Reduced pre- and post-operative LV velocities were associated with longer 
ventilation and PICU times. 
 
The assessment of ventricular function following paediatric cardiac surgery is complicated 
by the alteration to loading conditions caused by the elimination of intra-cardiac shunting 
and  variation  in  post-operative  pulmonary  and  systemic  vascular  resistances. 
1  The 
contractile  indices  of  maximal  elastance  (Emax)  and  preload-recruitable  stoke  work 
(PRSW), derived from pressure-volume data, are considered gold standard because of their 
load  independence. 
11  However  the  methodology  involved  in  ventricular  volume 
measurement, usually by conductance catheter, is invasive and not suitable for routine 
clinical use.  
 
In  this  study  contractility  was  quantified  using  absolute  (peak  systolic  and  isovolumic 
velocity)  and  derived  (isovolumic  acceleration)  tissue  Doppler  indices.  Peak  systolic 
myocardial  velocities  have  been  validated  as  an  index  of  contractility  in  animal 
experiments  of  ischaemia-reperfusion  and  in  studies  of  inotrope  modulation,  where 
velocities have correlated closely with fractional shortening measured by sonomicrometry 
and maximum elastance from pressure-volume data. 
4, 12 In clinical studies, systolic TDI 
velocities  have  proved  to  be  reliable  indicators  of  LV  and  RV  function  as  well  as End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 54 of 192 
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predicting  survival  in  patients  with  heterogeneous  cardiac  diseases. 
13-15  However,  the 
magnitude of systolic myocardial velocities has been shown to be preload- and afterload- 
dependent. 
5,  6,  16 Recently peak isovolumic velocity (IVV) and acceleration (IVA) have 
been proposed and validated through animal studies as load-independent contractile indices 
within the physiological range expected post-operatively. 
5-7, 17 The potential ability of TDI 
to  assess  ventricular  function  independent  of  load  is  particularly  important  when 
considering  the  RV  which  in  the  context  of  congenital  heart  disease  is  frequently 
characterised by pressure or volume loading. 
15, 17 Although RV function can be derived 
from  volumetric  data  obtained  through  cardiac  MRI,  multi-slice  CT  or  3D 
echocardiography their load-dependency, invasiveness, high cost, low availability and time 
consuming data analysis limits their use in children. 
8 The RV has a preponderance of 
longitudinal muscle fibres which allows optimal alignment of the tissue Doppler signal. 
This permits a sensitive measure of velocity variations within the RV and thus TDI has 
gained favour in its functional assessment. 
14, 15, 17, 18 This was confirmed in the present 
study where TDI indices were consistently higher in the RV compared with septum and 
LV for all patients, including controls.  
 
From the pre-operative data it was found that, not only were the patients with cardiac 
lesions observed to have reduced velocities compared to controls but also the extent of 
velocity  reduction  was  greater  with  increasing  cardiac  complexity.  By  contrast  the 
variation  observed  in  isovolumic  indices,  particularly  IVV,  was  much  less  across  the 
disease spectrum consistent with the load-independent character of these parameters. Of 
interest isovolumic acceleration appeared to be most reduced in the specific ventricle likely 
to be volume loaded by the cardiac lesion, i.e. RV with ASD and LV with VSD/AVSD. 
The study also identified that reduced pre-operative LV TDI indices were associated with 
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operative heart failure with VSD lesions, with large Qp:Qs and volume loaded LV, are 
likely to require longer post-operative recovery. Previous adult studies have also shown 
that LV systolic velocities may predict survival in patients with congestive heart failure. 
19 
Ultimately  it  may  be  that  LV  systolic  TDI  parameters  will  have  a  predictive  value  in 
determining  post-operative  course  and  can  be  factored  into  optimising  the  timing  of 
surgery.   
 
In the current study the finding of a reduction in all systolic TDI parameters measured at 
the  septum,  mitral  and  tricuspid  annuli  suggests  an  overall  global  impairment  of 
contractility in the early post-operative period. Of particular interest was the disparity seen 
between  RV  and  LV  TDI  parameters  post-operatively.  LV  peak  systolic  velocities 
recovered  towards  baseline  pre-operative  values  by  15  hours  post-operatively  and  this 
pattern  of  change  may  reflect  the  nadir  in  cardiac  index  described  by  Wernovsky. 
20 
However, peak systolic velocities are an ejection-phase index and therefore load-dependent 
and  the  initial  fall  in  LV  velocities  may  in  part  result  from  diminished  LV  preload 
following VSD closure. 
16 Similarly the observed later velocity recovery may represent a 
reduction  in  systemic  vascular  resistance  rather  than  an  improvement  in  intrinsic  LV 
contractility per se. 
10, 20 By contrast, RV and septal systolic velocities remained reduced 
with no significant recovery between the 2 post-operative time points. Potentially these 
velocities could also be reduced as a consequence of increased RV afterload by elevations 
in pulmonary arterial pressure common in post-operative patients with repaired VSD or 
canal defects. The greater and more significant reduction in RV isovolumic acceleration 
seen post-operatively supports the view that an intrinsic RV contractile impairment existed. 
Likewise the smaller reduction in post-operative LV isovolumic acceleration, although not 
initially statistically significant, could also indicate a contractile dysfunction within the 
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and  myocardial  contractility  that  are  often  interrelated  and  therefore  not  possible  to 
definitively isolate.   
 
In this study post-operative serum Troponin-I was measured to quantify myocardial injury 
sustained during surgery. Troponin-I has been shown to correlate well with the extent of 
peri-operative  myocardial  damage  and  is  predictive  of  post-operative  outcome  in  the 
paediatric population. 
21, 22 In this patient group although direct retraction trauma cannot be 
avoided, no ventricular incisions or myocardial resection were performed and therefore 
myocardial injury and cTnI release should relate to the duration of ischemia-reperfusion. 
This was strongly evident in our study with clear correlations between cross-clamp and 
bypass times and cTnI levels. The significant correlations between cTnI levels and RV and 
septal  TDI  parameters  would  implicate  myocardial  injury  as  the  principal  mechanism 
behind the reduced contractility. Of interest, although both ventricles were exposed to the 
same ischemic-reperfusion insult, no significant correlations between troponin-I and post-
operative LV TDI parameters were found. This may reflect a vulnerability of the RV to 
myocardial injury in this patient group. In the patients with VSD physiology, pre-operative 
exposure of the RV to systemic pressures will induce myocardial hypertrophy, which has 
been  shown  to  decrease  sub-endocardial  blood  flow  and  lower  concentrations  of  high 
energy  phosphates,  factors  which  may  render  the  ventricle  more  susceptible  to  injury 
during the cross-clamp period. 
23 The RV is also vulnerable to direct surgical trauma and 
contusion resulting from retraction, ventriculotomy (although not performed in this study) 
and  VSD  suture  placement.  Post-operative  conduction  abnormalities,  including  right 
bundle branch block may have a more pronounced effect on RV contraction although no 
conduction defects were seen in these patients. 
 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 57 of 192 
 
Tony Vassalos   2010 
In  the  acute  post-operative  setting  TDI  had  a  predictive  value  for  early  outcome  with 
reduced LV and septal TDI significantly correlating with longer ventilation time and PICU 
stay.  By  contrast  RV  TDI,  the  ventricle  with  the  most  marked  post-operative  TDI 
reduction, did not demonstrate a correlation with outcome. Although the reasons for this 
remain  unclear  it  may  be  that  the  RV  TDI  was  not  measured  beyond  15  hours  post-
operatively  and  it  is  possible  that  subsequent  ventricular  recovery  and  appropriate 
modulation of the contractile deficit by inotropes may confound a potential relationship. In 
addition  other  factors,  including  renal  and  pulmonary  impairment,  may  supersede  the 
influence of ventricular function on early outcome with respect to ventilation and PICU 
times. 
 
2.7  Clinical implications and future considerations 
Pre-operative TDI quantification of LV systolic function may prove to be a useful adjunct 
in  determining  the  timing  of  corrective  surgery.  TDI  also  has  the  ability  to  assess 
contractile  dysfunction  in  the  PICU  setting,  allowing  early  and  ongoing  assessment  of 
ventricular  performance  following  cardiac  surgery.  This  may  enable  appropriate 
therapeutic intervention prior to the onset of the systemic manifestations of low cardiac 
output including lactic acidosis and renal failure. Due to its particular sensitivity for RV 
contraction, TDI may provide better evaluation of right ventricular-pulmonary interaction 
post  cardiac  surgery  and  assessment  of  the  effectiveness  of  nitric  oxide  and  other 
intervention strategies. 
 
2.8  Study limitations 
Pulmonary arterial pressures were not directly measured and therefore this influence was 
not  evaluated.  Never  the  less,  no  patient  required  supportive  measures  including  nitric 
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variable and inconsistent pattern of change observed in LV post-operatively may reflect a 
misalignment of the Doppler signal with the predominant circular mid-wall fibres found in 
the  left  ventricle.  However,  the  majority  of  published  studies  of  TDI  quantifying  LV 
contraction used longitudinal mitral annular velocities and have satisfactorily predicted 
ventricular function and outcome. 
3, 4, 13, 19, 24  
 
TDI parameters were not analysed beyond the first post-operative day and it would have 
been interesting to know if the RV and septal parameters returned to normal during the 
early post-operative period. In a previous study of post-op Fallot’s patients a reduction in 
RV  myocardial  acceleration  persisted  late  after  repair. 
17  However  this  may  relate  to 
ongoing haemodynamic lesions including chronic pulmonary regurgitation rather than a 
permanent myocardial injury sustained at the time of surgical repair. 
 
2.9   Conclusion 
This study highlights the vulnerability of the RV to ischaemia-reperfusion injury sustained 
during  the  repair  of  congenital  heart  disease,  as  quantified  by  TDI.  TDI  is  a  readily 
accessible, non-invasive technique that allows real-time evaluation of ventricular function 
after  surgery  enabeling  the  clinician  to  make  rapid  therapeutic  management  decisions. 
Through its particular sensitivity to RV contraction, TDI may provide better evaluation of 
the RV-pulmonary interaction after cardiac surgery and the effectiveness of nitric oxide 
and other intervention strategies. Pre-operative evaluation of LV systolic TDI parameters 
may have a role in patient risk stratification and timing of cardiac surgical correction. 
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CHAPTER 3: RENAL FUNCTION 
 
3.1  Abstract 
 
3.1.1  Background 
Cardiopulmonary  bypass  (CPB)  and  post-operative  low  cardiac  output  are  important 
factors  in  acute  renal  injury  following  cardiac  surgery.  In  patients  with  renal  disease 
cystatin  C  has  emerged  as  a  new  biomarker  marker  that  is  sensitive  to  changes  in 
glomerular filtration rate (GFR) and may provide a better estimate of renal function than 
creatinine alone. In this study we wished to:  
1.  Evaluate cystatin C as a means of quantifying renal performance after cardiac surgery 
in children. 
2.  Utilize  cystatin  C  to  investigate  acute  changes  in  renal  function  following  cardiac 
surgery in children and its association with cardiopulmonary bypass factors and peri-
operative myocardial injury. 
 
3.1.2  Methods 
Twenty children, aged 4-58 months (median 5.5, 10 M: 10 F), undergoing surgery (AVSD 
n=7, VSD n=9, ASD n=4) were prospectively studied. Blood samples were collected pre-
operatively and on days 0, 1, 2 and 3 post-operatively to measure serum cystatin C (cysC) 
and creatinine (Cr). GFR was quantified by creatinine clearance during the first and second 
12hr post-operative periods; CrCl0-12 and CrCl12-24 respectively. Recorded CPB parameters 
included bypass duration, the lowest pump flow (Qmin), the lowest hematocrit (Hctmin) and 
the  corresponding  lowest  oxygen  delivery  (DO2  min).  Myocardial  injury  was  quantified 
post-operatively by Troponin-I release. 
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3.1.3  Results  
Serum  cystatin  C  and  creatinine  increased  post-operatively  to  peak  on  days  3  and  2 
respectively (cysCDay0 0.8±0.3 vs. cysCDay3 1.5±0.5; p=0.02) (CrPreOp 31.0±6.9 vs. CrDay2 
36.9±12.2; p=0.03). During the first 24hrs after surgery GFR remained unchanged (CrCl0-
12  63.6±37.0  vs.  CrCl12-24  65.1±27.5;  p=n.s.).  In  comparison  to  creatinine,  cystatin  C 
demonstrated a superior correlation with GFR (cysCDay0 r=0.58 p=0.018; CrDay0 r=0.09 
p=0.74).  Receiver-operator  cut-off  level  for  cystatin  C  >1.044mg/l  exhibited  a  100% 
sensitivity  and  67%  specificity  for  detecting  renal  dysfunction,  defined  as  a  GFR 
<55ml/min/1.73m
2,  compared  to  85%  sensitivity  and  88%  specificity  for  creatinine 
>34µmol/l. Serum cystatin C significantly increased during the first 24hr post-operative 
period (cysCDay0 0.8±0.3 vs. cysCDay1 1.1±0.4; p=0.003) and was strongly associated with 
CPB  duration  (cysCDay1  r=0.67,  p=0.001),  Qmin  (cysCDay1  r=0.61,  p=0.005)  and  greater 
Troponin-I release (cysCDay1 r=0.73, p<0.001). Lowest DO2 min and Hctmin did not correlate 
with cystatin C.  
 
3.1.4  Conclusions 
This study has shown that in comparison to creatinine, cystatin C provides a better estimate 
of  GFR  and  is  more  sensitive  in  detecting  significant  renal  dysfunction  in  children 
following  cardiac  surgery.  Cystatin  C  identified  a  transient  post-operative  renal 
impairment, the magnitude of which was associated with duration of bypass, low pump 
flows and the degree of myocardial injury. 
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3.2  Introduction 
Acute renal failure (ARF) following cardiopulmonary bypass (CPB) in children is a well 
recognised and serious complication of cardiac surgery whose incidence varies widely, 1to 
31%,  depending  on  the  defining  criteria. 
1-5  When  severe  enough  to  require  renal 
replacement  therapy  (RRT)  morbidity  and  mortality  are  significantly  increased  despite 
supportive measures. 
2, 3 
 
The artificial process of CPB necessary for cardiac surgery is known to trigger multiple 
inflammatory cascades within the body that culminate in a capillary leak syndrome and 
multi-organ  dysfunction. 
6-8  In  an  attempt  to  maximise  operating  conditions,  further 
potential stresses are often inflicted on the kidney through haemodilution, hypothermia, 
hypoperfusion and non-pulsatile flow. 
3,9,10 Younger and smaller patients as a group are 
particularly vulnerable due to higher metabolic demands, complex cardiac lesions, longer 
CPB  times,  reactive  pulmonary  vasculature  and  immature  organ  systems  with  altered 
homeostasis.
2,  5,  7 Evidence also exists of a low cardiac output syndrome (LCOS) that 
occurs 6 to 18 hours after paediatric cardiac surgery which is multi-factorial in aetiology 
and associated with increased mortality due to secondary organ failure. 
6, 11 
 
Glomerular filtration rate (GFR), defined as the volume of plasma completely cleared of a 
particular substance by the kidneys in a unit of time, is the best overall indicator of renal 
function. 
12-14  The  expensive,  labour-intensive  determinations  of  GFR  by  exogenous 
substances such as inulin remain the ‘gold standard’ but have been replaced clinically by 
more  straightforward  endogenous  substances  including  creatinine.  Although  the 
measurement of serum creatinine is the most common method for estimating GFR, it often 
fails to identify patients with moderately reduced renal function. 
12-15 Cysteine proteases 
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apoptosis, MHC class II immune responses, proteasome and lysosomal regulation, pro-
hormone processing and extracellular matrix remodeling important to bone development. 
16-18  Cystatin  C  (cysC)  is  a  cysteine  proteinase  inhibitor  uniquely  expressed  in  all 
nucleated cells and produced at a constant rate. 
16-18 It is considered to be a sensitive 
marker of renal injury and unlike creatinine its levels are not influenced by height, age, 
sex, muscle mass or acute phase reactions highlighting the potential diagnostic importance 
of this novel biomarker.
12-14,16-19  
 
The  value  of  cysC  in  quantifying  early  renal  dysfunction  following  paediatric  cardiac 
surgery in conjunction with measured GFR and serum creatinine has not been tested. This 
important issue has been addressed in this study as well as the association of cysC with 
peri-operative CPB factors, oxygen delivery and myocardial injury. 
 
3.3  Methods 
3.3.1  Patients 
Both local and regional research ethics committees approved the study. Following written 
informed consent the first twenty children enrolled to our prospective observational cohort 
study designed to assess cardiac and renal function, with a range of atrial and ventricular 
septal  defects  undergoing  corrective  surgical  repair,  were  prospectively  recruited. 
Exclusion criteria included neonates, patients with cyanotic heart disease and pre-operative 
use of mechanical ventilation, inotropes, extracorporeal life support or pre-existing renal 
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3.3.2  Data Collection and Definitions 
3.3.2.1  Renal Function 
Serum  creatinine  (Cr)  was  measured  as  part  of  routine  investigations  for  all  patients 
undergoing  cardiac  surgery  pre-operatively,  on  admission  to  paediatric  intensive  care 
(PICU) and days 1, 2 and 3 post-operatively using the Roche Creatinine Plus enzymatic 
assay with a normal range of 18 – 40 µmol/L.  
 
Plasma retained from routine investigations, at the above time points, was stored at -70
oC 
until  measurement  of  cysC  using  a  particle-enhanced  nephelometric  immunoassay 
(PENIA)  on  a  BN  ProSpec  analyser  (Dade  Behring  Ltd.,  Milton  Keynes,  UK)  with  a 
normal range of 0.54 – 1.06 mg/L.  
 
Urinary creatinine measured by the kinetic Jaffe method on an Abbott AEROSET analyser 
was used to estimate GFR through creatinine clearance (CrCl) during the first and second 
twelve-hour post-operative periods and indexed to body surface area (Normal range 54 – 
86 ml/min/1.73m
2). Hourly urine output (ml/kg) was recorded for the first twenty-four 
hours after surgery. 
 
3.3.2.2  Perfusion and Myocardial Injury 
Besides  CPB  and  cross-clamp  times  (min),  the  following  operative  parameters  were 
recorded at four time points during surgery (commencement of CPB, at 30 min, at 1hr and 
on removal of cross-clamp): haemoglobin (g/dL), haemoglobin saturation (%) and arterial 
oxygen tension (mmHg) from routine arterial blood gas analysis, pump flow (ml/min/m
2), 
mean arterial pressure (mmHg) and oxygen delivery (ml/min/m
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indexed pump flow (Qmin), lowest haematocrit (Hctmin) and corresponding oxygen delivery 
(DO2 min) that occurred during CPB were also noted. 
 
Oxygen  delivery  (DO2,  ml/min/m
2)  which  is  the  amount  of  oxygen  delivered  to  the 
peripheral tissues was calculated by multiplying the indexed pump flow (Q) by the arterial 
oxygen content according to the equation: DO2 = Q x (haemoglobin x 1.34 x haemoglobin 
saturation + 0.003 x arterial oxygen tension). 
3  
 
An arterial blood sample for cardiac Troponin-I (cTnl) was taken 15 hours post-operatively 
(Day1).  cTnI  concentration  was  measured  using  a  commercially  available 
chemiluminescent immunoassay (Beckman Coulter AccuTnI, UK), with the upper limit of 
normal being 0.04µg/litre. 
 
3.3.3  Cardiopulmonary Bypass 
All  patients  underwent  elective  surgery  by  the  same  surgeon  (MHD)  using  moderate 
hypothermic cardiopulmonary bypass (25-32
0C) with antegrade, cold, blood cardioplegia. 
The bypass circuit was primed with 4.5% albumin (150 - 200 mls), mannitol (0.5g/kg), 
NaHCO3 (10 – 15 mmol) and heparin (3000 – 5000 iu). Packed red cells were added to the 
prime to achieve a minimum haematocrit of 25%. Acid base was managed with alpha stat 
control. Conventional ultrafiltration (Minntech HPH 400 haemofilter) during re-warming 
occurred in all patients.  
 
Extracorporeal  circulation  was  performed  using  a  Medos  2800  (Chalice  Medical, 
Shireoaks,  Notinghamshire,  UK)  oxygenator,  Pall  AL3  (Chalice  Medical,  Shireoaks, 
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Gloucestershire,  UK).  Non-pulsatile  perfusion  was  maintained  at  1.0  –  1.8L/min  (<12 
months) and 1.8 – 3.0L/min (12 – 58 months): flow = body surface area x 2.4 L/min/m
2. 
 
3.4  Statistical Analysis 
Associations  between  peri-operative  variables  and  measures  of  post-operative  renal 
function  (CrCl12-24,  CrDay1  and  cysCDay1)  were  initially  investigated  univariately.  
Creatinine clearance was defined as a dependent binary variable (0 to 1; using cut-off 
values at 55 and 85 ml/min/1.73m
2 to further delineate any association with severity of 
renal impairment) and its association with the various independent variables was explored 
using a logistic regression analysis with each possible predictor tested one at a time. For 
continuous  outcomes,  a  general  linear  model  was  used  in  the  same  way.  Significant 
variables  from  the  univariate  analyses  were  then  used  in  multivariate  models  using 
backwards selection to determine the independent predictors of outcomes.  
 
Parameters of renal function (Cr, cysC and CrCl) were measured over time and a repeated 
measures analysis of variance was performed to test for differences between time points. 
Where  differences  existed,  post-hoc  comparisons  between  time  points  were  completed 
using the Bonferroni correction for multiple testing.  
 
Receiver  operating  characteristics  (ROC)  analyses  were  performed  to  investigate  the 
potential of CrDay1 and cysCDay1 as diagnostic predictors of abnormal CrCL12-24, coded as 
binary, with cut-offs at 55 and 85 ml/min/1.73m
2. 
 
All analyses were done using Minitab (version 15) or SPSS (version 17) at a significance 
level of 5%. 
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3.5  Results 
Twenty children were recruited to the study with demographic and peri-operative variables as 
outlined  in  Table  1  and  Figures  1a-d.  Within  this  group  there  was  no  surgical  hospital 
mortality; all patients were discharged home without complication.  
 
3.5.1  Table 1. Demographic characteristics between groups  
 
 
 
AVSD 
(n = 7) 
VSD 
(n = 9) 
ASD 
(n = 4) 
p-value 
 
All Patients 
(n = 20) 
Patient factors  Gender (Male)  2 (29%)  6 (67%)  2 (50%)  0.319  10 (50%) 
  Age (mth)  6.5 ± 1.7  8.1 ± 2.1  41.8 ± 6.8
  0.005  14.3 ± 15.9 
  Weight (Kg)  6.1 ± 1.5  6.0 ± 2.5  14.0 ± 3.0  0.007  7.7 ± 3.9 
Operative factors  XC (min)  106 ± 20
  54 ± 17  43 ± 23  <0.001  70.4 ± 33.4 
  BP (min)  147 ± 25
  86 ± 25  69 ± 28  <0.001  100 ± 41 
  Hctmin (%)  24.14 ± 3.13  23.43 ± 2.88  22.75 ± 2.36  0.725  23.75 ± 2.73 
  Qmin (ml/min/m
2)  2037.4 ± 408  2299.8 ± 430  2551 ± 262  0.111  2250.5 ± 398.7 
  DO2min (ml/min/m
2)  244.3 ± 47.7  309.9 ± 49.8  290.6 ± 11.4  0.034  281.0 ± 49.1 
Post-Op factors  cTnIDay-1 (µg/L)  11.6 ± 3.6
  4.9 ± 2.4  2.2 ± 0.6  <0.001  6.7 ± 4.8 
  Ventilation (hrs)  101 ± 67.4
  69.3 ± 66.9
  21.3 ± 26  0.05  70.8 ± 65.4 
  PICU stay (days)  5.7 ± 3.0  4.1 ± 3.0  1.3 ± 0.5  0.020  4.1 ± 3 
  Hospital stay (days)  19.1 ± 18.0
  8.8 ± 2.5  7.2 ± 2.2  0.035  12.1 ± 11.8 
 
Data expressed as mean ± SD. (p-value: refers to between group comparisons) 
AVSD, atrio-ventricular septal defect; VSD, ventricular septal defect; ASD, atrial septal 
defect;  XC,  cross-clamp  time;  BP,  cardiopulmonary  bypass  time;  Hctmin,  lowest 
haematocrit  during  bypass;  Qmin,  lowest  indexed  pump  flow  during  bypass;  DO2min, 
indexed oxygen delivery at lowest haematocrit during bypass; cTnIDay-1 , serum cardiac 
troponin-I on first post-operative day; Post-Op, post-operative; PICU, paediatric intensive 
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3.5.1.1  Figure 1a. Peri-operative pump flow (--- ideal parameter boundaries)  
Mean values interconnected. Wide variation in perfusion flow evident with 
general trend for increasing flows prior to removal of cross-clamp (XC). 
 
 
3.5.1.2  Figure 1b. Peri-operative haematocrit (--- ideal parameter boundaries)  
Mean  values  interconnected.  Wide  variation  in  haematocrit  levels  evident 
particularly on commencement of bypass (on BP). Increased haematocrit levels 
associated with ultrafiltration prior to cross-clamp removal (XC off). 
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3.5.1.3  Figure 1c. Peri-operative oxygen delivery (--- critical dysoxic threshold)  
Mean values interconnected. Wide variation in oxygen delivery demonstrated 
with increased levels prior to cross-clamp removal (XC off) in conjunction with 
increasing pump flows and haematocrit. 
 
3.5.1.4  Figure 1d. Peri-operative mean arterial pressure (--- ideal parameter boundaries) 
Mean values interconnected. 
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3.5.2  Renal Function 
There was no significant change in measured GFR in the first twenty-four hours after surgery 
(Figure 2). Pre-operatively, serum Cr and cysC were in the normal range for all patients and in 
contrast to CrCl both increased significantly during the early post-operative period continuing 
to peak on days two and three respectively (Figure 3). Serum Cr levels returned to normal by 
day three. This deterioration in renal function was associated with a non-significant drop in 
urine  output  in  the  early  post-operative  period  (Figure  4).  In  comparison  to  Cr,  cysC 
demonstrated  a  superior  correlation  to  measured  GFR  in  the  early  post-operative  period 
(Figure 5). No patients required post-operative renal replacement therapy. 
 
3.5.2.1  Figure 2. Indexed post-operative Creatinine Clearance 
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3.5.2.2  Figure 3. Peri-operative serum Creatinine and cystatin C 
 
3.5.2.3  Figure 4. Early post-operative urine output (24hrs) 
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3.5.2.4  Figure 5. Correlation of cystatin C and serum Creatinine with CrCl 
 
3.5.3  Univariate Analyses 
CrCl12-24  <85ml/min/1.73m
2  was  not  significantly  associated  with  any  of  the  measured 
variables  whereas  <55ml/min/1.73m
2  correlated  with  XC  (p=0.033)  time.  cysCDay-1  was 
significantly associated with Qmin (p=0.005; Figure 6a), cTnIDay-1 (p<0.001; Figure 6b), BP and 
XC times (both, p=0.001). cysCDay-1 did not correlate significantly with DO2 min (p=0.47) or 
Hctmin (p=0.336). However, DO2  min <300ml/min/m
2 demonstrated a significant association 
with cysCDay-1 (r=-0.68, p=0.007).  
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3.5.3.1  Figure 6a. Correlation of cystatin C and lowest pump flow during CPB 
 
3.5.3.2  Figure 6b. Correlation of cystatin C and cTnI 
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3.5.4  Multivariable Analyses 
XC time (OR 1.07, 95% CI (1.01,1.14)) in association with CrCl12-24 <55ml/min/1.73m
2 and 
cTnIDay-1 in association with cysCDay-1 (p=0.01) and CrDay-1 (p<0.001) were the only significant 
independent predictors of early post-operative renal dysfunction in this patient group. 
 
3.5.5  ROC Analyses 
cysCDay1  >1.044mg/l  exhibited  a  100%  sensitivity  and  67%  specificity  for  detecting  renal 
dysfunction,  defined  as  a  GFR<55ml/min/1.73m
2,  compared  to  85%  sensitivity  and  88% 
specificity  for  CrDay1  >34µmol/l.  DO2  min  <242ml/min/m
2  exhibited  a  72%  sensitivity  and 
100% specificity for detecting renal dysfunction, defined as a GFR<55ml/min/1.73m
2 (Figure. 
7). 
3.5.5.1  Figure 7. ROC  
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3.5.6  Clinical Outcomes 
cysCDay1 was the only marker of post-operative renal injury that significantly correlated with 
ventilation  time  (p<0.001)  and  PICU  stay  (p=0.002).  Compared  to  serum  Cr,  cysC 
demonstrated  superior  correlation  to  overall  hospital  stay  (hospital  stay  vs.  CrDay1  and 
cycCDay1: r=0.62, p=0.005 and r=0.73, p<0.001 respectively). 
 
3.6  Discussion 
Acute renal failure is a common complication after cardiac surgery which continues to be 
associated  with  significant  morbidity  and  in  the  presence  of  replacement  therapy, 
mortality. 
1-5  In  this  prospective  study,  the  use  of  cystatin  C  to  predict  early  renal 
dysfunction following paediatric cardiac surgery and the related impact of CPB parameters 
was  investigated.  Our  principal  findings  were  that:  (1)  cystatin  C  is  a  more  sensitive 
marker of early renal dysfunction than serum creatinine (2) CrCl is not significantly altered 
in the first 24hrs after surgery (3) intra-operative ischaemia-reperfusion and myocardial 
injury were independent predictors of early renal dysfunction and (4) a raised cystatin C 
post-operatively is significantly linked to clinical outcome measures of ventilation time 
and PICU stay. 
 
Serum creatinine and urine output are commonly used to define ARF whose pathophysiology 
involves a broad pattern of peri-operative mechanisms. 
1,  4,  5 However, in addition to being 
influenced by age, height, sex and muscle mass creatinine is actively secreted by the proximal 
tubules  resulting  in  as  much  as  a  twofold  overestimation  of  GFR.
1,  12-18  Importantly,  this 
disparity  increases  as  GFR  decreases  further  limiting  the  ability  of  creatinine  to  monitor 
moderate renal dysfunction. As a result, approximately 50% of renal function can be lost 
without an increase in serum creatinine. 
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function and severe ARF can exist despite normal urine production. 
1,  5 Changes in urine 
output, in the absence of diuretics, can occur long before biochemical changes are apparent 
making it an important consideration. According to published consensus definitions of ARF, 
no patient in this study developed an acute (<24hrs) post-operative renal injury or failure. 
5 
 
Cystatin C is also freely filtered by the glomerulus but unlike creatinine is neither secreted 
by the renal tubules nor reabsorbed into the bloodstream making it an ‘ideal’ endogenous 
marker of renal function.
13,  14-19 In adult patients with varying chronic and acute renal 
pathologies,  renal  transplant,  oncology  and  elderly  patients  cystatin  C  has  consistently 
been shown to be more sensitive than creatinine in measuring small changes in GFR. 
12, 13, 
16-18  The  independence  of  cystatin  C  on  height,  gender,  age  and  muscle  mass  is  of 
particular  importance  in  the  paediatric  population.  Pham-Huy  et  al  demonstrated  that 
compared to creatinine only cystatin C correlated with measured GFR (
99mTc DTPA) in 
children with spina bifida who tend to be of short stature and low muscle mass. 
19 Filler et 
al  provided  evidence  that  cystatin  C  is  independent  of  age  in  216  paediatric  urology 
patients (0.8 – 18 yrs) with normal GFR determined by 
51Cr-EDTA clearance. 
20 
 
To our knowledge the evaluation of cystatin C as a marker of acute renal injury has not 
been previously reported in this patient group. In keeping with the current evidence this 
study  demonstrated  that  cystatin  C  (>1.044mg/L)  was  more  sensitive  than  creatinine 
(100% vs. 85%) in predicting early renal dysfunction defined as CrCl <55 ml/min/1.73m
2. 
Furthermore,  cystatin  C  alone  correlated  significantly  with  CrCl  after  cardiac  surgery 
allowing earlier identification of at-risk patients with potential implications for reducing 
post-operative  morbidity  and  mortality.  Compared  to  creatinine,  cystatin  C  was  more 
significantly associated with post-operative clinical outcomes of ventilation time and PICU 
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and remains an expensive option (£15-20/test). Future studies demonstrating significant 
reductions in overall hospital stay with cystatin C based perioperative management are 
needed to drive the clinical impetus necessary for the routine availability of this test. 
 
In  agreement  with  previous  studies  significant  intra-operative  correlates  of  early  post-
operative renal dysfunction included myocardial injury, pump flow, cross-clamp and CPB 
duration. 
2-5  However,  after  adjusting  for  possible  confounding  influences  amongst 
variables only cross-clamp time and myocardial injury, measured by cardiac troponin-I, 
were  found  to  be  significant  independent  predictors.  Post-operative  troponin-I  has 
previously  been  shown  to  be  significantly  associated  with  the  extent  of  peri-operative 
myocardial injury, manifest post-operatively as a low cardiac output, and is predictive of 
outcome including acute renal failure in a similar patient group. 
6, 11, 21, 22 Both cystatin C 
and  creatinine  significantly  correlated  with  troponin-I  in  this  study  highlighting  the 
importance of maintaining cardiac output during the early post-operative period on renal 
dysfunction. Renal ischaemia, unlike cardiac, is generally silent with signs and symptoms 
unlikely  to  identify  high  risk  patients  making  the  availability  of  a  sensitive  serum 
biomarker an important clinical decision-making tool. 
 
The principal objective of CPB is the delivery of oxygen to the systemic circulation during 
periods of cardio-pulmonary arrest necessary for cardiac surgical repair. In addition to the 
inflammatory cascades and low cardiac output state associated with CPB the renal medulla 
is particularly vulnerable to even minor reductions in oxygen delivery.
3, 5-10 Risk of peri-
operative renal injury is further exacerbated in infants due to immature auto-regulatory 
function  and  reduced  renal  blood  flow. 
5,  7,  8  Current  evidence  suggests  that  a  low 
haematocrit level (<25%) during CPB is associated with post-operative renal dysfunction, 
low cardiac output syndrome, lower psychomotor scores and mortality. 
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mean haematocrit levels of 23.75% in this study only lowest pump flow during CPB was 
significantly linked with post-operative renal impairment as defined by cystatin C. This 
may imply that intra-operative oxygen delivery, which is dependent on both pump flow 
and  haematocrit,  is  of  greatest  overall  importance  in  preserving  post-operative  organ 
function.  The significance of oxygen delivery was however not readily apparent in our 
study  suggesting  either  that  renal-specific  oxygen  delivery  was  maintained  or  oxygen 
extraction  increased  during  CPB  or  that  a  ‘critical  threshold’  exists  within  the  renal 
parenchyma that has to be breached before notable damage occurs.  
 
Indeed Boston et al demonstrated an organ-specific hierarchical distribution of oxygen 
delivery during CPB in pigs with oxygen delivery to muscle and visceral organs sacrificed 
to  maintain  the  brain  and  kidneys.  It  was  not  until  pump  flow  dropped  to  less  than 
1.4L/min/m
2 that a significant reduction in oxygen delivery to the kidneys was observed. 
24 
Interestingly  in  this  study  a  mean  lowest  pump  flow  of  2.2L/min/m
2  during  CPB
  was 
significantly associated with acute post-operative renal dysfunction. Evidence of a dysoxic 
threshold exists in adult critical care patients in whom an oxygen delivery of less than 
325ml/min/m
2 results in anaerobic metabolism, lactic acidosis and eventual multi-organ 
dysfunction. 
3, 25 This concept is further supported in this study where an oxygen delivery 
of  less  than  300ml/min/m
2  became  significantly  associated  with  post-operative  renal 
impairment.  In addition, ROC analyses demonstrated that a cut-off value of 242ml/min/m
2 
exhibited a 72% sensitivity and 100% specificity for detecting renal dysfunction, defined 
as  a  GFR  <55ml/min/1.73m
2.  This  value  is  within  the  range  quoted  in  similar  studies 
involving adult CPB. 
3, 25 Our data therefore defends the hypothesis of an ischaemic insult 
ultimately being responsible for early renal dysfunction after paediatric cardiac surgery 
emphasising  the  need  for  improved  categorisation  and  optimisation  of  perfusion 
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3.7  Study Limitations 
Blood lactate measurements were not recorded peri-operatively in this study and we are 
therefore unable to demonstrate that patients with critical oxygen delivery developed an 
increased  lactic  acidosis.  The  relationship  between  haematocrit  on  CPB,  related  blood 
transfusion and post-operative renal dysfunction was not explored. The incidence of ‘low 
cardiac output syndrome’ which is a recognised cause of post-operative renal dysfunction 
in this patient group was not investigated in this study. 
 
3.8  Conclusion 
This study has shown that in comparison to serum creatinine, cystatin C provides a better 
estimate  of  GFR  in  children  immediately  after  corrective  cardiac  surgery.  Early  post-
operative renal impairment is independently predicted by ischaemia-reperfusion times and 
the  degree  of  myocardial  injury  measured  by  Troponin-I.  Oxygen  delivery  may  be  an 
important consideration for the future development of perfusion parameters. 
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CHAPTER 4: PULMONARY FUNCTION 
 
4.1   Abstract 
 
4.1.1  Background 
To investigate the acute effects of pre-operative sildenafil on haemodynamics, oxygenation 
and  cyclic-guanosine-monophosphate  (cGMP)  levels  in  children  at  risk  of  pulmonary 
hypertension after cardiac surgery. 
 
4.1.2  Methods 
24  children  (median  age,  0.4  years)  undergoing  repair  of  VSD-type  congenital  heart 
disease were randomized to oral sildenafil (0.5mg/kg) or placebo 6hrly the day before 
surgery.  Blood  samples  were  collected  peri-operatively  to  determine  cGMP  and  NO 
production. Haemodynamic and echocardiography data were acquired at 2 and 24 hours 
post-operatively:  (1)  Mean  pulmonary  artery  and  left  atrial  pressures  (2)  Pulmonary 
vascular  resistance  index  (PVRI)  =  transpulmonary  gradient/pulmonary  blood  flow  on 
spectral  Doppler  and  (3)  Bi-ventricular  systolic  tissue  Doppler  (TDI)  velocities  (SaLV, 
SaRV).  Post-operative  oxygenation  was  assessed  by  oxygen  delivery  (DO2)  and 
oxygenation index (OI) in PICU and on day-1.  
 
4.1.3  Results 
cGMP (pmol/ml) levels and NO (µM, total nitrate/nitrite) production trended higher in the 
sildenafil group (149.50 (0.5-344.80) vs. 19.30 (0-457.60), p=0.47; 0.70 (0-142.80) vs. 
0.00 (0-52.70), p=0.62) whilst PVRI (WU.m
2) remained unchanged at 2 (2.67±0.91 vs. 
2.07±1.98, p=0.43) and 24 hours (2.64±2.28 vs. 1.9±1.12, p=0.43) post-operatively. Bi-
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group both pre- (SaLV 3.78±0.94 vs. 4.55±1.08; SaRV 6.93±1.47 vs. 8.09±2.25, p=0.002) 
and  post-operatively  (SaLV  2.54±1.74  vs.  3.29±1.16;  SaRV  2.32±0.77  vs.  3.20±1.53, 
p=0.002).  Post-operative  DO2  (ml/min/m
2)  was  significantly  reduced  in  the  sildenafil 
group  (57.18±21.24  vs.  74.13±35.46,  p=0.04)  with  OI  trending  higher  (5.29±4.60  vs. 
3.38±2.54, p=0.26). 
 
4.1.4  Conclusion 
This study identified that pre-operatively administered sildenafil produced a modest but 
not significant increase in cGMP and NO production without effect on pulmonary vascular 
resistance.   Sildenafil  was  associated  with  reduced  ventricular  contractility  and  post-
operative oxygenation.  
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4.2  Introduction 
 
In children with ventricular septal defect physiology excessive pulmonary blood flow, at 
systemic pressures, can adversely affect the pulmonary endothelium evident as increased 
pulmonary vascular resistance (PVR) and episodes of pulmonary hypertension (PHT). 
1-3 
Pulmonary  endothelial  dysfunction  (PED)  can  be  further  exacerbated  by  subsequent 
cardiopulmonary  bypass  (CPB)  required  for  repair  by  several  mechanisms  including 
cytokine activation and ischaemia-reperfusion injury. 
1 Post-operatively, these children can 
demonstrate  an  increased  pulmonary  vascular  reactivity  with  acute  elevations  in  PVR 
initiating  a  cycle  of  right  ventricular  failure  and    reduced  cardiac  output.  Increased 
pulmonary  capillary  permeability  augments  the  alveolar-arterial  oxygen  gradient  with 
reduced  lung  compliance  and  decreased  systemic  oxygenation.  This  often  results  in 
prolonged  ventilation  and  intensive  care  stay,  that  correlates  with  the  degree  of  PVR 
reversibility.
 1-3 
 
In the normal lung, nitric oxide (NO) is produced by the endothelium to regulate vessel 
tone, blood flow and optimise ventilation-perfusion coupling. PED can be defined as a 
failure of the pulmonary endothelium to produce adequate amounts of NO with a loss of 
vascular homeostasis. 
2,  3 NO acts through a secondary messenger, intracellular cyclic-
guanosine-monophosphate (cGMP), to vasodilate pulmonary blood vessels and is finally 
oxidised  to  form  nitrate  and  nitrite. 
2,  4  cGMP  is  metabolized  by  phosphodiesterase-5 
(PDE-5)  which  is  the  predominant  phosphodiesterase  in  normal  lung  and  may  be  up 
regulated in patients with PED.
 2, 4, 5 
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Currently post-operative PED related complications, including PHT, are managed by the 
administration of inhaled NO (iNO). Although this has proved to be clinically effective, 
significant  disadvantages  do  exist  with  some  patients  failing  to  respond  and  others 
developing  life-threatening  PHT  upon  withdrawal.
  6,7  Recently  oral  sildenafil  citrate 
(Pfizer, Sandwich, Kent, UK), a potent PDE-5 inhibitor that prevents the breakdown of 
cGMP, has been shown to be as effective as iNO in treating PHT.
 8, 9 Oral sildenafil is now 
an established treatment for chronic PHT in children and is considered effective when 
given at therapeutic doses (0.5-2.0mg/kg; 4hrly). 
10  
 
To date the consequences of oral sildenafil given pre-operatively to children undergoing 
corrective cardiac surgery has not been evaluated. We hypothesised that the administration 
of sildenafil prior to surgery would augment pulmonary cGMP levels attenuating CPB-
induced post-operative endothelial dysfunction and the clinical consequences that ensue. A 
prospective,  randomized,  placebo-controlled,  double-blind  trial  was  performed  to 
determine whether pre-operative oral sildenafil supplementation produces: (1) an effect on 
NO production and plasma cGMP (2) a reduction in PVR index and pulmonary artery 
pressure  (3)  an  effect  on  cardiac  contractility  (4)  an  effect  on  ventilation  and  oxygen 
delivery and (5) clinical outcome including adverse events. 
 
4.3  Methods 
 
4.3.1  Patients 
Study approval was obtained from local ethics committee (R&D no. 05/CH/01) and UK 
Medicines and Healthcare products Regulatory Agency (EudraCT No. 2005-001034-32). 
Eligible patients were children over 3 months of age with either ventricular or complete 
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Parental  consent  was  obtained.  All  children  underwent  elective  surgery  using  standard 
techniques of CPB and blood cardioplegia.  
 
4.3.2  Study Protocol 
Following  admission  patients  were  randomised  to  either  placebo  or  sildenafil  by  the 
clinical trials pharmacist using a computer-based stratified minimisation algorithm based 
on  sex,  cardiac  diagnosis  and  the  presence  or  absence  of  Down’s  syndrome  (Minim, 
available  at  www.sghms.ac.uk/depts/phs/guide/randser.htm). 
11  All    clinicians  and  the 
child’s parents were blinded to the treatment allocation. 
 
Sildenafil (2.5mg/ml) and placebo suspensions (Ora Plus suspending vehicle, Ora sweet 
syrup +/- sildenafil) were prepared by the hospital pharmacy. Oral sildenafil (0.5mg/kg) or 
equivalent volume placebo was administered by the clinical trials pharmacist 6hrly the day 
before surgery. Patients were monitored pre-operatively on the ward and post-operatively 
in  intensive  care  (PICU).  Compliance  and  adverse  events  (systemic  hypotension,  post 
administration reactions etc.) were reported and monitored by the clinical trials pharmacist. 
 
4.3.3  Data Collection 
Patients returned to PICU after surgery and were sedated (morphine and/or midazolam), 
ventilated and haemodynamically stabilised with dopamine infusion. Residual intracardiac 
shunt  or  significant  atrioventricular  valve  regurgitation  was  excluded  through  intra-
operative  epicardial  and  post-operative  transthoracic  echocardiography.  All  other 
intravenous  NO-donors,  PDE  inhibitors  and  iNO  were  avoided.  Data  collection  was 
deferred  for  2  hours  following  admission  to  PICU  to  allow  for  rewarming,  tracheal 
suctioning,  adjustments  to  sedation  and  inotropic  support.  Mean  arterial  (MAP)  and 
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Inotrope scores and blood lactate levels were documented in all patients at 2 and 24 hours 
post-operatively. 
12 Arterial blood gas analysis was undertaken before any data collection 
to allow optimisation of ventilation and correction of acidosis. 
12 Echocardiography and 
haemodynamic data collection were carried out at 2 and 24 hours post-operatively under 
standardised conditions (ventilated with an inspired oxygen fraction (FiO2) of 0.65) to 
avoid variation in pulmonary vascular tone. 
1, 2  
 
4.3.4  Blood samples 
2mls of blood were aspirated directly from the LA and main PA before (post-heparin) and 
after CPB (pre-protamine). Samples were aliquoted and stored (-70
oC) until laboratory 
analysis. cGMP levels were measured using a commercially available competitive enzyme 
immunoassay  (R&D  Systems,  Abingdon,  UK)  with  a  calibration  range  of  0.56 –  3.06 
pmol/ml.  Nitrate  and  nitrite  levels  were  measured  using  a  commercially  available 
colorimetric assay kit (BioScience Ltd, Cambridge, UK) with a detection limit of 2.0 µM.  
 
4.3.5  Echocardiography 
All patients underwent transthoracic echocardiography using a Vivid 7 ultrasound scanner 
(GE Vingmed, Horten, Norway) with a 7-MHz probe by the same, experienced paediatric 
echocardiographer (1) pre-operatively, on table under anaesthesia (2) 2hrs and (3) 24hrs 
post-operatively. A cine loop of at least three consecutive cardiac cycles was recorded and 
stored digitally for later off-line analysis (Echopac, GE Vingmed). All echocardiographic 
measurements were repeated 3 times and then averaged. 
 
4.3.5.1  Estimated aortic and pulmonary outflow (L/min/m
2) 
Pulsed Doppler 2D echocardiography was used to estimate aortic (QS) and pulmonary (QP) 
outflow  according  to  the  formula:  Q  =  (Stroke  VolumeDoppler  x  heart  rate).  Doppler-End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 91 of 192 
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estimated stroke volume was determined using the velocity time integral of ﬂow through 
the left or right ventricular outﬂow tract x aortic or pulmonary annular cross-sectional area 
respectively. Both annuli were measured immediately proximal to the point of insertion of 
valve leaflets at maximal systolic leaflet separation (inner diameter).
13 
 
4.3.5.2  Post-operative PVRI (Wu.m
2) 
Transpulmonary gradient (mean PA - LA pressure measured from respective monitoring 
lines  placed  in  theatre  as  per  study  protocol)  and  estimated  pulmonary  blood  flow  on 
spectral Doppler were used to derive PVR from the equation: PVR = (transpulmonary 
gradient / pulmonary blood flow) which was then indexed to body surface area (PVR x 
BSA). 
12 
 
4.3.5.3  Tissue Doppler Imaging (TDI) 
Peak myocardial velocities (Sa) were recorded from basal septum (SaS) and lateral free 
walls of both ventricles immediately below (0.5cm) the insertion of the mural leaflet of the 
left  (SaMV)  and  right  (SaTV)  AV  valves.  RV  (IVARV)  and  LV  (IVALV)  isovolumic 
acceleration  was  calculated  for  respective  ventricles  by  dividing  the  peak  isovolumic 
velocity  by  the  time  interval  from  baseline  to  peak  isovolumic  velocity  as  previously 
described. 
14  
 
4.3.6  Post-operative Oxygenation 
Oxygen  delivery  (DO2)  at  2  and  24hrs  post-operatively  was  calculated  using  Doppler 
derived systemic CO (QS) and arterial oxygen content according to the equation: DO2 = Qs 
x [Hb x 1.34 x Hb saturation + 0.003 x PaO2 (mmHg)]. Oxygenation index (OI) was 
calculated at the same time using: ventilator mean airway pressure (cm H2O) x 100 x FiO2 
/ PaO2 (mmHg). The period of ventilation (hrs) and length of stay in PICU (hrs) were 
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4.4  Statistical Analysis 
The Anderson-Darling test assessed normality. Descriptive statistics are reported as means 
and standard deviations or medians and ranges according to distribution of data. Two-
sample  t-tests  were  used  for  between  group  comparisons  in  normally  distributed  data, 
otherwise Mann-Whitney tests were performed. A nested general linear model was used to 
examine the effects of drug and time on each outcome variable. If significant, post-hoc 
tests with Bonferroni correction were applied to quantify the effect. All analyses were 
performed  using  Minitab  (version  15,  Minitab  Ltd,  Coventry,  Warwickshire,  UK)  at  a 
significance level of 5%. 
 
The power calculation for this study was based on data published by Schulze-Neick et al.
 
where a mean PVRI of 8.32 Wu.m
2 and standard deviation of 3.464 was observed post-
cardiac surgery. 
2 A sample size of 12 patients in each group would have a power of 80% 
to  detect  a  minimum  difference  in  PVRI  of  4.14  WUm
2  between  oral  sildenafil  and 
placebo groups (nQuery, version 5.0, Statistical Solutions Ltd, Cork, Ireland). 
 
4.5  Results 
 
4.5.1  Patients 
Twenty-eight children were prospectively recruited into the trial at the Royal Hospital for 
Sick  Children,  Yorkhill  Division,  Glasgow,  UK  from  June  2006  to  January  2008.  4 
children were excluded following theatre cancellation leaving a total of 24 patients (age 
0.26  to  2.26  years,  median  0.4  years;  mean  weight  5.6kg)  who  completed  the  trial  as 
depicted in Figure 1. Demographic characteristics of the two groups are summarised in 
Table 1. 
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4.5.1.1   Figure 1. Trial Profile 
 
 
4.5.1.2   Table 1. Demographic characteristics between groups 
 
    Sildenafil 
(n = 11) 
  Placebo 
(n = 13) 
  P-value 
Patient factors  Gender (male)  5 (45%)    7 (54%)    0.681 
  Age (years)  0.62 ± 0.57
    0.42 ± 0.17
    0.286 
  Weight (kg)  5.6 ± 1.3
    5.7 ± 2.0
    0.884 
  Trisomy 21 present  6 (55%)    6 (46%)    0.681 
             
Diagnosis  AVSD  4 (36%)    7 (54%)    0.444 
  VSD  7 (64%)    6 (46%)    0.383 
             
Operative factors  XC (mins)  75.1 ± 45.0    77.5 ± 36.9
    0.889 
  BP (mins)  126.7 ± 60.9    122.8 ± 46.7
    0.864 
  Ventilation (hrs)  93.2 ± 126.0
    82.5 ± 56.6
    0.799 
  PICU stay (hrs)  128.3 ± 159.2
    125.7 ± 75.4
    0.961 
 
Data expressed as mean ± SD. 
AVSD, atrio-ventricular septal defect; VSD, ventricular septal defect; XC, cross-clamp 
time; BP, bypass time; PICU, paediatric intensive care unit  End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 94 of 192 
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4.5.2  Adverse Events 
 
There  were  no  post-administration  drug  reactions  and  no  mortality;  all  patients  were 
discharged  home  without  significant  complication.  No  significant  difference  in  MAP 
(mmHg) existed between sildenafil and placebo groups post-operatively (58.53±3.92 vs. 
57.49±1.65, p=0.15). 
 
4.5.3  Plasma cGMP levels (pmol/ml) 
Compared  to  placebo,  pre-operative  cGMP  levels  sampled  from  the  LA  and  PA  were 
higher in the sildenafil group (LA: 29.9 (0.5-391.5) vs. 5.2 (0-628.9), p=0.44 and PA: 8.7 
(1.1-150.5) vs. 2.6 (0.0-224.9), p=0.32). cGMP levels were also greater in the sildenafil 
group  post-operatively  on  admission  to  PICU  (149.5  (0.5-344.8)  vs.  19.3  (0-457.6), 
p=0.47). Overall 0.5mg/kg of oral, pre-operative sildenafil given 4 times the day before 
surgery  raised  peri-operative  plasma  cGMP  but  did  not  reach  statistical  significance 
(Figure 2). 
 
4.5.3.1   Figure 2. Plasma cGMP levels 
(PICU sample acquired during routine venous blood sampling) 
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4.5.4  Plasma Nitrate / Nitrite Levels (µM) 
NO breakdown products, within LA, trended higher following CPB in the sildenafil group 
(pre-CPB vs. post-CPB: 0.0 (0-1.0) vs. 0.7 (0-142.8), p=0.057) compared to placebo group 
which  remained  similar  (pre-CPB  vs.  post-CPB:  0.1  (0-41.4)  vs.  0.0  (0-52.7),  p=0.80) 
(Table 2). 
 
4.5.4.1   Table 2. Plasma nitrite / nitrate levels 
 
Total plasma nitrite / nitrate levels (µM)  Group  Time  Sample 
Mean  StDev  Min  Median  Max 
LA  3.95  11.34  0.00  0.09  41.39  Pre-CPB 
PA  2.36  6.55  0.00  0.00  23.70 
             
LA  5.49  14.34  0.00  0.00  52.73  Post-CPB 
PA  1.64  2.87  0.00  0.00  10.42 
Placebo 
             
LA  0.09  0.30  0.00  0.00  1.00 
Pre-CPB 
PA  0.23  0.75  0.00  0.00  2.47 
             
LA  20.5  44.7  0.00  0.70  142.80 
Sildenafil 
Post-CPB 
PA  6.37  17.31  0.00  0.73  58.37 
 
 
4.5.5  Echocardiography  
 
4.5.5.1  Estimated pulmonary and aortic outflow (L/min/m
2)  
Pre-operative  Qp:Qs  shunt  fraction  was  similar  between  sildenafil  and  placebo  groups 
(10.49:4.28  vs.  13.23:4.36,  p=0.20)  (Figure  3a).  Doppler  derived  cardiac  index  was 
significantly reduced in the sildenafil group compared to control post-operatively in PICU 
(4.78±1.70 vs. 3.62±1.21, p<0.001) and day-1 (4.83±1.71 vs. 4.16±1.71, p<0.001). End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 96 of 192 
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4.5.5.1.1   Figure 3a. Pre-operative aortic and pulmonary outflow 
 
 
 
 
4.5.5.2  PVRI (Wu.m
2) 
Post-operatively, no significant alteration in PVRI was demonstrated in sildenafil patients 
at 2 (2.67±0.91 vs. 2.07±1.98) and 24 hours (2.64±2.28 vs. 1.90±1.12) (Figure 3b). Mean 
PA  pressure  (mmHg)  in  sildenafil  and  placebo  groups  was  similar  post-operatively 
(20.72±1.09 vs. 19.88±0.84, p=0.30). 
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4.5.5.2.1   Figure 3b. Post-operative PVRI 
 
 
4.5.5.3  TDI 
LV, RV and septal peak systolic velocities and biventricular isovolumic acceleration were 
all  significantly  reduced  in  both  groups  in  the  immediate  post-operative  period.  All 
velocities  trended  towards  recovery  by  day-1,  particularly  in  the  LV.  Pre-  and  post-
operative  bi-ventricular  and  septal  systolic  function  were  significantly  reduced  in  the 
sildenafil group compared to placebo and this persisted onto day-1 (Figure 4a, b; Table 3). 
RV and  LV isovolumic accelerations were also lower in the sildenafil group but this did 
not reach statistical significance (Table 4). 
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4.5.5.3.1   Figure 4a. LV systolic function 
 
4.5.5.3.2   Figure 4b. RV systolic function 
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4.5.5.3.3   Table 3. Peri-operative TDI peak systolic velocities 
Peak Systolic Myocardial Velocity (cm/sec)  Group  Variable  Time 
Mean  StDev  Min  Median  Max 
LV  PreOp  4.55  1.08  3.07  4.47  6.24 
  PICU  3.29  1.16  2.03  2.96  6.44 
  Day-1  3.95  1.60  1.87  3.28  7.33 
             
RV  PreOp  8.09  2.25  4.95  7.95  13.55 
  PICU  3.20  1.53  1.12  2.69  6.74 
  Day-1  3.35  1.38  1.56  2.99  5.99 
             
Septum  PreOp  4.70  1.03  2.39  4.86  5.8 
  PICU  2.30  1.13  0.83  2.09  4.53 
Placebo 
  Day-1  2.61  1.26  0.97  2.45  4.65 
               
LV  PreOp  3.78  0.94  2.36  3.70  5.16 
  PICU  2.54  1.74  1.05  1.97  6.67 
  Day-1  3.10  0.83  1.76  3.33  4.40 
             
RV  PreOp  6.93  1.47  4.87  6.77  9.86 
  PICU  2.32  0.77  1.61  1.93  3.98 
  Day-1  2.06  0.75  0.95  2.00  3.60 
             
Septum  PreOp  3.91  0.69  2.96  3.85  4.97 
  PICU  1.56  1.11  0.80  1.065  4.39 
Sildenafil 
  Day-1  2.09  0.98  0.55  2.00  3.66 
 
 
4.5.5.3.4   Table 4. Peri-operative TDI isovolumic acceleration 
Isovolumic Myocardial Acceleration (cm/sec
2)  Group  Variable  Time 
Mean  StDev  Min  Median  Max 
LV  PreOp  154.47  89.06  50.93  126.37  309.18 
  PICU  71.00  21.68  41.95  69.85  101.67 
  Day-1  101.84  61.89  42.04  94.47  259.64 
             
RV  PreOp  309.55  107.74  177.34  282.44  527.17 
  PICU  133.50  55.75  50.33  132.63  227.92 
Placebo 
  Day-1  103.92  53.28  42.49  97.70  200.19 
               
LV  PreOp  162.73  51.83  82.33  157.77  265.40 
  PICU  64.40  14.54  46.01  68.51  79.46 
  Day-1  90.71  37.18  51.83  84.48  158.5 
             
RV  PreOp  303.88  84.16  187.66  290.12  489.43 
  PICU  116.66  59.20  63.78  108.22  229.82 
Sildenafil 
  Day-1  135.07  69.45  55.92  117.07  290.70 
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4.5.6  Inotrope Scores 
No significant difference in inotrope score existed between sildenafil and placebo patients 
at 2 (5.73±5.12 vs. 5.15±4.36, p=0.884) and 24 (5.55±4.61 vs. 5.62±5.59, p=0.884) hours 
post-operatively. 
  
4.5.7  Post-operative oxygenation 
OI trended higher in the sildenafil group compared with control on admission to PICU 
(5.3±4.6 vs. 3.4±2.5) with further increases in both groups on day-1 (5.7±4.3 vs. 4.8±3.4, 
Figure 4c). DO2 (ml/min/m
2) was significantly reduced in the sildenafil group compared 
with  control  on  admission  to  PICU  (57.18±21.24  vs.  74.13±35.46)  and  on  to  day-1 
(56.98±23.64  vs.  72.13±33.00,  Figure  4d)  (Table  5).  No  significant  differences  in 
ventilation time (hrs) or PICU stay (hrs) were found between sildenafil and placebo groups 
(Table 1). Subgroup analysis of T21 patients demonstrated no significant differences in 
post-operative OI (p=0.09), DO2 (0.07), ventilation time (p=0.07) or PICU stay (p=0.141). 
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4.5.7.1   Figure 4c. Peri-operative Oxygenation Index 
 
 
4.5.7.2   Figure 4d. Post-operative Oxygen Delivery 
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4.5.7.3   Table 5. PaO2 values at 2 and 24 hours post-operatively 
 
 
 
 
 
 
 
 
 
 
4.5.8  Lactate 
No significant differences were seen in blood lactate levels (mmol/L) between sildenafil 
and  placebo  patients  at  2  (1.1±0.2  vs.  1.2±0.4,  p=0.307)  and  24  (1.2±0.3  vs.  1.1±0.3, 
p=0.307) hours post-operatively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PaO2 (mmHg)  Group  Time 
Mean  StDev  Min  Median  Max 
2 hrs  178.17  59.03  90.00  179.25  321.00  Placebo 
24 hrs  93.41  25.88  32.25  100.50  126.00 
             
2 hrs  142.57  49.34  71.25  141.00  221.60 
Sildenafil 
24 hrs  91.53  28.61  54.75  86.13  135.00 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 103 of 192 
 
Tony Vassalos   2010 
4.6  Discussion 
 
In children with congenital heart disease post-operative pulmonary endothelial dysfunction 
and pulmonary hypertension continue to be an important cause of morbidity, prolonged 
PICU stay and in severe cases mortality.
1-5 The purpose of this study was to investigate 
whether  administrating  sildenafil  prior  to  paediatric  cardiac  surgery  mitigates  clinical 
consequences of post-operative pulmonary endothelial dysfunction by maintaining cGMP 
levels.  Our  principal  findings  were  that  pre-operative  sildenafil  dosing  resulted  in:  (1) 
modest elevations in plasma cGMP levels both pre- and post- CPB but this did not reach 
statistical significance (2) increased post-CPB NO production (3) no significant effects on 
post-operative PVRI (4) a significant reduction in peri-operative bi-ventricular contractility 
and (5) a significant reduction in post-operative oxygen delivery. 
 
Although children with VSD or AVSD operated on at 6 months of age or less are unlikely 
to  demonstrate  classical  clinical  pulmonary  hypertensive  crises  post-operatively  the 
clinical  consequences  of  pulmonary  endothelial  dysfunction  are  commonplace. 
1  The 
endothelial  injury  following  CPB  is  primarily  related  to  ischaemia-reperfusion  and 
cytokine  activation  characterized  by  capillary  permeability  leading  to  decreased 
oxygenation manifest as increased alveolar-arterial oxygen gradient and decreased lung 
compliance. 
1-3, 5, 15 The pulmonary endothelium plays an important role in vasomotor tone, 
inhibiting platelet aggregation and neutrophil adhesion through the release of vasoactive 
factors  including  NO. 
5,  9,  16  CPB  results  in  PDE-5  over  activity,  activation  of  NO 
antagonists,  reduction  in  NO  precursors  and  production  of  vasoconstrictive  factors. 
1-4 
Ultimately this can increase right ventricular afterload, adversely affecting right ventricular 
function and increasing the duration of ventilation. 
1 Many centers will now liberally use 
iNO and sildenafil in the post-operative setting to manage these complications.  
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Sildenafil  is  a  potent  and  selective  inhibitor  of  3’5’-cGMP-specific  PDE-5  with 
substantially lower affinity for the other PDE isoenzymes. Tissue distribution of PDE-5 
and  hence  site  of  action  of  sildenafil  is  well  defined  (corpus  cavernosum,  pulmonary 
vasculature, platelets, skeletal and visceral muscle). Sildenafil is rapidly absorbed orally 
with  an  absolute  bioavailability  of  40%.  It  undergoes  hepatic  metabolism  with  an 
elimination half-life of 3 to 5 hours. 
17, 18 Children in the active arm of our study received 
0.5mg/kg of oral sildenafil 6hrly, the day before surgery. This dose was based on our own 
clinical  experience  and  current  best  available  evidence  that  (0.025-0.66mg/kg)  of 
intravenous sildenafil and (0.25-1mg/kg; 6hrly) of oral sildenafil, safely and significantly 
reduces PHT in this patient group. 
2, 15, 16, 19 
 
In this study the direct effect of sildenafil on pulmonary endothelial function was assessed 
by measuring plasma cGMP and NO production via its breakdown products nitrates and 
nitrites. Our study demonstrated that although sildenafil increased cGMP levels both pre- 
and  post-  bypass,  the  effect  was  modest  and  variable  between  patients.  The  effects  of 
sildenafil on plasma cGMP levels is not widely reported particularly in relation to peri-
operative  paediatric  cardiac  surgery.  Atz  et  al  demonstrated  that  rebound  pulmonary 
hypertension on withdrawal of iNO following paediatric cardiac surgery was attenuated by 
sildenafil. In their study, post-operative oral sildenafil (0.33mg/kg), in association with 
iNO,  resulted  in  cGMP  levels  of  up  to  45  pmol/ml. 
7  Sildenafil  infusions  used  pre-
operatively by Schulze-Neick et al produced a non-significant increase in plasma cGMP 
(44±18 pmol/ml) associated with significant reductions in PVRI. 
2  
 
In  this  study  NO  products  inclined  to  be  higher  post-CPB  in  the  sildenafil  group, 
suggesting a greater capacity of the pulmonary endothelium in these patients to respond to 
the  CPB  mediated  injury. 
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products tended to be higher in the placebo group pre-CPB. It is possible that increased 
cGMP levels induced by sildenafil in the treatment group down-regulated NO production 
pre-CPB. Again, in a similar  pattern to cGMP, there was considerable variation amongst 
sildenafil treated patients and the NO response. These findings support the conclusion that 
sildenafil  administered  at  0.5mg/kg  was  associated  with  a  biological  effect  at  the 
pulmonary endothelial level.   
 
Despite trends in the sildenafil group, to higher cGMP levels pre-CPB (108 pmol/ml) and 
increased NO production post-CPB no significant haemodynamic effect on PVRI or post-
operative PA pressure was apparent. The reasons for this are likely to be multi-factorial. 
The majority of children recruited to the trial were under 6 months and therefore at low 
risk for post-operative PHT crises. Furthermore, none of the children recruited to the trial 
had pre-existing PHT by echo criteria (bi-directional flow at VSD). It is possible that in a 
more at-risk group (longstanding VSD with pre-operative PHT) sildenafil may have had a 
significant impact on PA pressures and PVRI. Alternatively, larger doses of oral sildenafil 
may have been required pre-operatively to produce a measureable pulmonary vasodilatory 
effect. Intra-individual variations in the response to oral sildenafil have been demonstrated 
in some patients with persistently high PVR despite increasing vasodilator therapy. 
15 This 
supports our findings of patient variation in cGMP and NO production in the sildenafil 
group. However, it should be noted that other studies with a similar patient cohort have 
demonstrated reductions in PVR with sildenafil administrated during the post-operative 
phase. 
1, 2, 15  
 
An  important  finding  of  this  study  was  that  bi-ventricular  systolic  function  was 
significantly reduced in the sildenafil group compared to placebo. This contractile change 
was measured using tissue Doppler peak systolic velocities, which are limited by their End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 106 of 192 
 
Tony Vassalos   2010 
load-dependant;  right  ventricular  velocities  could  be  reduced  by  acute  elevations  in 
afterload. 
14,  20,  21  However,  this  mechanism  is  not  supported  by  the  study  findings  of 
similar  post-operative  PA  pressures  between  groups.  Furthermore  the  velocities  were 
reduced in all myocardial areas measured. Post-operatively, this was associated with a 
significant  reduction  in  cardiac  index  in  the  sildenafil  group  which  also  impacted  on 
oxygen delivery. To our knowledge such a negative inotropic effect has not been described 
in  any  clinical  studies  although  transient  falls  in  systemic  blood  pressure  are  widely 
reported.  One  possible  explanation  for  the  impaired  contractility  demonstrated  in  the 
sildenafil  group  could  have  been  an  increase  in  intra-cardiac  shunting  and  subsequent 
volume loading through reduced PVR. However the Qp:Qs derived by spectral Doppler, 
on-table  immediately  prior  to  surgery,  did  not  indicate  an  increased  shunt  volume  in 
sildenafil group compared with placebo.  
 
Experimental  models  of  isolated  cardiomyocytes,  perfused  rodent  hearts  and  human 
studies  of  normal  and  heart  failure  patients  at  the  time  of  cardiac  catheterisation  have 
shown  that  elevated  levels  of  cGMP  (produced  through  iNO  or  oral  sildenafil)  can 
suppress contractility by decreasing myocardial calcium sensitivity, cAMP inhibition and 
blunting the contractile response to adrenergic stimulation.
 17, 22-24 We propose that this is 
relevant  in  the  context  of  paediatric  cardiac  surgery  where  myocardial  contraction  is 
modulated by endogenous and exogenous catecholamine stimuli and may explain why pre-
operative sildenafil inhibits peri-operative contractility in this patient group. Ultimately, 
the reduced contractility seen in the sildenafil group was not clinically apparent in terms of 
increased inotrope usage, ventilation time or intensive care stay.  
 
In this study the pre-operative administration of oral sildenafil resulted in a significant 
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increasing post-operative oxygenation index and significant reduction in oxygen delivery 
from admission to PICU. In contrast to iNO which is selectively delivered to ventilating 
areas of the lung, the systemic administration of sildenafil acts throughout the pulmonary 
vasculature with resulting dose-dependent increase in ventilation-perfusion mismatch seen 
in both human and animal studies. 
1, 2, 15, 25 Stocker et al showed that intravenous sildenafil 
(0.35mg/kg) resulted in a significant decrease in PaO2 post-operatively associated with 
increased oxygenation index and alveolar-arterial gradient. 
15 Crucially these deleterious 
effects  on  oxygenation  were  not  reversed  by  iNO  and  the  trial  was  terminated  early. 
Similarly Schulze-Neick et al demonstrated significant dose-dependent increases in intra-
pulmonary shunt ratio during sildenafil infusion in children following corrective cardiac 
surgery. 
2 Kleinsasser et al investigated the dose dependent effects of oral sildenafil (25-
100mg) on pulmonary function in anaesthetised and ventilated pigs. All doses of sildenafil 
caused significant increases in intrapulmonary shunt flow measured by inert gases and 
reflected through marked decreases in PaO2. 
25 This is further exacerbated by the acute lung 
injury, related to the systemic inflammatory response, that is associated with CPB. 
5 The 
effects on post-operative oxygenation were well tolerated in our stable group of study 
patients and were not associated with prolonged ventilation or PICU stay. However, in a 
group of children with higher ventilatory requirements or borderline pulmonary function a 
similar degree of impairment could have adverse effects. 
 
Certain  limitations  of  this  study  should  be  mentioned.  Intra-pulmonary  shunt  was  not 
measured  as  part  of  the  study  and  as  such  we  can  only  infer  this  probable  hypoxic 
mechanism.  Pre-operative  PVRI  was  also  not  measured  and  as  such  the  compounding 
effects  of  CPB  could  not  be  excluded  or  evaluated.  Peri-operative  plasma  sildenafil 
concentrations were not measured making it impossible to comment on the intra-individual 
variations in drug levels post-operatively and the effects if any of CPB. End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 108 of 192 
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4.7  Conclusion 
Oral sildenafil (0.5mg/kg) administered before elective cardiac surgery in children with 
VSD physiology resulted in modest elevations in plasma cGMP levels and post-operative 
NO  production  but  no  effect  on  pulmonary  haemodynamics  or  clinical  outcome. 
Significant  impairments  to  global  peri-operative  systolic  function  and  post-operative 
oxygenation would caution the use of pre-operative sildenafil. 
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CHAPTER 5: FINAL DISCUSSION 
 
The  aim  of  this  thesis  was  primarily  to  investigate  end  organ  effects  of  modern  day 
cardiopulmonary  bypass  in  children  with  common  congenital  heart  defects  undergoing 
elective  repair  utilising  cardiopulmonary  bypass.  End  organ  function  was  investigated 
through two prospective clinical trials which in turn examined the relationships between 
tissue  Doppler  imaging  and  myocardial  injury,  cystatin  C  and  renal  dysfunction  and 
sildenafil and pulmonary endothelial dysfunction.  
 
It  is  clear  from  Chapter  2  that  myocardial  dysfunction  is  commonplace  following 
paediatric cardiac surgery with some recovery of at least left ventricular function evident 
within twenty four hours after surgery. TDI appears to offer a sensitive, non-invasive, load-
independent, real time assessment of peri-operative myocardial function which until the 
completion  of  this  study  was  not  routinely  used  within  the  Department  of  Paediatric 
Cardiac Surgery, Yorkhill Hospital. Indeed there are very few studies published in the 
literature which characterise the typical pattern of change of these parameters within this 
patient population.  
 
Right ventricular dysfunction is often clinically difficult to treat and the unique ability of 
TDI to examine the longitudinal fibres predominating in this ventricle makes it a very 
attractive tool in this regard. This study has demonstrated that TDI parameters can be 
easily and reliably obtained within the paediatric population allowing the possibility for 
pre-operative risk stratification and earlier post-operative optimisation, further preventing 
additional  end  organ  effects  of  low  cardiac  output.  As  mentioned  previously  TDI 
parameters  were  not  analysed  beyond  the  first  post-operative  day  and  it  would  be 
interesting  to  see  when  and  if  bi-ventricular  systolic  function  returned  to  normal  pre-
operative  values.  With  the  advent  of  3D  echocardiography  absolute  and  derived  TDI End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 113 of 192 
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parameters are likely to play an important role in the assessment of myocardial function in 
children in the future. 
 
Despite  extensive  and  ongoing  research  in  the  prediction  and  treatment  of  acute  renal 
injury in the post-operative paediatric cardiac surgery population there has been limited 
success in altering patient outcomes. Wide ranging definitions of injury and the limited 
availability of reliable serum biomarkers further complicates this problem. Cystatin C is a 
novel biomarker which, as demonstrated in chapter 3 of this thesis, is a sensitive measure 
of early post-operative renal injury that may be in a position to play a pivotal role in the 
identification,  classification  and  customisation  of  treatment  therapies.  Moreover,  this 
research has shown that cystatin C is also predictive of other clinical outcomes including 
ventilation time and intensive care stay further enhancing its profile.  
 
This is one of the very few studies in the literature which has investigated the effectiveness 
of cystatin C in such a patient group and the findings are therefore clinically important. 
The independence of cystatin C of age, sex and mass is a key prerequisite of the paediatric 
population and immediately separates it from the most commonly used serum marker, 
creatinine. However, the assay used to measure cystatin C is relatively expensive and only 
available in specialised centres in the UK making it difficult for clinicians to routinely 
access at present. As a result, despite growing evidence the likelihood of this biomarker 
predominating within the clinical environment remains to be seen. 
 
When compared to medicine as a whole the specialty of paediatric cardiac surgery is still 
in its youth. However, 50 years have passed since the advent of cardiopulmonary bypass 
and still there are no defining guidelines regarding optimal perfusion. In chapter 3 of this 
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association with intra-operative perfusion-related factors of renal injury was investigated. 
The relative ease with which renal injury can be monitored makes it an attractive organ to 
assess perfusion. In keeping with the published literature this research demonstrated that an 
ischaemic  insult  was  the  most  likely  intra-operative  mechanism  responsible  for  post-
operative  renal  dysfunction.  A  critical  dysoxic  threshold  was  apparent  below  which 
significant injury occurred. Interestingly, oxygen delivery during cardiopulmonary bypass 
is not currently calculated, even though the individual variables of the equation are all 
noted  by  the  perfusionist,  and  furthermore  does  not  represent  a  parameter  by  which 
perfusion is altered. This is an important clinical consideration which can be drawn from 
this work and is currently being taken forward within the Department of Paediatric Cardiac 
Surgery at Yorkhill Hospital. Further work in this area would be merited in the form of a 
trial specifically designed to evaluate whether targeting a specific oxygen delivery during 
bypass improves outcome overall. 
 
In chapter 4 of this thesis the vicious circle of pulmonary hypertension, right ventricular 
failure and decreased oxygenation often seen post-operatively in children with high flow 
pulmonary physiology was investigated. The administration of pre-operative oral sildenafil 
to this patient group, particularly as a randomised clinical trial, has not been previously 
undertaken.  The  minimal  effect  of  pre-operative  sildenafil  on  pulmonary  vascular 
resistance seen in this study is not surprising when one considers that none of the children 
enrolled  in  the  trial  had  or  indeed  developed  post-operative  pulmonary  hypertension. 
However, some of the findings were both surprising and concerning with regards to peri-
operative ventricular function. Considering the relatively routine use of this drug within the 
paediatric intensive care environment the consistent reduction in peri-operative ventricular 
function demonstrated in our trial raises significant clinical concerns and future work in 
this area is needed to further clarify or refute these findings. One of the main limitations of End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 115 of 192 
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this  trial  was  that  intra-cardiac  shunt  was  not  formally  assessed  and  although  data 
regarding Doppler-derived pulmonary and systemic flows was available a sildenafil related 
increase in shunt as the cause of ventricular impairment was not conclusively exclude. 
 
In addition to the concerns raised regarding contractility pre-operative sildenafil was also 
associated  with  reduced  oxygen  delivery  and  a  trend  for  increasing  ventilatory 
requirements post-operatively. Although not formally analysed in this trial several other 
studies  have  demonstrated  the  association  between  systemic  sildenafil  therapy  and 
ventilation perfusion uncoupling. Furthermore the impact of the systemic inflammatory 
response,  to  the  process  of  cardiopulmonary  bypass,  on  pulmonary  function  was  not 
addressed in this chapter or as part of this thesis. This is an important limitation which 
should be factored into any further studies specifically addressing this issue. 
 
In conclusion this thesis has, through a prospective observational study and a randomised 
controlled  trial,  successfully  considered  some  key  issues  and  developments  in  the 
management  and  assessment  of  end  organ  dysfunction  commonly  seen  after  paediatric 
heart surgery. Several important contributions to clinical knowledge have been made with 
as many questions raised for future deliberation. 
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CHAPTER 6: APPENDICIES 
 
6.1   Prospective Observational Study  
6.1.1  Appendix 1: Local Research Ethics Committee Approval 
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6.1.2  Appendix 2: Data Entry Proforma 
 
 
  
 
 
 
PATIENT FACTORS 
1.  Age (Months)    5.  BSA (m
2)   
2.  Weight (Kg)    6.  WCC (Preop) 
 …./….   
3.  Height (cm)    7.  Admitted          /         / 
4.  Sex (M/F)    8.  Discharged         /         / 
 
 
 
PREOPERATIVE FACTORS 
  1.  Cardiac Diagnosis 
 
  2.  Non-Cardiac 
Diagnosis 
 
  3.  Cardiac Catheter 
(PAP/AO/PVR 
 PCWP/Qp:Qs)   
  4.  Signs / Symptoms 
(L > R Shunt) 
 
  5.  Medication 
 
6.  Aspirin / Warfarin / 
Sildenafil  
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OPERATIVE FACTORS  
1.  DATE  ….. / ….. / …..  7.  CPB Temp 
(minimum rectal)   
2.  XC time (mins)    8.  UF volume (mls)   
3.  BP time (mins)   
4.  Surgeon & 
Anaesthetist                                               / 
   
5. 
Inotropes 
(coming off)     
6. 
Aprotinin Regimen  L =   P =  M = 
 
 
 
 
RENAL OUTCOMES 
                       Postop Day    PreOp 
Day…  
…/… 
Th 
1
st 
12hrs 
Th 2
nd 
12hrs 
1 
.../... 
2 
…/.. 
3 
…/.. 
4 
…/.. 
5 
…/.. 
6 
…/.. 
7 
…/.. 
1. 
SCr (µmol/l) 
(18-40) 
                   
2.  CrCl (54-86) 
(ml/min/1.73m
2)                     
(Normal values in 
parenthesis) 
 
1hr  
 
2hrs 
 
3hrs 
 
4hrs 
 
5hrs 
 
Total Urine 
1
st 24hr 
Diuretics 
(Inf / 
Bolus) 
3.  Urine (mls)           
 
 
4.  Dopamine 
(µg/kg/min)                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timing 
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RESPIRATORY OUTCOMES 
  Post 
Intubation 
Post 
CPB 
2 hrs 
Postop 
4hrs 
Postop 
8am 
Day 1 
 
1. 
Oxygenation 
Index (OI)           
2. 
Dynamic Compliance  
(CL) (ml/cmH2O/kg)           
(Hrs)  3.  Mech. Ventilation  
(Days) 
Sildenafil 
(dose/days) 
(Hrs) 
4. 
Period in PICU  
(Days) 
Hospital  
Stay 
(days) 
 
 
 
Oxygenation Index: Mean airway pressure (cmH2O x 100 x FiO2 / PaO2 (mmHg)) 
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ECHOCARDIOGRAPHIC OUTCOMES 
 
Pre-Op  <1hr post return 
to PICU  Day 1 Post-Op 
1. 
LVEDD (mm) [23 +/- 3]       
LVESD (mm) [14 +/- 2]       
RVEDD (mm) [9-13]       
LV % FC [38.9 +/- 4.1]       
LV EF % [52-65] (1-18yr olds)       
M
-
m
o
d
e
 
[
m
e
a
n
 
+
/
-
 
S
D
]
  VP (cm/sec) [54.6 +/- 14] (2mn – 6yrs)       
2. 
Peak AO (LVOT) (cm/sec)  median 107.0
* [73-141]       
Peak PA (RVOT) (cm/sec) median 84.4
* [63.8-70.5]       
AO annular diameter [11-13mm]       
PA annular diameter [8.4 – 11.6mm] (up to 10kg)       
VTIPA (stroke distance cm) [heart rate] 
       
VTIAO (stroke distance cm) [heart rate] 
       
MV Peak E wave (cm/sec) [79.7 +/- 18.8]       
S
P
E
C
T
R
A
L
 
MV Peak A wave (cm/sec) [65.3 +/- 13.3]       
3. 
MV E/A Ratio [1.24 +/- 0.3]       
4. 
Regurgitation (L + R AV) (Y/N)         
5. 
Sa: Lateral Mitral (5.7 +/- 1.6) [5.3 – 6.1]       
Sa: Lateral Tricuspid (10.2 +/- 5.5) [8.8 – 11.7]             
Sa: Septum (5.4 +/- 1.2) [5.1 – 5.7]       
IVA (cm/sec
2) [248 +/- 35]       
Ea: Lateral Mitral (9.7 +/- 3.3) [8.8 – 10.5]       
Ea: Lateral Tricuspid (13.8 +/- 8.2) [11.7 – 15.9]       
Ea: Septum (8.1 +/- 2.5) [7.5-8.7]       
Aa: Lateral Mitral (5.7 +/- 1.8) [5.3 – 6.2]       
Aa: Lateral Tricuspid (9.8 +/- 2.4) [9.1 - 10.5]       
Aa: Septum (6.1 +/- 1.5) [5.7 – 6.4]       
T
D
I
 
c
m
/
s
e
c
 
 
(
m
e
a
n
 
+
/
-
 
S
D
)
 
 
[
9
5
%
 
C
I
]
  E/Ea Ratio (L AV valve) (8.8 +/- 2.7) [8.1 – 9.5]       
(Normal values in parenthesis) 
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Timing  1
st 24Hrs Post-Op    Pre-
op  <1 
Hr  4hr  8hr  12 
Hr 
16 
Hr 
20 
Hr 
24 
Hr 
             
1. 
TEMP (
OC) 
Periph / 
Core 
 
             
2.  INOTROPE 
Score                 
3.  LA pressure                 
 
 
 
HAEMATOLOGY OUTCOMES 
  1hr  
Post-op 
2hr 
Post-op 
3hr  
Post-op 
4hr 
Post-op 
5hr 
Post-op 
Total 1
st  
24 hrs     
1.  Chest Tube 
Drainage (ml)                 
  Intra-operatively  Post-operatively 
2.  PRC (units/ml)     
3.  FFP (units/ml)     
4.  Platelets  
(units/ml)     
5. 
Other: 
 
 
 
 
 
 
 
 
COMMENTS / COMPLICATIONS: 
- 
- 
- 
 
 
 
 
Test End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 123 of 192 
 
Tony Vassalos   2010 
 
 
6.1.3   Appendix 3: Lab Specimen Data Proforma 
 
CPB SAMPLES                                                         ALIQUOT Nos. 
1.  5mins into CPB 
 
                 
2.  30mins into CPB 
 
                 
3.  2mins off X-
clamp 
 
                 
4.  Coming off 
 
                 
 
 
 
RETAINED PLASMA  
Pre-OP 
Samples 
Aliquot Nos. 
                   
Volume P (µL)                     
Day 1 Samples 
Aliquot Nos.                     
Volume D1 
(µL)                     
Day 2 Sample 
Aliquot Nos.                     
Volume D2 
(µL)                     
Post-Op 
Samples  Th  D1  D2  D3  D4  D5  D6  D7  ……  …… 
Tick if present                     
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6.1.4   Appendix 4: Patient Protocol 
 
PRE-ASSESSMENT  
 
-  Study introduced to parents by consultant cardiac surgeon at the clinic 
-  Routine cardiology investigations (echocardiography) 
 
ADMISSION/PRE-OPERATIVELY 
 
-  Study re-introduced to parents by consultant cardiac surgeon  
-  If parents agreeable, study discussed in greater detail by principal investigator 
-  Parental consent for study obtained 
-  Plasma retained from routine bloods (day 2 pre-op)  
 
POST-OPERATIVELY (PICU) 
 
-  Plasma retained from routine bloods on admission to PICU 
-  Transthoracic echocardiography and Doppler tissue imaging <2hr post admission to 
PICU 
-  Two 12hr urine collections into provided containers (over 1
st 24hrs) 
-  Transthoracic echocardiography and Doppler tissue imaging (day 1 post op) 
-  Plasma retained from routine bloods (day 1 post-op) 
-  Plasma retained from routine bloods (day 2 post-op – if still in PICU) 
 
POST-OPERATIVELY (WARD) 
 
-  Plasma retained from routine bloods (prior to discharge) 
 
 
DISCHARGE 
 
-  Patient’s involvement in the study ends on hospital discharge 
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6.1.5  Appendix 5: Echocardiography Protocol 
 
TIMING: pre-operatively vs. <2hr admission to PICU and day-1 post-operatively 
 
1.  M-MODE & SPECTRAL DOPPLER 
 
SYSTOLIC FUNCTION  
(M-MODE) 
SYSTOLIC FUNCTION  
(SPECTRAL DOPPLER) 
- LVEDD  - Peak AO (aortic, LVOT) velocity 
- LVESD  - Peak PA (pulmonary, RVOT) velocity 
- RVEDD  - AO annular diameter 
- Fractional Shortening (% FS)  - PA annular diameter 
- Ejection Fraction (EF %)  - VTIPA 
  - VTIAO 
 
DIASTOLIC FUNCTION 
(SPECTRAL DOPPLER) 
- E & A wave velocity across mitral valve 
- Note any regurgitation 
 
 
2.  TISSUE DOPPLER IMAGING 
 
SYSTOLIC FUNCTION  
- Sa wave velocity at septum, lateral mitral and tricuspid annuli 
- IVA isovolumic acceleration at lateral tricuspid and mitral annuli 
 
DIASTOLIC FUNCTION 
- Ea and Aa wave velocity at septum, lateral mitral and tricuspid annuli 
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6.1.6  Appendix 6: Parent Information Sheet 
Version 2 (01 February 2005) 
 
1.  Study Title: End organ effects of paediatric cardiopulmonary bypass 
 
2.  Lay Title: Effects of heart surgery, requiring the use of the heart-lung bypass machine, 
on the function of vital body organs in children 
 
3.  Invitation paragraph: You and your child are being invited to take part in a research 
study. Before you decide it is important for you to understand why the research is being 
done  and  what  it  will  involve.  Please  take  time  to  read  the  following  information 
carefully and discuss it with others if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
 
 
Thank you for reading this. 
 
 
 
 
Q1. What is the purpose of the study? 
 
Ans: The purpose of this initial (pilot) study is to investigate the effects of heart surgery 
using the heart-lung bypass machine on the function of the heart, lungs and kidneys. 
 
Q2. Why have I been chosen? 
 
Ans: Participation in this study is being offered to all parents with children aged over 3 
months with inborn acyanotic heart disease who require heart surgery using the heart-lung 
bypass machine. 
 
Q3. Do I have to take part? 
 
Ans: NO. It is up to you to decide whether or not you wish your child to take part.  If you 
do decide to take part you will be given this information sheet to keep and be asked to sign 
a consent form. If you decide to take part you are still free to withdraw at any time and 
without giving a reason.  A decision to withdraw at any time, or a decision not to take part, 
will not affect the standard of care you receive. 
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Q4. What will happen to my child, if my child takes part?  
 
Ans:  If you decide that you would like your child to take part: 
-  Your child’s surgery and treatment will follow the normal practice of your consultant 
heart surgeon.  
-  Your child’s progress before and after surgery will be closely monitored.  
 
(a) Data from ward charts, intensive care charts and routine blood results will be 
recorded.  
(b) Images from routine echocardiography used before and after surgery to assess the 
heart’s function will be studied on the computer.  
(c) Urine samples normally discarded in intensive care will be sent to the laboratory 
to measure markers of kidney function.  
(d) Blood samples taken for routine tests will be stored and used to test for markers 
of heart, lung and kidney function. 
 
  -  Your child will remain part of the study until the day of discharge (usually 5 days). 
-  You and your child will not need to visit your GP or attend any additional clinics. 
-  Your child will not need to take any specific medications. 
 
Q5. What do I have to do? 
 
Ans: There are no associated restrictions with taking part in this study. Your child’s stay in 
hospital should follow the normal course.  
 
Q6. What is the drug or procedure that is being tested? 
 
Ans: There are no drugs or procedures being tested in this initial (pilot) study.  
 
Q8. What are the side effects of any treatment received when taking part? 
 
Ans: Your child will not be receiving any treatment specifically related to this study.  
 
Q9. What are the possible disadvantages and risks of taking part? 
 
Ans: This initial study is mainly an observational study aimed at following your child’s 
progress through hospital more closely. It is not associated with any specific therapy and 
we do not foresee any potential risks to them. 
 
Q10. What are the possible benefits of taking part? 
 
Ans: By taking part in the study your child’s progress through hospital will be closely 
monitored. As a result we would expect that any change to your child’s condition would be 
detected at an early stage and the clinical team could make the relevant decisions earlier. 
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Q11. What if new information becomes available? 
 
Ans: All relevant additional information on the function of the heart, lungs or kidneys 
found during the study will be made available to the clinical team caring for your child to 
allow them to make the appropriate clinical decisions early. 
 
Q12. What happens when the research study stops? 
 
Ans: The research study stops when your child is discharged from hospital. There is no 
further participation or responsibility.  
 
Q13. What if something goes wrong? 
 
Ans: If taking part in this research project harms your child, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms should be available to you. 
 
 
Q14. Will my taking part in this study be kept confidential? 
 
Ans: All information that is collected about your child during the course of the research 
will be kept strictly confidential. Any information about your child which leaves the 
hospital/surgery will have his/her name and address removed so that he/she cannot be 
recognised from it. 
 
Q15. What will happen to the results of the research study? 
 
Ans: The results of this initial study will hopefully serve as a basis for further more 
specific research into this area. Any publications that arise should be available to everyone 
on-line. The information may also be used in presentations to local charities and parent 
groups. You will not be specifically identified in any report or publication. 
 
Q16. Who is organising and funding the research? 
 
Ans: Laboratory tests associated with this study are being funded locally.  
 
Q17. Who has reviewed the study? 
 
Ans: The Research Ethics Committee based in Yorkhill Hospital has reviewed the study. 
The study has also been reviewed by the doctors and other clinical staff involved in your 
child’s care. 
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Q18. Who can I contact for further information? 
 
Ans:  If there is anything you do not understand or feel you would like further information 
on please do not hesitate to contact either of the persons named below through the Cardiac 
Surgery secretaries at Yorkhill Hospital (0141 201 0251). 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Yorkhill 
- Mr Mark Danton, Consultant Paediatric Cardiac Surgeon, Yorkhill 
 
Q19. With whom can I register any complaints? 
 
Ans:  Any complaints should be directed to the complaints officer or research fellow 
detailed below. All complaints will follow the standard NHS complaints mechanism. 
- Mrs Kate Colquhoun, Complaints Officer, Yorkhill NHS Trust, Dalnair Street, Glasgow 
G3 8SJ. (0141 201 9278) 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Level 5 Children’s 
Hospital, Yorkhill NHS Trust, Dalnair Street, Glasgow G3 8SJ. 
 
 
All patients precipitating in this study will be given a copy of the information sheet and a 
signed consent form to keep. 
 
Thank you for your co-operation and patience. 
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6.1.7  Appendix 7: Parent Consent Form 
Centre Number: : 
Study Number: 05/CA/01 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project: End organ effects of paediatric cardiopulmonary bypass 
 
 
 
Name of Researcher: Mr Tony Vassalos 
 
 
 
 
       
  Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 1 February 2005 
February 2005 (version 2) for the above study and have had the opportunity to ask 
opportunity to ask questions. 
 
2.  I understand that my child’s participation is voluntary and that I am free to withdraw at 
withdraw at any time, without giving any reason, without my child’s medical care or legal 
medical care or legal rights being affected. 
 
3.  I understand that sections of my child’s medical notes may be looked at by responsible 
by responsible individuals from the Yorkhill Division or from regulatory authorities where 
authorities where it is relevant to my child taking part in research. I give permission for 
permission for these individuals to have access to my child’s records. 
 
4.  I give permission for my child to take part in the above study.   
 
 
 
 
 
 
_________________________  ________________  ____________________ 
Name of Parent or Guardian  Date  Signature 
 
 
 
_________________________  ________________  ____________________ 
Researcher  Date  Signature     
 
 
 
 
  1 for parent/guardian;  1 for researcher;  1 to be kept with hospital notes 
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6.2  Randomised Controlled Trial 
6.2.1  Appendix 1: Study Protocol 
A phase IV, randomised, double-blind, placebo-controlled, single-centre study of the 
pre-operative effect of Sildenafil Citrate on pulmonary related complications 
following cardiopulmonary bypass in children undergoing cardiac surgical repair 
 
 
Sponsor:  NHS Greater Glasgow 
      Yorkhill Division, Royal Hospital for Sick Children 
      Dalnair Street, Glasgow G3 8SJ 
 
Chief Investigator:    Mr Tony Vassalos (CI), Research Fellow Cardiac Surgery 
   Yorkhill Division, Royal Hospital for Sick Children 
   Dalnair Street, Glasgow G3 8SJ 
 
Supervisors:    Mr Mark Danton (PI), (Consultant Cardiac Surgeon) 
  Professor Fiona Lyall (Professor of Maternal and Fetal Health) 
 
Collaborators:    Dr Peter Galloway, Mr Kenneth MacArthur, Mr Jim Pollock, Mr 
Stuart Lilley, Dr Brodie Knight, Dr Alastair Gracie, Dr Jennifer 
Scarth,  Dr  Crispin  Best,  Sr  Gael  Tinney,  Mrs  Ida  Torrance,  Dr 
James Paton, Dr Brenda Gibson, Dr David Young, Ms Sarah Casey 
 
Main Funder:  Yorkhill Children’s Foundation 
  Royal Hospital for Sick Children 
  Glasgow, G3 8SJ 
  (Tele: 0141 201 0723) 
 
Study Product:  Sildenafil Citrate (Viagra, Pfizer) 
 
Protocol Code No:  05/CH/01 
 
EudraCT Number:  2005-001034-32   
 
Protocol Version:  Version 1 (10/11/2005) 
 
 
 
CONFIDENTIAL 
 
This document is confidential and the property of Greater Glasgow Health Board, 
North Glasgow University Hospital Division. No part of it may be transmitted, 
reproduced, published or used by other persons without prior written authorisation 
from the study Sponsor. 
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List of Abbreviations (In order of appearance) 
 
• CI  :  chief investigator 
• PI  :  principal investigator 
• cGMP  :  cyclic guanosine monophosphate 
• PVRI  :   pulmonary vascular resistance index 
• PED  :   pulmonary endothelial dysfunction 
• CPB  :   cardiopulmonary bypass 
• PICU  :   pediatric intensive care unit 
• NO  :   nitric oxide 
• PDE5  :   phosphodiesterase-5 
• iNO  :  inhaled nitric oxide 
• Tmax  :  time from administration to peak plasma concentration 
• Cmax  :  peak plasma concentration 
• Vss  :  volume of distribution 
• CLcr  :  creatinine clearance 
• AUC  :  area under the plasma concentration-time curve 
• IC50  :  half-maximal inhibition 
• RCT  :   randomised controlled trial 
• CHD  :  congenital heart disease 
• PVR  :  pulmonary vascular resistance 
• NYHA  :  New York Heart Association 
• WUm
2  :  woods units per metre squared body surface area 
• PA  :   pulmonary artery 
• LA  :   left atrium 
• VTIPA  :   velocity time integral of the pulmonary artery 
• TDI  :   tissue Doppler imaging 
• RV  :   right ventricle 
• IVA  :   peak myocardial acceleration during isovolumetric contraction 
• IVC  :   isovolumetric contraction 
• OI  :   oxygenation index 
• ERS  :   European Respiratory Society 
• ELISA  :   enzyme linked immunosorbent assay 
• VCAM-1  :   vascular cell adhesion molecule  
• REC  :  Research Ethics Committee 
• SAE  :  serious adverse event 
• ASD  :  atrial septal defect 
• VSD  :  ventricular septal defect 
• AV Canal  :  atrioventricular defect 
• ECMO  :  extra-corporeal membrane oxygenation 
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STUDY SUMMARY 
 
 
Title:   Does pre-operative Sildenafil protect against pulmonary related complications following 
cardiopulmonary bypass? A randomised trial in children undergoing cardiac surgical repair 
 
Short Title: Randomised trial of pre-operative Sildenafil in children 
 
Lay Title:   Will giving the drug Sildenafil to children before open heart surgery improve the function 
of the lungs after surgery? 
 
Design:  Phase IV, randomised, double-blind, placebo-controlled 
 
Duration:  12 months 
 
Centre:  Single-centre 
 
 
Research Hypothesis 
Oral  Sildenafil  (Viagra,  Pfizer)  given  pre-operatively  to  children  with  left  to  right 
intracardiac shunts, undergoing corrective surgery utilizing cardiopulmonary bypass, will 
amplify cGMP levels in the pulmonary endothelium and reduce post-operative pulmonary 
dysfunction.  
 
Number of subjects 
A sample size of 12 in each group will have 80% power to detect a minimum difference in 
PVRI of 4.14 WUm
2 between the control and intervention groups. This computation is 
based on data published by Schulze-Neick et al.
 (Circulation 2003:108[suppl II];II-167-II-
173)
 where a mean of 8.32 WUm
2 and standard deviation of 3.464 was observed in the 
post-operative group. The sample size calculation was done using nQuery, version 5.0, 
under the supervision of Dr David Young (Senior Statistician, Yorkhill Hospital). 
 
Inclusion Criteria 
-    pediatric  patients  undergoing  open  heart  surgery  utilising  cardiopulmonary  bypass  to 
correct acyanotic congenital heart disease 
-   age >3 months 
-  parents that show a good understanding of their child's condition and are happy for their 
child to participate in the study 
 
Exclusion Criteria 
-   patients with known organ dysfunction prior to surgery (pulmonary, renal or hepatic) 
-   communication barriers resulting in poor basic comprehension of the proposed study (e.g. 
language barrier) 
-   patients with cyanotic heart disease 
-  patients undergoing heart surgery without the use of cardiopulmonary bypass 
-   patients  who  do  not  tolerate  oral  Sildenafil  (e.g.  Vomiting)  or  whose  surgery  is 
subsequently cancelled 
 
 
 
 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 134 of 192 
 
Tony Vassalos   2010 
Study Product 
-  Name  :  Sildenafil Citrate (Viagra, Pfizer) 
-  Dose  :   0.5mg/kg (Max 100mg/day) 
-  Route  :   Oral (suspension) 
-  Regimen  :   6hrly (day before surgery only), 4 doses total 
 
Reference Therapy 
Alternatively, an identical and inactive Placebo (equal volume) will be given 6hrly the day 
before surgery. 
 
Data Analysis 
Data  will  be  tested  for  normality  and  two-sample  t-tests  or  Mann-Whitney  tests  done 
accordingly. Analysis will be done on an intention-to-treat basis with any missing values 
being replaced by previous recorded measures, or based on group averages as appropriate. 
All analyses will be done using Minitab (version 14) with a significance level of 5% and 
results displayed as between-group effect sizes with 95% confidence intervals. Analysis 
will be carried out under the supervision of Dr David Young (Senior Statistician, Yorkhill 
Hospital). 
 
Introduction 
This document is a clinical research protocol. The research trial detailed within will be 
conducted in compliance with the principles of the Declaration of Helsinki (1989), the 
principles of ICH-GCP and all applicable regulatory requirements. 
 
  Background 
Specific congenital heart defects such as ventricular septal defects that result in left to right 
intracardiac shunting lead to excessive blood flow through the pulmonary circulation. This 
has an adverse effect on the pulmonary endothelium clinically manifest as episodes of 
pulmonary hypertension and hemodynamic instability. This phenomenon of ‘pulmonary 
endothelial dysfunction’ (PED) is exacerbated by cardiopulmonary bypass (CPB) utilised 
during surgical repair. 
[1] Post-operatively such patients are prone to developing pulmonary 
infiltrations,  decreased  oxygenation  and  pulmonary  hypertension  with  associated  right-
sided heart failure and hemodynamic instability. This often results in a prolonged stay in 
intensive care (PICU) and is associated with significant morbidity and mortality.
 [1, 2] 
 
In the normal lung, nitric oxide (NO) is produced by the endothelium to regulate blood 
flow and optimise ventilation. PED is defined as a failure of the pulmonary endothelium to 
produce adequate amounts of NO. 
[2] This failure is amplified by cardiac surgery and is 
thought to be a specific consequence of a more generalised inflammatory response to CPB. 
NO acts through a secondary messenger, intracellular cyclic guanosine monophosphate 
(cGMP), to dilate pulmonary blood vessels. cGMP is metabolized by phosphodiesterase-5 
(PDE5)  which  is  the  predominant  phosphodiesterase  in  normal  lung  and  may  be  up 
regulated in patients with PED.
 [2, 3, 4]  
 
Administration of inhaled NO (iNO) is currently the standard treatment for post-operative 
pulmonary hypertension. Although this has proved to be clinically effective, significant 
disadvantages do exist with some patients failing to respond and others developing life-
threatening pulmonary hypertension upon withdrawal.
  [5,  6] Recently Sildenafil (Viagra, 
Pfizer),  a  potent  PDE-5  inhibitor  that  prevents  the  breakdown  of  cGMP,  has  been 
introduced as a potential new therapy and has been shown to be as effective as iNO in 
treating  pulmonary  hypertension.
  [7,  8]  Sildenafil,  however,  does  not  require  a  special 
delivery system and does not cause life-threatening rebound pulmonary hypertension. Oral End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 135 of 192 
 
Tony Vassalos   2010 
Sildenafil is now an established treatment for chronic pulmonary hypertension in children 
and  is  safe  and  effective  when  given  at  therapeutic  doses  (0.5-2.0mg/kg;  4hrly). 
[9] 
Currently,  Sildenafil  is  used  on  an  ‘ad  hoc’  basis  in  our  PICU  to  treat  post-operative 
pulmonary hypertension with or without iNO.  
 
Our hypothesis is that oral Sildenafil liquid (0.5mg/kg) administered 6hrly the day before 
surgery  will  maintain  intracellular  cGMP  levels  during  the  insult  of  cardiopulmonary 
bypass, protecting the pulmonary endothelium and avoiding the consequences of PED in 
the  post-operative  period.  To  date,  the  limited  number  of  trials  reporting  the  use  of 
Sildenafil  have  been  small  in  number  and  not  specifically  related  to  surgery.
  [10] 
Furthermore, the pre-operative role of Sildenafil in protecting the pulmonary endothelium 
has not been previously addressed. 
 
Investigational Medicinal Product (direct from Pfizer) 
Generic Name:  Sildenafil Citrate (Discovered in 1989) 
Trade Name:  Viagra 
Chemical Name:  1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-oxo-3-
propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl) 
phenylsulfonyl 
Molecular Formula:  C22H30N6O4S·C6H8O7 
Molecular Weight:  666.7 (citrate salt) 
Pharmacological Class:  cyclic guanosine monophosphate (cGMP)-specific 
phosphodiesterase type 5 (PDE5) inhibitor 
Formulation and Dose:  Oral Suspension; 0.5mg/kg; 6hrly (Max 100mg/day) 
Route of Administration:  Oral 
Structure: 
 
  Rationale 
Normally, stimulation of the pulmonary vascular endothelium causes local release of NO 
which in turn regulates pulmonary blood flow to optimize ventilation. NO activates the 
enzyme guanylate cyclase, which in turn results in increased levels of cyclic guanosine 
monophosphate  (cGMP),  producing  smooth  muscle  relaxation  in  the  pulmonary 
vasculature and reducing pulmonary vascular resistance. Sildenafil has no direct relaxant 
effect on isolated pulmonary blood vessels, but enhances the effect of NO by inhibiting 
phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP.  
 
Studies in vitro have shown that Sildenafil is selective for PDE5. Its effect is more potent 
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>700-fold  for  PDE2,  PDE3,  PDE4,  PDE7,  PDE8,  PDE9,  PDE10,  and  PDE11).  The 
approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is 
involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for 
PDE5  compared  to  PDE6,  an  enzyme  found  in  the  retina  which  is  involved  in  the 
phototransduction pathway of the retina. This lower selectivity is thought to be the basis 
for  abnormalities  related  to  color  vision  observed  with  higher  doses  or  plasma  levels. 
PDE5  is  found  in  high  concentrations  in  human  corpus  cavernosum  and  pulmonary 
vascular  smooth  muscle.  PDE5  is  also  found  in  lower  concentrations  in  other  tissues 
including  platelets,  vascular  and  visceral  smooth  muscle,  and  skeletal  muscle.  The 
inhibition of PDE5 in these tissues by sildenafil may be the basis for the enhanced platelet 
antiaggregatory activity of nitric oxide observed in vitro, an inhibition of platelet thrombus 
formation in vivo and peripheral arterial-venous dilatation in vivo. 
 
  Pharmacokinetics and Metabolism 
Sildenafil is rapidly absorbed after oral administration, with absolute bioavailability of 
about 40%. Its pharmacokinetics are dose-proportional over the recommended dose range. 
It is eliminated predominantly by hepatic metabolism (mainly cytochrome P450 3A4) and 
is converted to an active N-demethylated metabolite with properties similar to the parent, 
sildenafil.  The  concomitant  use  of  potent  cytochrome  P450  3A4  inhibitors  (e.g., 
erythromycin,  ketoconazole,  itraconazole)  as  well  as  the  nonspecific  CYP  inhibitor, 
cimetidine, is associated with increased plasma levels of sildenafil. Both sildenafil and the 
metabolite have terminal half lives of about 4 hours.  
 
  Absorption and Distribution 
Sildenafil  is  rapidly  absorbed.  Maximum  observed  plasma  concentrations  are  reached 
within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When 
Sildenafil is taken with a high fat meal, the rate of absorption is reduced, with a mean 
delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady 
state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the 
tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 
96% bound to plasma proteins. Protein binding is independent of total drug concentrations.  
 
  Metabolism and Excretion 
Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor 
route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-
desmethylation of sildenafil, and is itself further metabolized. This metabolite has a PDE 
selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 
50% of the parent drug. Plasma concentrations of this metabolite are approximately 40% 
of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafil’s 
pharmacologic  effects.  After  either  oral  or  intravenous  administration,  sildenafil  is 
excreted as metabolites predominantly in the feces (approximately 80% of administered 
oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral 
dose). Similar values for pharmacokinetic parameters were seen in normal volunteers and 
in the patient population, using a population pharmacokinetic approach. 
 
  Pharmacokinetics in Special Populations 
-  Renal  Insufficiency:  In  volunteers  with  mild  (CLcr=50-80  mL/min)  and  moderate 
(CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose of 
Sildenafil (50 mg) were not altered. In volunteers with severe (CLcr=<30 mL/min) renal 
impairment, sildenafil clearance was reduced, resulting in approximately doubling of AUC 
and Cmax compared to age-matched volunteers with no renal impairment. 
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-  Hepatic  Insufficiency:  In  volunteers  with  hepatic  cirrhosis  (Child-Pugh  A  and  B), 
sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax (47%) 
compared to age-matched volunteers with no hepatic impairment.  
 
Therefore, hepatic impairment and severe renal impairment are associated with increased 
plasma levels of sildenafil. A starting oral dose of 25 mg should be considered in those 
patients. 
 
Pre-clinical Data 
Sildenafil is a potent and selective inhibitor of 3’5’-cGMP-specific PDE-5 with a half-
maximal inhibition (IC50) of PDE-5 activity at a concentration of 3.5nmol/L.
 Sildenafil has 
a substantially lower affinity for the other PDE isoenzymes (at least 11 isoforms of PDE 
have been discovered) manifested by the much higher concentrations needed to inhibit 
50% of their activities (IC50). The tissue distribution of PDE-5 is well defined and the 
effects of Sildenafil can be expected to be limited to these tissues (corpus cavernosum, 
platelets,  skeletal  muscle,  vascular  and  visceral  smooth  muscle).
[11-13]  The  estimated 
degree  of  PDE-5  inhibition  in  humans  after  oral  dosing  would  be  as  follows:  25mg 
(~11nmol/L free drug) would give approximately 76% inhibition; 50 mg (~22nmol/L free 
drug) approximately 86% inhibitions and 100mg (~47nmol/L free drug) approximately 
93% inhibition. These estimations are based on a number of assumptions, one of which is 
that the inhibition of the enzyme is sigmoid with respect to inhibitor concentration.
[14] 
 
  Clinical Data to Date 
In  the  levels  of  clinical  evidence,  the  randomised  controlled  trial  (RCT)  is  generally 
considered the best approach to ascertain the value of a particular therapy. To date only 
one  RCT  has  investigated  the  effects  of  Sildenafil  in  children  undergoing  corrective 
cardiac surgery for congenital heart disease (CHD). Stocker et al 
[15] investigated the acute 
effects of intravenous Sildenafil in 16 ventilated infants at risk of pulmonary hypertension 
after cardiac surgery on haemodynamics, oxygenation and its interaction with iNO. The 
study was completed in 15 patients. Seven infants received iNO (20ppm) first with the 
addition of intravenous Sildenafil (0.35mg/kg over 20mins) after 20mins. Eight infants 
received Sildenafil first, iNO was added after 20mins. In infants receiving iNO first, iNO 
lowered the PVRI from 3.45 to 2.95 units (p<0.01); Sildenafil further reduced PVRI to 
2.45 units (p<0.05). In those receiving Sildenafil first, PVRI was reduced from 2.84 to 
2.35 units (p<0.05) with Sildenafil and fell to 2.15 units (p<0.01) with the addition of iNO. 
In  both  groups,  these  potentially  beneficial  effects  were  associated  with  a  significant 
reduction  in  systemic  blood  pressure  and  deterioration  in  oxygenation  that  was  not 
improved by iNO (p<0.05). The latter effects were well tolerated by all study patients and 
were not associated with any clinical decline. 
 
In a prospective non-randomised study, Schulze-Neick et al 
[2] compared the effects of iNO 
before  and  after  specific  PDE-5  inhibition  by  intravenous  Sildenafil  in  pre-  and  post-
operative children with increased pulmonary vascular resistance (PVR) due to CHD. 12 
children (0.2-15.7yrs) with CHD and increased mean pulmonary artery pressure and 12 
children (0.11-0.65yrs) with increased PVR were studied during cardiac catheterisation or 
within 2hrs after return from cardiac surgery, respectively. All were sedated, tracheally 
intubated  and  paralysed.  In  the  pre-operative  group  0.33-0.66mg/kg  of  intravenous 
Sildenafil more effectively reduced PVR than iNO (11.5% versus 4.3%) (p<0.05). This 
result  was  repeated  in  the  post-operative  group  where  intravenous  Sildenafil  0.025-
0.25mg/kg more effectively reduced PVR than iNO (25.8% versus 14.6%) (p=0.09). This 
was however associated with a clinically insignificant increase in intrapulmonary shunting 
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Kothari et al 
[16] reported the outcome of long-term oral Sildenafil therapy in 14 patients 
with severe pulmonary artery hypertension, 5 of whom had surgery for CHD. Sildenafil 
was started at low dose and empirically increased such that the upper dosage limit of 
Sildenafil was not strictly defined but left to the functional improvement in individual 
cases (75-300mg/day). On a mean follow up 7.3 +/- 2.4 months oral Sildenafil was well 
tolerated and produced a significant and sustained improvement in exercise performance 
(Six-minute  walk  test),  New  York  Heart  Association  (NYHA)  functional  class,  right 
ventricular and pulmonary artery pressures (p<0.002). Two patients died during follow up 
despite clinical improvement. 
 
Humpl et al 
[17] performed a 12 month open-label, single-drug, pilot study into the effects 
of  oral  Sildenafil  in  14  children  (5.3-18yrs)  with  pulmonary  artery  hypertension,  7  of 
whom had had surgery for CHD. The median time from cardiac surgical repair to start of 
Sildenafil therapy was 7 years. Oral Sildenafil (0.25mg/kg for 2 doses and then increased 
to 1mg/kg; 4 times daily) was commenced after baseline assessment of haemodynamics by 
cardiac  catheterisation  and  exercise  performance  (Six-minute  walk  test).  Exercise 
performance was repeated in all children at 6 weeks and at 3, 6 and 12 months. Cardiac 
catheterisation was repeated in 9 children after a median follow up of 10.8 months (6-
15.3). Oral Sildenafil improved exercise performance at 6 months (278+/-114 to 443+/-
107m)  (p=0.02)  and  at  12  months  (432+/-156m)  (p=0.005).  A  plateau  was  reached 
between 6 and 12 months (p=0.48). Mean pulmonary artery pressure decreased from a 
median of 60mmHg to 50mmHg (p=0.014) and mean PVR decreased from 15WUm
2 to 
12WUm
2 (p=0.024). Sildenafil was well tolerated and no patient withdrew. There was no 
change in urea, creatinine, liver function tests or platelet count.  
 
  Dose Rationale and Risk/Benefits 
Clinical evidence relating to the efficacy of Sildenafil in reducing pulmonary hypertension 
due to congenital heart disease is limited and described in detail above. The current best 
available  evidence  suggests  that  a  dosing  range  of  0.025-0.66mg/kg  of  intravenous 
Sildenafil and 0.25-1mg/kg (6hrly) of oral Sildenafil would safely and significantly reduce 
pulmonary hypertension in this patient group. Our personal clinical experience to date also 
supports the opinion that oral Sildenafil (commenced at 0.5mg/kg and increased up to 
2mg/kg; 6hrly) is a safe and effective treatment for post-operative pulmonary hypertension 
in this patient group with or without iNO.   
 
In  general,  Sildenafil  has  been  very  well  tolerated  in  all  clinical  trials  with  the  most 
commonly  reported  adverse  events  being  headache,  flushing,  dyspepsia  and  nasal 
congestion. Adverse events were generally transient and mild to moderate. Furthermore, 
no  serious  adverse  events  were  judged  to  be  related  to  Sildenafil  therapy. 
[18,  19]  Oral 
Sildenafil is now an established treatment for chronic pulmonary hypertension in children 
and is safe and effective when given at therapeutic doses (0.5-2.0mg/kg; 4hrly). 
[9]  
 
It is on this basis that the dosing regimen for oral Sildenafil in the proposed trial was 
chosen: 0.5mg/kg; 6hrly. Due to the sigmoidal dose-related response of Sildenafil and in 
an attempt to reduce the risk of potential adverse effects we elected a dosing regimen 
representative of the lower end of our normal post-operative prescribing practice. 
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  Study Objectives 
-  Primary  Objective:  Does  pre-operative  administration  of  Sildenafil  (Viagra,  Pfizer) 
reduce the lung injury associated with cardiopulmonary bypass in children undergoing 
corrective surgical repair of congenital heart disease? 
 
-  Secondary Objectives: To further delineate the mechanism(s) of action of Sildenafil in 
this setting. Specifically, does pre-operative Sildenafil: 
− reduce post-operative pulmonary vascular resistance index? 
− improve post-operative oxygenation? 
− affect cardiac contractility? 
− increase peri-operative cGMP levels? 
 
  Study Design 
 
  General Design 
-  Phase IV, randomised, double-blind, placebo-controlled, single-centre study 
 
  Primary Study Endpoints 
The  efficacy  of  pre-operative  Sildenafil  given  to  children  undergoing  corrective  heart 
surgery for congenital heart disease in reducing PVRI, the systemic inflammatory response 
to CPB and improving oxygenation post-operatively. 
 
  Primary Safety Endpoints 
-  Anaphylaxis 
-  Clinically significant hemodynamic instability pre-operatively 
 
  End of Study Definition 
The study will end when 24 patients with completed data sets have been enrolled or in the 
event that criteria for stopping the study early are met. 
 
  Subject Selection and Withdrawal 
 
  Inclusion criteria 
-    pediatric  patients  undergoing  open  heart  surgery  utilising  cardiopulmonary  bypass  to 
correct acyanotic congenital heart disease 
-   age >3 months 
-  parents that show a good understanding of their child's condition and are happy for their 
child to participate in the study 
 
  Exclusion criteria 
-   patients with known organ dysfunction prior to surgery (pulmonary, renal or hepatic) 
-   communication barriers resulting in poor basic comprehension of the proposed study (e.g. 
language barrier) 
-   patients with cyanotic heart disease 
-  patients undergoing heart surgery without the use of cardiopulmonary bypass 
-   patients  who  do  not  tolerate  oral  Sildenafil  (e.g.  Vomiting)  or  whose  surgery  is 
subsequently cancelled 
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  Subject Enrolment 
-  Identification: patients who fulfill the inclusion criteria on paper will be invited to take 
part in this randomized clinical trial.  
-  Introduction: the randomized trial will be introduced to the identified patient's parents by 
their consultant cardiac surgeon at the pre-assessment clinic. A patient information sheet 
will also be available for those who want one. Patients will be electively admitted to the 
cardiology ward 48hrs prior to surgery as is the current practice. The chief investigator 
will introduce himself at that time to potential participants and their families to further 
discuss the randomized clinical trial and potential recruitment. 
-  Recruitment:  during  the  pre-operative  period  a  comprehensive  explanation  specifically 
discussing  potential  risks  and  benefits  will  be  given  to  parents  regarding  their  child. 
Thereafter, they will be offered the opportunity to participate and complete the informed 
consent. There will be no obligation to take part in the trial. Everyone involved appreciates 
and understands the emotional turmoil associated with this type of surgery. 
 
Early Withdrawal of Subjects 
 
  When and How to Withdraw Subjects 
Subjects will be withdrawn from the trial prior to the expected completion where: 
-  their subsequent surgery is cancelled 
-  there is a failure of the subject to adhere to protocol requirements 
-  the study drug is not tolerated (e.g. Vomiting) 
-  subject consent is withdrawn 
 
We do not anticipate abrupt withdrawal from the trial to impact subject safety or clinical 
management thereafter. 
   
  Data Collection and Follow-up for Withdrawn Subjects 
There will be no specific follow up associated with participation in this randomised trial. 
In the event that a subject is withdrawn from the trial due to their surgery being cancelled 
or intolerability to the study drug their data will not be included in the final analysis and 
they will be replaced. Where a subject’s consent is withdrawn and in the event that the 
study  drug  has  been  successfully  administered  an  attempt  will  be  made  to  obtain 
permission  to  record  survival  data  up  to  the  protocol-described  end  of  subject 
participation. Serious adverse events will be recorded in all cases irrespectively. 
 
  Study Drug 
 
  Description 
-  Sildenafil (Viagra, Pfizer), is a potent and selective inhibitor of cGMP-specific PDE5. It is 
rapidly absorbed orally with dose-proportional peak plasma concentrations within 1 hour 
of  administration.  It  is  eliminated  predominantly  by  hepatic  metabolism  (mainly 
cytochrome P450 3A4) and is converted to an active metabolite with properties similar to 
parent. The elimination half-life for both Sildenafil and its active metabolite is 3 to 5 
hours. Sildenafil is excreted as metabolites predominantly in the faeces (~80%) and to a 
lesser extent in the urine (~13%). Hepatic and severe renal impairment are associated with 
increased plasma levels. 
-  Drug  product  will  appear  as:  ‘Sildenafil  /  Placebo  Suspension  of  2.5  mg/ml’.  Total 
volume, expiry date and date dispensed will be stated on the drug product bottle.  
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  Treatment Regimen 
Sildenafil regimen prescribed: 0.5mg/kg, orally, 6hrly (4 doses; Max 100mg/day), day 
before surgery 
 
  Method for Assigning Subjects to Treatment Groups 
Randomisation of the patients to receive oral Sildenafil or equivalent volume of Placebo 
liquid will be undertaken by the clinical trials technician using a minimisation programme 
(MINIM). Only the clinical trials technician will know which subjects have received the 
active drug. This will be disclosed at the interim analysis, in the event of an emergency 
and at the end of the trial to the chief investigator once all data has been recorded and 
analysed. Each subject will be given a specific number upon trial entry, the identity of 
which will only be known by the chief investigator and the clinical trials technician.  
 
Preparation and Administration of Study Drug  
 
Placebo  
The placebo suspension will be prepared by the Pharmacy Production Unit based at the 
Western  Infirmary  Glasgow  (IMP  Licence  Number  18324).  The  ingredients  of  this 
suspension include Ora Plus Suspending Vehicle and Ora Sweet Syrup Sugar Free.  
 
Sildenafil 
The  Sildenafil  suspension  (2.5mg/ml)  will  be  prepared  by  Pharmacy  Production  Unit 
based at the Western Infirmary Glasgow (IMP Licence Number 18324). The ingredients of 
this suspension include Sildenafil tablets (25-100mg), Ora Plus Suspending Vehicle and 
Ora Sweet Syrup Sugar Free.  
 
Administration 
Upon successful informed consent, a study specific prescription sheet will be completed 
for each participant. Following randomisation an appropriately labelled bottle (Sildenafil / 
Placebo) will be dispensed by the Pharmacy Department in Yorkhill and stored in a locked 
locker at the participant’s bed space on the Cardiology Ward (5A). The appropriate dose 
detailed on the label and prescribed on the drug Kardex will then be administered by the 
nursing staff. The suspension will be placed in the participant’s mouth either directly (oral 
syringe) or using a spoon as per normal practice. 
 
  Subject Compliance Monitoring 
Compliance  to  the  study  treatment  regimen  will  be  overlooked  by  the  clinical  trials 
technician, ward pharmacist and the chief investigator. As the study regimen only involves 
4 doses we expect subject compliance to be easily monitored. Any subject that is non-
compliant with the study treatment regimen will be withdrawn from the trial. 
 
  Prior and Concomitant Therapy 
The  concomitant  use  of  potent  cytochrome  P450  3A4  inhibitors  (e.g.,  erythromycin, 
ketoconazole,  itraconazole)  as  well  as  the  nonspecific  CYP  inhibitor,  cimetidine,  is 
associated with increased plasma levels of Sildenafil and will be avoided the day before 
surgery. Otherwise all patients will be managed according to the normal practice of the 
Cardiology/Cardiac Surgery Departments at Yorkhill Hospital. 
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  Packaging 
 
  Placebo 
The placebo suspension supplied by the Pharmacy Production Unit, Glasgow in 3 x 50ml, 
amber bottles. The bottles will be clearly labelled and transported individually as required 
in a small cardboard box wrapped in bubble-wrap.  
 
  Sildenafil 
Sildenafil suspension supplied by the Pharmacy Production Unit, Glasgow in 3 x 50ml, 
amber bottles and received in bulk-pack by courier. Each batch will have a corresponding 
batch number and expiry date. Bottles will be wrapped in bubble-wrap and packed into a 
cardboard box for transportation. 
 
Blinding of Study Drug 
Randomisation  for  this  study  will  be  undertaken  by  the  clinical  trial  technician  once 
informed  consent  has  been  obtained  using  the  minimisation  programme  MINIM.  The 
participants  will  therefore  be  placed  into  either  the  active  (Sildenafil)  arm  or  inactive 
(Placebo)  arm  of  the  study.  This  will  be  recorded  by  the  clinical  trials  technician  on 
individual patient study files held in the clinical trials department. The code will be broken 
for interim analysis, in the event of an emergency and then at the end of the trial.  
 
  Receiving, Storage, Dispensing and Return 
 
  Receipt of Drug Supplies 
The Study medication bottles will be delivered to pharmacy stores by courier.  Packed in 
cardboard box, bottles will be wrapped in bubble wrap. The pharmacy store staff will 
check the delivery receipt and match with corresponding order.  After the paper work has 
been  checked  and  completed  the  clinical  trials  department  will  accept  delivery  and 
complete  the  drug  accountability  record  sheet  before  supplies  are  stored  in  a  locked 
cupboard in the Clinical Trials Department. 
 
  Storage 
Sildenafil and corresponding placebo suspension will be stored (below 25° C) in a locked 
cupboard in the Clinical Trials Department at Yorkhill Hospital. The expiry date for both 
is 28 days. Temperatures will be checked and recorded Monday-Friday. 
 
  Dispensing of Study Drug 
The Study medication will be dispensed into 50ml, amber glass bottles with 22mm click 
lock  caps.  The  label  will  contain  all  the  information  required  to  meet  the  applicable 
regulatory requirements. A register of pharmacy personnel dispensing and checking trial 
medication will be completed and filed in the Study filing cabinet. A dispensing record 
and prescription sheet will be completed and checked for each patient. 
 
  Return or Destruction of Study Drug 
Study medication that has been returned or expired will be checked and recorded before 
destruction. Each trial subject will have a returns record sheet and drug container disposal 
procedure. Certification of destruction is retained with the Directory of Pharmacy, Mr 
James Wallace. 
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  Study Procedures 
The trial will be introduced to the parents by their consultant cardiac surgeon at the pre-
assessment clinic. Upon admission to the ward for elective surgery the parents will meet 
the  chief  investigator  if  willing  to  discuss  the  trial  further.  If  consent  is  given,  the 
pharmacy will randomise patients to receive Sildenafil or Placebo using a minimisation 
programme (MINIM). The corresponding suspension (0.5mg/kg Sildenafil or equivalent 
volume  placebo)  will  be  dispensed  to  be  taken  6hrly  (orally)  the  day  before  surgery. 
Complete  surgical  repair  and  associated  medical  care  thereafter  will  be  undertaken 
according to the normal practice of Cardiology/Cardiac Surgery Departments at Yorkhill 
Hospital. Participation in the trial will end upon hospital discharge. 
 
- Data collection under standardised conditions (FiO2 0.65) will occur at 2hrs and 24hrs 
post-operatively in the paediatric intensive care unit to assess: 
 
Pulmonary Haemodynamics: 
 
• Measured indices:  
- Pressure  catheter  measurements:  pulmonary  artery  (PA)  and  left  atrial  (LA)  pressures 
recorded from routine invasive monitoring lines placed in theatre. 
 
• Echocardiography: 
- Velocity time integral (VTIPA): spectral Doppler of the right ventricular outflow tract will 
be used together with the pulmonary annular measurement to estimate pulmonary blood 
flow. 
-  Tissue  Doppler  Imaging  (TDI):  load  independent  assessment  of  right  ventricular  (RV) 
function. Pulsed wave TDI in the apical 4-chamber view will be used to obtain the Sa, Ea 
and Aa wave velocities and the peak myocardial IVC acceleration at the lateral tricuspid 
annulus.  Each  parameter  will  be  measured  over  3  consecutive  cardiac  cycles  and  the 
average value used in the analysis (100mm/s sweep speed). On and off-line analysis will 
be used to assess RV systolic and diastolic function.  
 
Peak myocardial IVC acceleration (IVA): represents global myocardial contractility and is 
calculated by dividing peak myocardial velocity during isovolumetric contraction (IVC) 
by the time interval from the onset of this wave to the time at peak velocity. The period of 
IVC is taken as the onset of the QRS complex, on simultaneous ECG, to the beginning of 
the Sa wave. This index has been shown to be a sensitive indicator of RV systolic function. 
 
• Derived indices: 
- Transpulmonary gradient: calculated by subtracting the LA pressure from the PA pressure 
measurement 
 
- Pulmonary vascular resistance index (PVRI) (WUm
2): is derived from the transpulmonary 
gradient  and  estimated  pulmonary  blood  flow  on  spectral  Doppler.  The  value  is 
standardised against body surface area.  
 
  Ventilation:  
 
• Oxygenation  Index  (OI)  Calculation:  [mean  airway  pressure  (cm  H20)  x  100  x  FiO2  /  PaO2 
(mmHg)] where the mean airway pressure is recorded off the ventilator, Fi02 refers to the 
inspired  oxygen  concentration  (standardised  at  65%)  and  PaO2  refers  to  the  arterial 
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severity of respiratory illness in ventilated patients. The OI is generally preferred because 
it is incorporates a measure of ventilator pressures. 
 
• Oxygen delivery (DO2) Calculation: Oxygen delivery calculated post-operatively using 
Doppler derived CO (QS) and arterial oxygen content according to the equation: DO2 = Qs 
x  [Haemoglobin  x  1.34  x  Haemoglobin  saturation  +  0.003  x  arterial  oxygen  tension 
(mmHg)]. 
 
• Period of ventilation & length of stay in PICU: data extracted directly from PICU charts 
 
cGMP:  
 
- cGMP  levels:  measured  using  commercially  available  radioimmunoassay  (Du  Pont 
Speciality Diagnostics).  
 
Statistical Plan 
 
Statistical Methods and Sample Size Determination 
A sample size of 12 in each group will have 80% power to detect a minimum difference in 
PVRI of 4.14 WUm
2 between the control and intervention groups. This computation is 
based on data published by Schulze-Neick et al.
 (Circulation 2003:108[suppl II];II-167-II-
173)
 where a mean of 8.32 WUm
2 and standard deviation of 3.464 was observed in the 
post-operative group. The sample size calculation was done using nQuery, version 5.0, 
under the supervision of Dr David Young (Senior Statistician, Yorkhill Hospital). 
 
A mid-point analysis of the data will be undertaken to evaluate trends and any unforeseen 
adverse effects. The interim and complete data set will be tested for normality and two-
sample  t-tests  or  Mann-Whitney  tests  done  accordingly.  Analysis  will  be  done  on  an 
intention-to-treat  basis  with  any  missing  values  being  replaced  by  previous  recorded 
measures, or based on group averages as appropriate. All analyses will be done using 
Minitab (version 14) with a significance level of 5% and results displayed as between-
group effect sizes with 95% confidence intervals. Analysis will be carried out under the 
supervision of Dr David Young. 
 
  Safety and Adverse Events 
 
Definitions 
Research participant safety will be closely monitored during the study as is the case in all 
pediatric  cardiac  surgical  cases.  This  will  involve  routine  case  conference,  physical 
examination, echocardiography +/- cardiac catheterisation, monitoring of vital signs and 
blood  tests  pre-operatively.  All  participants  will  undergo  routine  intra-operative 
echocardiography to assess the cardiac surgical repair. Thereafter all participants will be 
admitted to PICU where they will be invasively monitored, undergo routine post-operative 
echocardiography and overlooked by the cardiac surgery, cardiology and intensive care 
teams. Normally children with intracardiac shunts undergoing cardiac surgical correction 
are expected to remain in PICU for 48hrs post-operatively before being transferred to the 
Cardiology  Ward  prior  to  discharge  around  day  7.  Adverse  event  recording  will  be 
undertaken throughout the admission. 
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Potential Serious Adverse Events Associated with Study Population 
 
Pre-operative 
-  Cardiac arrhythmias 
-  Episodic pulmonary hypertension 
-  Eisenmenger Syndrome 
-  Embolism 
-  Left / Right sided heart failure 
-  Endocarditis 
-  Anaphylaxic reaction to anaesthetic agents 
 
Intra-operative 
-  Cardiopulmonary  bypass  circuit  failure  +/-  air  embolus,  circulatory  arrest,  multi-organ 
dysfunction 
-  Myocardial infarction  
-  Mortality (1% for ASD/VSD; <5% for AV Canal) 
 
Post-operative 
-  Cardiac Tamponade +/- Re-sternotomy 
-  Cardiac arrhythmias 
-  Episodic severe pulmonary hypertension 
-  Myocardial infarction 
-  Right / Left sided heart failure +/- multi-organ dysfunction, prolonged inotropic support or 
extra-corporeal membrane oxygenation (ECMO) 
-  Cerebral injury (hypoxic, embolic, hemorrhagic)  
-  Acute renal failure +/- renal replacement therapy 
-  Hepatic failure 
-  Ischaemic gastrointestinal tract 
-  Sternal wound infection +/- Mediastinitis 
-  Systemic sepsis +/- multi-organ dysfunction 
-  Coagulopathies 
-  Tension Pneumothorax / Simple Pneumothorax / Chylothorax 
 
 
Potential Adverse Events Associated with Sildenafil Toxicity (directly from Pfizer) 
 
ADVERSE EVENTS REPORTED BY ≥2% OF PATIENTS TREATED WITH VIAGRA 
AND MORE FREQUENT ON DRUG THAN PLACEBO IN PRN FLEXIBLE-DOSE PHASE II/III 
STUDIES 
 
Percentage of Patients Reporting Event  Adverse Event 
VIAGRA  [N=734]  PLACEBO  [N=725] 
Headache  16%  4% 
Flushing  10%  1% 
Dyspepsia  7%  2% 
Nasal Congestion  4%  2% 
Urinary Tract Infection  3%  2% 
Abnormal Vision†  3%  0% 
Diarrhea  3%  1% 
Dizziness  2%  1% 
Rash  2%  1% 
†Abnormal Vision: Mild and transient, predominantly color tinge to vision, but also increased sensitivity to light or 
blurred vision. In these studies, only one patient discontinued due to abnormal vision. 
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  Potential Risks or Hazards for Research Participants 
The  mainstay  of  surgical  and  medical  management  of  all  research  participants  before, 
during and after surgery will follow the normal clinical practice of their consultant cardiac 
surgeon,  cardiologist  and  intensive  care  team.  Possible  disadvantages  and  risks  would 
therefore be related to taking 4 oral doses of Sildenafil liquid (0.5mg/kg) the day before 
surgery. As we are not currently aware of any significant clinical side effects associated 
with oral Sildenafil at this dosage we do foresee any clinical disadvantages or side effects. 
We do not anticipate any potential for pain, discomfort, distress, inconvenience or changes 
to lifestyle directly related to taking part in this study. 
 
  Potential Benefit to Research Participants 
We anticipate that pre-operative Sildenafil will protect the lungs during cardiopulmonary 
bypass  to  improve  lung  function  and  reduce  related  complications  post-operatively. 
Clinically  this  may  manifest  as  reduced  episodic  pulmonary  hypertension,  improved 
hemodynamics, reduced ventilation period, reduced requirements of Sildenafil or iNO and 
reduced overall intensive care and hospital stay. All children undergoing corrective heart 
surgery are closely monitored throughout their admission. Although this will also be the 
case  for  all  research  participants  they  will  undergo  a  more  detailed  echocardiographic 
assessment both before and after surgery, providing additional clinical information that 
may be beneficial to the caring medical team. 
 
Recording of Adverse Events 
Adverse event reporting will be undertaken throughout the admission period. All events 
will be evaluated for seriousness, followed until resolution, recorded and stored in the 
master file. Each individual adverse event will be discussed in detail by the CI, project 
supervisors and the Sponsor. Any serious adverse event that occurs after the study period 
and  is  considered  to  be  related  to  the  study  treatment  or  study  participation  will  be 
recorded and reported immediately. 
 
  Reporting of Serious Adverse Events 
All serious adverse events will be reported to the Sponsor by telephone (Dr Alison Wood, 
ext 86935) within 24 hrs of the event. A serious adverse event (SAE) form will also be 
completed by the PI and given to the Sponsor, a copy of which will be stored in the master 
file. 
 
  Study Sponsor Notification by Investigator 
All safety and adverse events (as defined in the Protocol) will be reported by the CI to the 
Sponsor via the arrangements set up by the Yorkhill R&D Office within 24hrs. 
 
  MHRA and REC Notification by Sponsor 
The Sponsor has delegated the task of reporting safety and adverse events to the MHRA 
and the REC to the Yorkhill R&D Department, who undertake to meet appropriate time-
lines for reporting to the relevant authorities. 
 
  Annual Safety Reports 
The Sponsor has delegated the task of providing the MHRA and the REC with an annual 
safety report on the investigational medicinal product used in the study to the Yorkhill 
R&D Department who will undertake to meet appropriate time-lines for reporting to the 
relevant authorities. 
 
   
 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 147 of 192 
 
Tony Vassalos   2010 
 
  Unblinding Procedures 
Any concerns with study participants should be highlighted to the CI or consultant cardiac 
surgeon responsible for their care in the first instance. In the event that the code needs to 
be broken to ensure subject’s safety the clinical trials technician will be available during 
normal working hours (9am-5pm) to provide the relevant information (Ms Sarah Casey, 
ext  89367).  Between  the  hours  of  5pm  and  9am  and  during  the  weekend  the  on-call 
pharmacist at Yorkhill will undertake this responsibility. 
 
Stopping Rules 
The mainstay of clinical care will be unchanged by the participation in this study. Criteria 
for electively stopping the trial prematurely would be dependent on new contraindications 
to  giving  pre-operative  Sildenafil  arising  in  the  literature  or  directly  from  the 
manufacturer. Adverse advents will be monitored throughout the trial by the CI and the 
pharmacy department at Yorkhill. In addition a midpoint review of the trial data will be 
undertaken to highlight any unforeseen issues. 
 
Medical Safety Monitoring 
The CI will undertake the responsibility of overseeing the safety of the study. In this 
respect  a  monitoring  form  will  be  constructed  in  conjunction  with  the  clinical  trials 
pharmacist and the R&D Department at Yorkhill Hospital prior to commencement of the 
study and attached to the protocol. This will include a regular assessment of the number 
and type of serious adverse events. 
 
  Data Handling and Record Keeping 
 
Confidentiality 
Information about study subjects will be kept confidential and managed according to the 
requirements of the Data Protection Act (1998). Informed consent will be obtained from 
the parents of research participants in accordance with regulations outlined in the stated 
act. In the event that authorisation to collect or use confidential information is revoked by 
a  subject’s  parents,  the  investigator,  by  regulation,  will  retain  the  ability  to  use  all 
information collected prior to the revocation or subject authorisation. Additional attempts 
will be made in this situation to obtain permission to collect information on vital status at 
the end of the study. 
 
Individual patient’s samples will be labelled with an allocated patient number to maintain 
anonymity during analysis. All samples will be stored for the duration of the trial within 
the  laboratory  at  Yorkhill.  The  CI  and  lab  supervisor  will  have  access  to  the  stored 
samples. Results will be stored on a Yorkhill desktop computer based in Cardiology. 
 
Source Documentation 
All source documentation will be held by the CI in a trial master file. 
 
Case Report Forms 
An appropriate datasheet, detailing all mandatory data fields, will be constructed prior to 
commencement of the trial and attached to the study protocol. All missing data will be 
explained. 
 
Archiving/Record Retention 
Data will be archived for 10 years from the end of the study, in accordance with MRC 
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  Study Monitoring, Auditing and Inspecting 
 
  Study Monitoring Plan 
The study will be largely self-monitored by the research team, following a monitoring plan 
agreed  with  the  Sponsor  of  the  study,  NHS  Greater  Glasgow,  Yorkhill  Division.  In 
addition, members of the Yorkhill R&D Department may attend study team meetings to 
discuss monitoring reports. 
 
  Auditing and Inspecting 
The  PI  will  permit  study-related  monitoring,  auditing  and  inspections  by  ethics 
committees, the Sponsor, regulatory bodies and the R&D Department of all study-related 
documents. 
 
Ethical Considerations 
This protocol and any amendments will be submitted to a properly constituted Research 
Ethics Committee (REC) in agreement with local legal prescriptions, for formal approval 
of study conduct. A copy of the documented decision of the REC concerning the conduct 
of the study will be provided to the Sponsor before commencement of the study. 
 
Parent’s whose children meet the entry criteria and who are willing to discuss the study 
further will be provided with a consent form describing this study and providing sufficient 
information to enable an informed decision about their child’s participation in this study. 
(Appendix  2)  This  consent  form  will  be  submitted  with  the  protocol  for  review  and 
approval by the REC for the study. The formal consent of a subject, using the REC-
approved  consent  form  will  be  obtained  before  that  subject  is  submitted  to  any  study 
procedure. The consent form will be signed by the subject’s parents and the PI. 
 
Study Finances 
The study is being funding from a successful research grant application to the Yorkhill 
Children’s Foundation. As the study will not commence until R&D Management approval 
has been obtained, the study will be covered by the NHS CNORIS arrangements for acts 
of negligence. 
 
  Publication policy 
The primary responsibility for publication of the results of this study is held by the PI. 
Approval must be obtained directly from the PI before any information can be used or 
passed onto a third party. 
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6.2.2  Appendix 2: Investigational Medicinal Product Dossier (IMPD) 
 
 
 
 
 
INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER (IMPD) 
 
 
 
 
 
 
Sponsor:  NHS Greater Glasgow 
    Yorkhill Division, Royal Hospital for Sick Children 
    Dalnair Street, Glasgow G3 8SJ 
 
 
Drug Substance:  VIAGRA (Sildenafil Citrate - discovered in 1989) 
 
 
Edition No:  1 
 
 
Date:  6 December 2005 
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LIST OF ABBREVIATIONS 
 
•  cGMP  :  cyclic guanosine monophosphate 
•  PDE5  :  phosphodiesterase type 5 
•  NO  :  nitric oxide 
•  Tmax  :  time from administration to peak plasma concentration 
•  Cmax  :  peak plasma concentration 
•  Vss  :  volume of distribution 
•  CLcr  :  creatinine clearance 
•  AUC  :  area under the plasma concentration-time curve 
•  ECG  :  electrocardiography 
•  ED  :  erectile dysfunction 
•  IIEF  :  the international index of erectile function 
•  CABG  :  coronary artery bypass grafting 
•  TURP  :  transurethral resection of the prostate 
•  NAION  :  non-arteritic anterior ischaemic optic neuropathy 
•  HIV  :  human immunodeficiency virus 
•  MRHD  :  maximum recommended human daily dose 
•  MTD  :  maximum tolerated dose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 154 of 192 
 
Tony Vassalos   2010 
 
VIAGRA® (sildenafil citrate) 
Tablets 
 
 
1.  DESCRIPTION 
VIAGRA®, an oral therapy for erectile dysfunction, is the citrate salt of sildenafil, a 
selective  inhibitor  of  cyclic  guanosine  monophosphate  (cGMP)-specific 
phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as 1-
[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)-4-
ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural 
formula:  
 
 
 
 
 
Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 
mg/mL in water and a molecular weight of 666.7. VIAGRA (sildenafil citrate) is 
formulated as blue, film-coated rounded-diamond-shaped tablets equivalent to 25 
mg, 50 mg and 100 mg of sildenafil for oral administration. In addition to the active 
ingredient, sildenafil citrate, each tablet contains the following inactive ingredients: 
microcrystalline cellulose, anhydrous dibasic calcium phosphate, croscarmellose 
sodium,  magnesium  stearate,  hypromellose,  titanium  dioxide,  lactose,  triacetin, 
and FD & C Blue #2 aluminum lake. 
 
2.  CLINICAL PHARMACOLOGY 
2.1  Mechanism of Action 
The physiologic mechanism of erection of the penis involves release of nitric oxide 
(NO) in the corpus cavernosum during sexual stimulation. NO then activates the 
enzyme guanylate cyclase, which results in increased levels of cyclic guanosine 
monophosphate  (cGMP),  producing  smooth  muscle  relaxation  in  the  corpus 
cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on 
isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) 
by  inhibiting  phosphodiesterase  type  5  (PDE5),  which  is  responsible  for 
degradation of cGMP in the corpus cavernosum. When sexual stimulation causes 
local release of NO, inhibition of PDE5 by sildenafil causes increased levels of 
cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow 
of  blood  to  the  corpus  cavernosum.  Sildenafil  at  recommended  doses  has  no 
effect in the absence of sexual stimulation. 
Studies in vitro have shown that sildenafil is selective for PDE5. Its effect is more 
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fold for PDE1, >700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, 
and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is 
important because PDE3 is involved in control of cardiac contractility. Sildenafil is 
only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the 
retina which is involved in the phototransduction pathway of the retina. This lower 
selectivity  is  thought  to  be  the  basis  for  abnormalities  related  to  color  vision 
observed with higher doses or plasma levels (see Pharmacodynamics). In addition 
to  human  corpus  cavernosum  smooth  muscle,  PDE5  is  also  found  in  lower 
concentrations in other tissues including platelets, vascular and visceral smooth 
muscle, and skeletal muscle. The inhibition of PDE5 in these tissues by sildenafil 
may be the basis for the enhanced platelet antiaggregatory activity of nitric oxide 
observed in vitro, an inhibition of platelet thrombus formation in vivo and peripheral 
arterial-venous dilatation in vivo.  
 
2.2  Pharmacokinetics and Metabolism 
VIAGRA is rapidly absorbed after oral administration, with absolute bioavailability 
of about 40%. Its pharmacokinetics are dose-proportional over the recommended 
dose  range.  It  is  eliminated  predominantly  by  hepatic  metabolism  (mainly 
cytochrome P450 3A4) and is converted to an active metabolite with properties 
similar to the parent, sildenafil. The concomitant use of potent cytochrome P450 
3A4  inhibitors  (e.g.,  erythromycin,  ketoconazole,  itraconazole)  as  well  as  the 
nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels 
of  sildenafil  (see  DOSAGE  AND  ADMINISTRATION).  Both  sildenafil  and  the 
metabolite have terminal half lives of about 4 hours. 
 
Mean  sildenafil  plasma  concentrations  measured  after  the  administration  of  a 
single oral dose of 100 mg to healthy male volunteers is depicted below: 
 
 
Figure 1: Mean Sildenafil Plasma Concentrations n Healthy Male Volunteers. 
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2.3   Absorption and Distribution 
VIAGRA  is  rapidly  absorbed.  Maximum  observed  plasma  concentrations  are 
reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted 
state.  When  VIAGRA  is  taken  with  a  high  fat  meal,  the  rate  of  absorption  is 
reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax 
of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, 
indicating  distribution  into  the  tissues.  Sildenafil  and  its  major  circulating  N-
desmethyl  metabolite  are  both  approximately  96%  bound  to  plasma  proteins. 
Protein  binding  is  independent  of  total  drug  concentrations.  Based  upon 
measurements  of  sildenafil  in  semen  of  healthy  volunteers  90  minutes  after 
dosing, less than 0.001% of the administered dose may appear in the semen of 
patients.  
 
2.4  Metabolism and Excretion 
Sildenafil  is  cleared  predominantly  by  the  CYP3A4  (major  route)  and  CYP2C9 
(minor  route)  hepatic  microsomal  isoenzymes.  The  major  circulating  metabolite 
results from N-desmethylation of sildenafil, and is itself further metabolized. This 
metabolite has a PDE selectivity profile similar to sildenafil and an in vitro potency 
for PDE5 approximately 50% of the parent drug. Plasma concentrations of this 
metabolite  are  approximately  40%  of  those  seen  for  sildenafil,  so  that  the 
metabolite  accounts  for  about  20%  of  sildenafil’s  pharmacologic  effects.  After 
either  oral  or  intravenous  administration,  sildenafil  is  excreted  as  metabolites 
predominantly in the feces (approximately 80% of administered oral dose) and to a 
lesser  extent  in  the  urine  (approximately  13%  of  the  administered  oral  dose). 
Similar  values  for  pharmacokinetic  parameters  were  seen  in  normal  volunteers 
and in the patient population, using a population pharmacokinetic approach. 
 
2.5  Pharmacokinetics in Special Populations 
Geriatrics: Healthy elderly volunteers (65 years or over) had a reduced clearance 
of  sildenafil,  with  free  plasma  concentrations  approximately  40%  greater  than 
those seen in healthy younger volunteers (18-45 years). 
 
Renal Insufficiency: In volunteers with mild (CLcr=50-80 mL/min) and moderate 
(CLcr=30-49 mL/min) renal impairment, the pharmacokinetics of a single oral dose 
of VIAGRA (50 mg) were not altered. In volunteers with severe (CLcr=<30 mL/min) 
renal  impairment,  sildenafil  clearance  was  reduced,  resulting  in  approximately 
doubling of AUC and Cmax compared to age-matched volunteers with no renal 
impairment. 
 
Hepatic Insufficiency: In volunteers with hepatic cirrhosis (Child-Pugh A and B), 
sildenafil clearance was reduced, resulting in increases in AUC (84%) and Cmax 
(47%) compared to age-matched volunteers with no hepatic impairment. 
 
Therefore,  age  >65,  hepatic  impairment  and  severe  renal  impairment  are 
associated with increased plasma levels of sildenafil. A starting oral dose of 25 mg 
should be considered in those patients (see DOSAGE AND ADMINISTRATION). 
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3.  PHARMACODYNAMICS 
3.1  Effects of VIAGRA on Erectile Response 
In eight double-blind, placebo-controlled crossover studies of patients with either 
organic  or  psychogenic  erectile  dysfunction,  sexual  stimulation  resulted  in 
improved erections, as assessed by an objective measurement of hardness and 
duration  of  erections  (RigiScan®),  after  VIAGRA  administration  compared  with 
placebo. Most studies assessed the efficacy of VIAGRA approximately 60 minutes 
post dose. The erectile response, as assessed by RigiScan®, generally increased 
with increasing sildenafil dose and plasma concentration. The time course of effect 
was examined in one study, showing an effect for up to 4 hours but the response 
was diminished compared to 2 hours. 
 
3.2  Effects of VIAGRA on Blood Pressure 
Single  oral  doses  of  sildenafil  (100  mg)  administered  to  healthy  volunteers 
produced  decreases  in  supine  blood  pressure  (mean  maximum  decrease  in 
systolic/diastolic  blood  pressure  of  8.4/5.5  mmHg).  The  decrease  in  blood 
pressure  was  most  notable  approximately  1-2  hours  after  dosing,  and  was  not 
different than placebo at 8 hours. Similar effects on blood pressure were noted 
with 25 mg, 50 mg and 100 mg of VIAGRA, therefore the effects are not related to 
dose  or  plasma  levels  within  this  dosage  range.  Larger  effects  were  recorded 
among patients receiving concomitant nitrates (see CONTRAINDICATIONS). 
 
 
Figure 2: Mean Change from Baseline in Sitting Systolic Blood Pressure, Healthy Volunteers. 
 
 
3.3  Effects of VIAGRA on Cardiac Parameters 
Single  oral  doses  of  sildenafil  up  to  100  mg  produced  no  clinically  relevant 
changes in the ECGs of normal male volunteers. Studies have produced relevant 
data  on  the  effects  of  VIAGRA  on  cardiac  output.  In  one  small,  open-label, 
uncontrolled,  pilot  study,  eight  patients  with  stable  ischemic  heart  disease 
underwent  Swan-Ganz  catheterization.  A  total  dose  of  40  mg  sildenafil  was 
administered by four intravenous infusions. End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 158 of 192 
 
Tony Vassalos   2010 
The results from this pilot study are shown in Table 1; the mean resting systolic 
and diastolic blood pressures decreased by 7% and 10% compared to baseline in 
these  patients.  Mean  resting  values  for  right  atrial  pressure,  pulmonary  artery 
pressure, pulmonary artery occluded pressure and cardiac output decreased by 
28%, 28%, 20% and 7% respectively. Even though this total dosage produced 
plasma  sildenafil  concentrations  which  were  approximately  2  to  5  times  higher 
than the mean maximum plasma concentrations following a single oral dose of 
100 mg in healthy male volunteers, the hemodynamic response to exercise was 
preserved in these patients. 
 
TABLE 1. HEMODYNAMIC DATA IN PATIENTS WITH STABLE ISCHEMIC HEART 
DISEASE AFTER IV ADMINISTRATION OF 40 MG SILDENAFIL 
 
 
 
In a double-blind study, 144 patients with erectile dysfunction and chronic stable 
angina limited by exercise, not receiving chronic oral nitrates, were randomized to 
a single dose of placebo or VIAGRA 100 mg 1 hour prior to exercise testing. The 
primary endpoint was time to limiting angina in the evaluable cohort. The mean 
times  (adjusted  for  baseline)  to  onset  of  limiting  angina  were  423.6  and  403.7 
seconds  for  sildenafil  (N=70)  and  placebo,  respectively.  These  results 
demonstrated that the effect of VIAGRA on the primary endpoint was statistically 
non-inferior to placebo.  
 
3.4  Effects of VIAGRA on Vision  
At single oral doses of 100 mg and 200 mg, transient dose-related impairment of 
color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-
hue test, with peak effects near the time of peak plasma levels. This finding is 
consistent with the inhibition of PDE6, which is involved in phototransduction in the 
retina.  An  evaluation  of  visual  function  at  doses  up  to  twice  the  maximum 
recommended dose revealed no effects of VIAGRA on visual acuity, intraocular 
pressure, or pupillometry.  
 
4.  CLINICAL STUDIES 
In clinical studies, VIAGRA was assessed for its effect on the ability of men with 
erectile  dysfunction  (ED)  to  engage  in  sexual  activity  and  in  many  cases 
specifically  on  the  ability  to  achieve  and  maintain  an  erection  sufficient  for 
satisfactory sexual activity. VIAGRA was evaluated primarily at doses of 25 mg, 50 
mg and 100 mg in 21 randomized, double-blind, placebo-controlled trials of up to 6 
months in duration, using a variety of study designs (fixed dose, titration, parallel, 
crossover). VIAGRA was administered to more than 3,000 patients aged 19 to 87 
years,  with  ED  of  various  etiologies  (organic,  psychogenic,  and  mixed)  with  a 
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improvement compared to placebo in all 21 studies. The studies that established 
benefit  demonstrated  improvements  in  success  rates  for  sexual  intercourse 
compared with placebo.  
 
The  effectiveness  of  VIAGRA  was  evaluated  in  most  studies  using  several 
assessment  instruments.  The  primary  measure  in  the  principal  studies  was  a 
sexual function questionnaire (the International Index of Erectile Function - IIEF) 
administered during a 4-week treatment-free run-in period, at baseline, at follow-
up visits, and at the end of double-blind, placebo-controlled, at-home treatment. 
Two of the questions from the IIEF served as primary study endpoints; categorical 
responses  were  elicited  to  questions  about  (1)  the  ability  to  achieve  erections 
sufficient  for  sexual  intercourse  and  (2)  the  maintenance  of  erections  after 
penetration. The patient addressed both questions at the final visit for the last 4 
weeks of the study. The possible categorical responses to these questions were 
(0)  no  attempted  intercourse,  (1)  never  or  almost  never,  (2)  a  few  times,  (3) 
sometimes, (4) most times, and (5) almost always or always. Also collected as part 
of  the  IIEF  was  information  about  other  aspects  of  sexual  function,  including 
information on erectile function, orgasm, desire, satisfaction with intercourse, and 
overall sexual satisfaction. Sexual function data were also recorded by patients in 
a daily diary. In addition, patients were asked a global efficacy question and an 
optional partner questionnaire was administered. 
 
The  effect  on  one  of  the  major  end  points,  maintenance  of  erections  after 
penetration, is shown in Figure 3, for the pooled results of 5 fixed-dose, dose-
response studies of greater than one month duration, showing response according 
to baseline function. Results with all doses have been pooled, but scores showed 
greater improvement at the 50 and 100 mg doses than at 25 mg. The pattern of 
responses was similar for the other principal question, the ability to achieve an 
erection  sufficient  for  intercourse.  The  titration  studies,  in  which  most  patients 
received 100 mg, showed similar results. Figure 3 shows that regardless of the 
baseline levels of function, subsequent function in patients treated with VIAGRA 
was better than that seen in patients treated with placebo. At the same time, on-
treatment  function  was  better  in  treated  patients  who  were  less  impaired  at 
baseline. 
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Figure 3. Effect of VIAGRA and Placebo on Maintenance of Erection by Baseline Score 
 
 
The  frequency  of  patients  reporting  improvement  of  erections  in  response  to  a 
global question in four of the randomized, double-blind, parallel, placebo-controlled 
fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 4. 
These  patients  had  erectile  dysfunction  at  baseline  that  was  characterized  by 
median categorical scores of 2 (a few times) on principal IIEF questions. Erectile 
dysfunction  was  attributed  to  organic  (58%;  generally  not  characterized,  but 
including diabetes and excluding spinal cord injury), psychogenic (17%), or mixed 
(24%) etiologies. Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 
mg  and  100  mg  of  VIAGRA,  respectively,  reported  an  improvement  in  their 
erections, compared to 24% on placebo. In the titration studies (n=644) (with most 
patients eventually receiving 100 mg), results were similar. 
 
 
Figure 4. Percentage of Patients Reporting an Improvement in Erections. 
 
The patients in studies had varying degrees of ED. One-third to one-half of the 
subjects in these studies reported successful intercourse at least once during a 4-
week, treatment-free run-in period.  
In many of the studies, of both fixed dose and titration designs, daily diaries were 
kept  by  patients.  In  these  studies,  involving  about  1600  patients,  analyses  of 
patient  diaries  showed  no  effect  of  VIAGRA  on  rates  of  attempted  intercourse 
(about 2 per week), but there was clear treatment-related improvement in sexual 
function: per patient weekly success rates averaged 1.3 on 50-100 mg of VIAGRA 
vs. 0.4 on placebo; similarly, group mean success rates (total successes divided 
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During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label 
studies, few patients withdrew from active treatment for any reason, including lack 
of effectiveness. At the end of the long-term study, 88% of patients reported that 
VIAGRA improved their erections.  
 
Men with untreated ED had relatively low baseline scores for all aspects of sexual 
function measured (again using a 5-point scale) in the IIEF. VIAGRA improved 
these  aspects  of  sexual  function:  frequency,  firmness  and  maintenance  of 
erections;  frequency  of  orgasm;  frequency  and  level  of  desire;  frequency, 
satisfaction and enjoyment of intercourse; and overall relationship satisfaction.  
 
One  randomized,  double-blind,  flexible-dose,  placebo-controlled  study  included 
only  patients  with  erectile  dysfunction  attributed  to  complications  of  diabetes 
mellitus (n=268). As in the other titration studies, patients were started on 50 mg 
and allowed to adjust the dose up to 100 mg or down to 25 mg of VIAGRA; all 
patients, however, were receiving 50 mg or 100 mg at the end of the study. There 
were  highly  statistically  significant  improvements  on  the  two  principal  IIEF 
questions  (frequency  of  successful  penetration  during  sexual  activity  and 
maintenance of erections after penetration) on VIAGRA compared to placebo. On 
a  global  improvement  question,  57%  of  VIAGRA  patients  reported  improved 
erections versus 10% on placebo. Diary data indicated that on VIAGRA, 48% of 
intercourse attempts were successful versus 12% on placebo. 
 
One randomized, double-blind, placebo-controlled, crossover, flexible-dose (up to 
100 mg) study of patients with erectile dysfunction resulting from spinal cord injury 
(n=178) was conducted. The changes from baseline in scoring on the two end 
point  questions  (frequency  of  successful  penetration  during  sexual  activity  and 
maintenance of erections after penetration) were highly statistically significantly in 
favor of VIAGRA. On a global improvement question, 83% of patients reported 
improved erections on VIAGRA versus 12% on placebo. Diary data indicated that 
on VIAGRA, 59% of attempts at sexual intercourse were successful compared to 
13% on placebo.  
 
Across all trials, VIAGRA improved the erections of 43% of radical prostatectomy 
patients compared to 15% on placebo.  
 
Subgroup analyses of responses to a global improvement question in patients with 
psychogenic  etiology  in  two  fixed-dose  studies  (total  n=179)  and  two  titration 
studies (total n=149) showed 84% of VIAGRA patients reported improvement in 
erections compared with 26% of placebo. The changes from baseline in scoring on 
the two end point questions (frequency of successful penetration during sexual 
activity  and  maintenance  of  erections  after  penetration)  were  highly  statistically 
significantly in favor of VIAGRA. Diary data in two of the studies (n=178) showed 
rates  of  successful  intercourse  per  attempt  of  70%  for  VIAGRA  and  29%  for 
placebo. 
 
A review of population subgroups demonstrated efficacy regardless of baseline 
severity, etiology, race and age. VIAGRA was effective in a broad range of ED 
patients, including those with a history of coronary artery disease, hypertension, 
other cardiac disease, peripheral vascular disease, diabetes mellitus, depression, 
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resection  of  the  prostate  (TURP)  and  spinal  cord  injury,  and  in  patients  taking 
antidepressants / antipsychotic and antihypertensive / diuretics. 
 
Analysis of the safety database showed no apparent difference in the side effect 
profile in patients taking VIAGRA with and without antihypertensive medication. 
This analysis was performed retrospectively, and was not powered to detect any 
pre-specified difference in adverse reactions. 
 
5.  INDICATION AND USAGE 
VIAGRA is indicated for the treatment of erectile dysfunction. 
 
6.  CONTRAINDICATIONS 
Consistent  with  its  known  effects  on  the  nitric  oxide/cGMP  pathway  (see 
CLINICAL PHARMACOLOGY), VIAGRA was shown to potentiate the hypotensive 
effects of nitrates, and its administration to patients who are using organic nitrates, 
either regularly and/or intermittently, in any form is therefore contraindicated.  
 
After patients have taken VIAGRA, it is unknown when nitrates, if necessary, can 
be safely administered. Based on the pharmacokinetic profile of a single 100 mg 
oral dose given to healthy normal volunteers, the plasma levels of sildenafil at 24 
hours post dose are approximately 2 ng/ml (compared to peak plasma levels of 
approximately 440 ng/mL) (see CLINICAL PHARMACOLOGY: Pharmacokinetics 
and  Metabolism).  In  the  following  patients:  age  >65,  hepatic  impairment  (e.g., 
cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and 
concomitant use of potent cytochrome P450 3A4 inhibitors (erythromycin), plasma 
levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher 
than those seen in healthy volunteers. Although plasma levels of sildenafil at 24 
hours post dose are much lower than at peak concentration, it is unknown whether 
nitrates  can  be  safely  co-administered  at  this  time  point.  VIAGRA  is 
contraindicated in patients with a known hypersensitivity to any component of the 
tablet. 
 
7.  WARNINGS 
There is a potential for cardiac risk of sexual activity in patients with preexisting 
cardiovascular  disease.  Therefore,  treatments  for  erectile  dysfunction,  including 
VIAGRA,  should  not  be  generally  used  in  men  for  whom  sexual  activity  is 
inadvisable because of their underlying cardiovascular status. 
VIAGRA has systemic vasodilatory properties that resulted in transient decreases 
in  supine  blood  pressure  in  healthy  volunteers  (mean  maximum  decrease  of 
8.4/5.5 mmHg), (see CLINICAL PHARMACOLOGY: Pharmacodynamics). While 
this normally would be expected to be of little consequence in most patients, prior 
to prescribing VIAGRA, physicians should carefully consider whether their patients 
with  underlying  cardiovascular  disease  could  be  affected  adversely  by  such 
vasodilatory effects, especially in combination with sexual activity. 
 
Patients with the following underlying conditions can be particularly sensitive to the 
actions of 
vasodilators  including  VIAGRA  –  those  with  left  ventricular  outflow  obstruction 
(e.g.  aortic  stenosis,  idiopathic  hypertrophic  subaortic  stenosis)  and  those  with 
severely  impaired  autonomic  control  of  blood  pressure.  There  is  no  controlled 
clinical  data  on  the  safety  or  efficacy  of  VIAGRA  in  the  following  groups;  if 
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•   Patients  who  have  suffered  a  myocardial  infarction,  stroke,  or  life-threatening 
arrhythmia within the last 6 months; 
•   Patients with resting hypotension (BP <90/50) or hypertension (BP >170/110); 
•   Patients with cardiac failure or coronary artery disease causing unstable angina; 
•   Patients  with  retinitis  pigmentosa  (a  minority  of  these  patients  have  genetic 
disorders of retinal phosphodiesterases). 
 
Prolonged erection greater than 4 hours and priapism (painful erections greater 
than 6 hours in duration) have been reported infrequently since market approval of 
VIAGRA. In the event of an erection that persists longer than 4 hours, the patient 
should seek immediate medical assistance. If priapism is not treated immediately, 
penile tissue damage and permanent loss of potency could result. 
 
The  concomitant  administration  of  the  protease  inhibitor  ritonavir  substantially 
increases serum concentrations of sildenafil (11-fold increase in AUC). If VIAGRA 
is  prescribed  to  patients  taking  ritonavir,  caution  should  be  used.  Data  from 
subjects  exposed  to  high  systemic  levels  of  sildenafil  are  limited.  Visual 
disturbances  occurred  more  commonly  at  higher  levels  of  sildenafil  exposure. 
Decreased  blood  pressure,  syncope,  and  prolonged  erection  were  reported  in 
some  healthy  volunteers  exposed  to  high  doses  of  sildenafil  (200-800  mg).  To 
decrease the chance of adverse events in patients taking ritonavir, a decrease in 
sildenafil  dosage  is  recommended  (see  Drug  Interactions,  ADVERSE 
REACTIONS and DOSAGE AND ADMINISTRATION). 
 
8.  PRECAUTIONS 
8.1  General 
The evaluation of erectile dysfunction should include a determination of potential 
underlying  causes  and  the  identification  of  appropriate  treatment  following  a 
complete medical assessment.  
 
Before prescribing VIAGRA, it is important to note the following: 
 
Patients  on  multiple  antihypertensive  medications  were  included  in  the  pivotal 
clinical trials for VIAGRA. In a separate drug interaction study, when amlodipine, 5 
mg or 10 mg, and VIAGRA, 100 mg were orally administered concomitantly to 
hypertensive  patients  mean  additional  blood  pressure  reduction  of  8  mmHg 
systolic and 7 mmHg diastolic were noted (see Drug Interactions). 
 
When  the  alpha  blocker  doxazosin  (4  mg)  and  VIAGRA  (25  mg)  were 
administered simultaneously to patients with benign prostatic hyperplasia (BPH), 
mean additional reductions of supine blood pressure of 7 mmHg systolic and 7 
mmHg diastolic were observed. When higher doses of VIAGRA and doxazosin (4 
mg) were administered simultaneously, there were infrequent reports of patients 
who experienced symptomatic postural hypotension within 1 to 4 hours of dosing. 
Simultaneous administration of VIAGRA to patients taking alpha-blocker therapy 
may lead to symptomatic hypotension in some patients. Therefore, VIAGRA doses 
above 25 mg should not be taken within 4 hours of taking an alpha-blocker. 
 
The safety of VIAGRA is unknown in patients with bleeding disorders and patients 
with active peptic ulceration. 
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VIAGRA should be used with caution in patients with anatomical deformation of 
the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in 
patients who have conditions which may predispose them to priapism (such as 
sickle cell anemia, multiple myeloma, or leukemia). 
 
The  safety  and  efficacy  of  combinations  of  VIAGRA  with  other  treatments  for 
erectile  dysfunction  have  not  been  studied.  Therefore,  the  use  of  such 
combinations is not recommended. 
 
In  humans,  VIAGRA  has  no  effect  on  bleeding  time  when  taken  alone  or  with 
aspirin. In vitro studies with human platelets indicate that sildenafil potentiates the 
antiaggregatory  effect  of  sodium  nitroprusside  (a  nitric  oxide  donor).  The 
combination of heparin and VIAGRA had an additive effect on bleeding time in the 
anesthetized rabbit, but this interaction has not been studied in humans. 
 
8.2  Information for Patients 
Physicians  should  discuss  with  patients  the  contraindication  of  VIAGRA  with 
regular and/or 
intermittent use of organic nitrates. Physicians should discuss with patients the 
potential cardiac risk of sexual activity in patients with preexisting cardiovascular 
risk factors. Patients who experience symptoms (e.g., angina pectoris, dizziness, 
nausea) upon initiation of sexual activity should be advised to refrain from further 
activity and should discuss the episode with their physician. 
 
Physicians  should  advise  patients  to  stop  use  of  all  PDE5  inhibitors,  including 
VIAGRA, and seek medical attention in the event of a sudden loss of vision in one 
or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic 
neuropathy  (NAION),  a  cause  of  decreased  vision  including  permanent  loss  of 
vision, that has been reported rarely post-marketing in temporal association with 
the use of all PDE5 inhibitors. It is not possible to determine whether these events 
are related directly to the use of PDE5 inhibitors or to other factors. Physicians 
should also discuss with patients the increased risk of NAION in individuals who 
have already experienced NAION in one eye, including whether such individuals 
could be adversely affected by use of vasodilators, such as PDE5 inhibitors (see 
POST-MARKETING  EXPERIENCE/Special  Senses).  Physicians  should  warn 
patients  that  prolonged  erections  greater  than  4  hours  and  priapism  (painful 
erections greater than 6 hours in duration) have been reported infrequently since 
market approval of VIAGRA. In the event of an erection that persists longer than 4 
hours, the patient should seek immediate medical assistance. If priapism is not 
treated immediately, penile tissue damage and permanent loss of potency may 
result. 
 
Physicians  should  advise  patients  that  simultaneous  administration  of  VIAGRA 
doses above 25 mg and an alpha-blocker may lead to symptomatic hypotension in 
some patients. Therefore, VIAGRA doses above 25 mg should not be taken within 
four hours of taking an alpha-blocker. 
 
The use of VIAGRA offers no protection against sexually transmitted diseases. 
Counseling of patients about the protective measures necessary to guard against 
sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), 
may be considered. 
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9.  Drug Interactions 
9.1  Effects of Other Drugs on VIAGRA 
In vitro studies: Sildenafil metabolism is principally mediated by the cytochrome 
P450 (CYP) 
isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these 
isoenzymes may reduce sildenafil clearance. 
 
In vivo studies: Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% 
increase in plasma sildenafil concentrations when coadministered with VIAGRA 
(50 mg) to healthy volunteers. 
 
When a single 100 mg dose of VIAGRA was administered with erythromycin, a 
specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 
182%  increase  in  sildenafil  systemic  exposure  (AUC).  In  addition,  in  a  study 
performed  in  healthy  male  volunteers,  co-administration  of  the  HIV  protease 
inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with 
VIAGRA (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and 
a  210%  increase  in  sildenafil  AUC.  VIAGRA  had  no  effect  on  saquinavir 
pharmacokinetics.  Stronger  CYP3A4  inhibitors  such  as  ketoconazole  or 
itraconazole would be expected to have still greater effects, and population data 
from patients in clinical trials did indicate a reduction in sildenafil clearance when it 
was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, 
or cimetidine) (see DOSAGE AND ADMINISTRATION). 
 
In  another  study  in  healthy  male  volunteers,  co-administration  with  the  HIV 
protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state 
(500  mg  bid)  with  VIAGRA  (100  mg  single  dose)  resulted  in  a  300%  (4-fold) 
increase in sildenafil Cmax and a 1000% (11-fold) increase in sildenafil plasma 
AUC.  At  24  hours  the  plasma  levels  of  sildenafil  were  still  approximately  200 
ng/mL, compared to approximately 5 ng/mL when sildenafil was dosed alone. This 
is consistent with ritonavir’s marked effects on a broad range of P450 substrates. 
VIAGRA  had  no  effect  on  ritonavir  pharmacokinetics  (see  DOSAGE  AND 
ADMINISTRATION). 
 
Although the interaction between other protease inhibitors and sildenafil has not 
been studied, their concomitant use is expected to increase sildenafil levels.  
 
It can be expected that concomitant administration of CYP3A4 inducers, such as 
rifampin, will decrease plasma levels of sildenafil.  
 
Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect 
the bioavailability of VIAGRA.  
 
Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil 
pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 
inhibitors  (such  as  selective  serotonin  reuptake  inhibitors,  tricyclic 
antidepressants),  thiazide  and  related  diuretics,  ACE  inhibitors,  and  calcium 
channel blockers. The AUC of the active metabolite, N-desmethyl sildenafil, was 
increased 62% by loop and potassium-sparing diuretics and 102% by nonspecific 
beta-blockers. These effects on the metabolite are not expected to be of clinical 
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9.2  Effects of VIAGRA on Other Drugs 
In vitro studies: Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 
2C9,  2C19,  2D6,  2E1  and  3A4  (IC50  >150  µM).  Given  sildenafil  peak  plasma 
concentrations of approximately 1 µM after recommended doses, it is unlikely that 
VIAGRA will alter the clearance of substrates of these isoenzymes.  
 
In vivo studies: When VIAGRA 100 mg oral was coadministered with amlodipine, 5 
mg  or  10  mg  oral,  to  hypertensive  patients,  the  mean  additional  reduction  on 
supine blood pressure was 8 mmHg  systolic and 7 mmHg diastolic. No significant 
interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of 
which are metabolized by CYP2C9. 
 
VIAGRA (50 mg) did not potentiate the increase in bleeding time caused by aspirin 
(150 mg). 
 
VIAGRA (50 mg) did not potentiate the hypotensive effect of alcohol in healthy 
volunteers with mean maximum blood alcohol levels of 0.08%. 
 
In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady 
state  pharmacokinetics  of  the  HIV  protease  inhibitors,  saquinavir  and  ritonavir, 
both of which are CYP3A4 substrates. 
 
9.3  Carcinogenesis, Mutagenesis, Impairment of Fertility 
Sildenafil was not carcinogenic when administered to rats for 24 months at a dose 
resulting  in  total  systemic  drug  exposure  (AUCs)  for  unbound  sildenafil  and  its 
major metabolite of 29- and 42-times, for male and female rats, respectively, the 
exposures observed in human males given the Maximum Recommended Human 
Dose (MRHD) of 100 mg. Sildenafil was not carcinogenic when administered to 
mice for 18-21 months at dosages up to the Maximum Tolerated Dose (MTD) of 
10 mg/kg/day, approximately 0.6 times the MRHD on a mg/m2 basis.  
 
Sildenafil was negative in in vitro bacterial and Chinese hamster ovary cell assays 
to  detect  mutagenicity,  and  in  vitro  human  lymphocytes  and  in  vivo  mouse 
micronucleus assays to detect clastogenicity. 
 
There was no impairment of fertility in rats given sildenafil up to 60 mg/kg/day for 
36 days to females and 102 days to males, a dose producing an AUC value of 
more than 25 times the human male AUC. There was no effect on sperm motility 
or morphology after single 100 mg oral doses of VIAGRA in healthy volunteers. 
 
9.4  Pregnancy, Nursing Mothers and Pediatric Use 
VIAGRA is not indicated for use in newborns, children, or women. 
 
9.5  Pregnancy Category B.  
No evidence of teratogenicity, embryotoxicity or fetotoxicity was observed in rats 
and  rabbits  which  received  up  to  200  mg/kg/day  during  organogenesis.  These 
doses represent, respectively, about 20 and 40 times the MRHD on a mg/m2 basis 
in  a  50  kg  subject.  In  the  rat  pre-  and  postnatal  development  study,  the  no 
observed  adverse  effect  dose  was  30  mg/kg/day  given  for  36  days.  In  the 
nonpregnant rat the AUC at this dose was about 20 times human AUC. There are 
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9.6  Geriatric Use 
Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil 
(see  CLINICAL  PHARMACOLOGY:  Pharmacokinetics  in  Special  Populations). 
Since  higher  plasma  levels  may  increase  both  the  efficacy  and  incidence  of 
adverse events, a starting dose of 25 mg should be considered (see DOSAGE 
AND ADMINISTRATION). 
 
10  ADVERSE REACTIONS 
10.1 Pre-marketing experience 
VIAGRA was administered to over 3700 patients (aged 19-87 years) during clinical 
trials worldwide. Over 550 patients were treated for longer than one year. 
 
In  placebo-controlled  clinical  studies,  the  discontinuation  rate  due  to  adverse 
events for VIAGRA (2.5%) was not significantly different from placebo (2.3%). The 
adverse events were generally transient and mild to moderate in nature. 
 
In trials of all designs, adverse events reported by patients receiving VIAGRA were 
generally  similar.  In  fixed-dose  studies,  the  incidence  of  some  adverse  events 
increased with dose. The nature of the adverse events in flexible-dose studies, 
which more closely reflect the recommended dosage regimen, was similar to that 
for fixed-dose studies. 
 
 
When VIAGRA was taken as recommended (on an as-needed basis) in flexible-
dose, placebo-controlled clinical trials, the following adverse events were reported: 
 
TABLE 2. ADVERSE EVENTS REPORTED BY ≥2% OF PATIENTS TREATED WITH VIAGRA 
AND MORE FREQUENT ON DRUG THAN PLACEBO IN PRN FLEXIBLE-DOSE PHASE II/III 
STUDIES 
 
 
 
†Abnormal  Vision:  Mild  and  transient,  predominantly  color  tinge  to  vision,  but  also  increased 
sensitivity to light or blurred vision. In these studies, only one patient discontinued due to abnormal 
vision. 
 
 
 
 
Other  adverse  reactions  occurred  at  a  rate  of  >2%,  but  equally  common  on 
placebo: respiratory tract infection, back pain, flu syndrome, and arthralgia. End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 168 of 192 
 
Tony Vassalos   2010 
 
In  fixed-dose  studies,  dyspepsia  (17%)  and  abnormal  vision  (11%)  were  more 
common at 100 mg than at lower doses. At doses above the recommended dose 
range, adverse events were similar to those detailed above but generally were 
reported more frequently. 
 
The  following  events  occurred  in  <2%  of  patients  in  controlled  clinical  trials;  a 
causal relationship to VIAGRA is uncertain. Reported events include those with a 
plausible relation to drug use; omitted are minor events and reports too imprecise 
to be meaningful: 
 
Body  as  a  whole:  face  edema,  photosensitivity  reaction,  shock,  asthenia,  pain, 
chills,  accidental  fall,  abdominal  pain,  allergic  reaction,  chest  pain,  accidental 
injury.  
 
Cardiovascular:  angina  pectoris,  AV  block,  migraine,  syncope,  tachycardia, 
palpitation,  hypotension,  postural  hypotension,  myocardial  ischemia,  cerebral 
thrombosis,  cardiac  arrest,  heart  failure,  abnormal  electrocardiogram, 
cardiomyopathy. 
 
Digestive:  vomiting,  glossitis,  colitis,  dysphagia,  gastritis,  gastroenteritis, 
esophagitis,  stomatitis,  dry  mouth,  liver  function  tests  abnormal,  rectal 
hemorrhage, gingivitis. 
Hemic and Lymphatic: anemia and leukopenia. 
 
Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, 
peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. 
Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone 
pain, myasthenia, synovitis. 
 
Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, 
depression,  insomnia,  somnolence,  abnormal  dreams,  reflexes  decreased, 
hypesthesia. 
 
Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum 
increased, cough increased. 
 
Skin  and  Appendages:  urticaria,  herpes  simplex,  pruritus,  sweating,  skin  ulcer, 
contact dermatitis, exfoliative dermatitis.  
 
Special  Senses:  mydriasis,  conjunctivitis,  photophobia,  tinnitus,  eye  pain, 
deafness, ear pain, eye hemorrhage, cataract, dry eyes. 
 
Urogenital:  cystitis,  nocturia,  urinary  frequency,  breast  enlargement,  urinary 
incontinence, abnormal ejaculation, genital edema and anorgasmia. 
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10.3 Post-marketing experience 
Cardiovascular and cerebrovascular: serious cardiovascular, cerebrovascular, and 
vascular events, including myocardial infarction, sudden cardiac death, ventricular 
arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, 
subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have 
been reported post-marketing in temporal association with the use of VIAGRA. 
Most,  but  not  all,  of  these  patients  had  preexisting  cardiovascular  risk  factors. 
Many of these events were reported to occur during or shortly after sexual activity, 
and a few were reported to occur shortly after the use of VIAGRA without sexual 
activity.  Others  were  reported  to  have  occurred  hours  to  days  after  the  use  of 
VIAGRA and sexual activity. It is not possible to determine whether these events 
are  related  directly  to  VIAGRA,  to  sexual  activity,  to  the  patient’s  underlying 
cardiovascular disease, to a combination of these factors, or to other factors (see 
WARNINGS for further important cardiovascular information). 
 
Other  events  reported  post-marketing  to  have  been  observed  in  temporal 
association with VIAGRA and not listed in the pre-marketing adverse reactions 
section above include: 
 
Nervous: seizure and anxiety. 
 
Urogenital: prolonged erection, priapism (see WARNINGS) and hematuria. 
 
Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness 
or  bloodshot  appearance,  ocular  burning,  ocular  swelling/pressure,  increased 
intraocular  pressure,  retinal  vascular  disease  or  bleeding,  vitreous 
detachment/traction, paramacular edema and epistaxis.  
 
Non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased 
vision including permanent loss of vision, has been reported rarely post-marketing 
in  temporal  association  with  the  use  of  phosphodiesterase  type  5  (PDE5) 
inhibitors, including VIAGRA. Most, but not all, of these patients had underlying 
anatomic  or  vascular  risk  factors  for  developing  NAION,  including  but  not 
necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, 
hypertension,  coronary  artery  disease,  hyperlipidemia  and  smoking.  It  is  not 
possible to determine whether these events are related directly to the use of PDE5 
inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to 
a  combination  of  these  factors,  or  to  other  factors  (see 
PRECAUTIONS/Information for Patients). 
 
11.  OVERDOSAGE 
In studies with healthy volunteers of single doses up to 800 mg, adverse events 
were similar to those seen at lower doses but incidence rates were increased. 
 
In  cases  of  overdose,  standard  supportive  measures  should  be  adopted  as 
required. Renal dialysis is not expected to accelerate clearance as sildenafil is 
highly bound to plasma proteins and it is not eliminated in the urine. 
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12.  DOSAGE AND ADMINISTRATION 
For  most  patients,  the  recommended  dose  is  50  mg  taken,  as  needed, 
approximately  1  hour  before  sexual  activity.  However,  VIAGRA  may  be  taken 
anywhere from 4 hours to 0.5 hour before sexual activity. Based on effectiveness 
and toleration, the dose may be increased to a maximum recommended dose of 
100 mg or decreased to 25 mg. The maximum recommended dosing frequency is 
once per day. 
 
The following factors are associated with increased plasma levels of sildenafil: age 
>65  (40%  increase  in  AUC),  hepatic  impairment  (e.g.,  cirrhosis,  80%),  severe 
renal impairment (creatinine clearance <30 mL/min, 100%), and concomitant use 
of  potent  cytochrome  P450  3A4  inhibitors  [ketoconazole,  itraconazole, 
erythromycin  (182%),  saquinavir  (210%)].  Since  higher  plasma  levels  may 
increase both the efficacy and incidence of adverse events, a starting dose of 25 
mg should be considered in these patients. 
 
Ritonavir greatly increased the systemic level of sildenafil in a study of healthy, 
non-HIV  infected  volunteers  (11-fold  increase  in  AUC,  see  Drug  Interactions.) 
Based  on  these  pharmacokinetic  data,  it  is  recommended  not  to  exceed  a 
maximum single dose of 25 mg of VIAGRA in a 48 hour period. VIAGRA was 
shown to potentiate the hypotensive effects of nitrates and its administration in 
patients  who  use  nitric  oxide  donors  or  nitrates  in  any  form  is  therefore 
contraindicated.  
 
Simultaneous administration of VIAGRA doses above 25 mg and an alpha-blocker 
may lead to symptomatic hypotension in some patients. Doses of 50 mg or 100 
mg of VIAGRA should not be taken within 4 hours of alpha-blocker administration. 
A 25 mg dose of VIAGRA may be taken at any time. 
 
 
13.  HOW SUPPLIED 
VIAGRA® (sildenafil citrate) is supplied as blue, film-coated, rounded-diamond-
shaped tablets containing sildenafil citrate equivalent to the nominally indicated 
amount of sildenafil as follows: 
 
 
 
Recommended Storage: Store at 25°C (77°F); excursions permitted to 15-30°C 
(59-86°F) [see USP Controlled Room Temperature]. 
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14.  PATIENT SUMMARY OF INFORMATION ABOUT 
(Sildenafil citrate) tablets 
 
This summary contains important information about VIAGRA®. It is not meant to 
take the place of your doctor’s instructions. Read this information carefully before 
you start taking VIAGRA. Ask your doctor or pharmacist if you do not understand 
any of this information or if you want to know more about VIAGRA. 
 
This medicine can help many men when it is used as prescribed by their doctors. 
However, VIAGRA is not for everyone. It is intended for use only by men who have 
a condition called erectile dysfunction. VIAGRA must never be used by men who 
are taking medicines that contain nitrates of any kind, at any time. This includes 
nitroglycerin. If you take VIAGRA with any nitrate medicine your blood pressure 
could suddenly drop to an unsafe or life threatening level. 
 
WHAT IS VIAGRA? 
VIAGRA is a pill used to treat erectile dysfunction (impotence) in men. It can help 
many  men  who  have  erectile  dysfunction  get  and  keep  an  erection  when  they 
become sexually excited (stimulated). You will not get an erection just by taking 
this medicine. VIAGRA helps a man with erectile dysfunction get an erection only 
when he is sexually excited. 
 
HOW SEX AFFECTS THE BODY 
When a man is sexually excited, the penis rapidly fills with more blood than usual. 
The penis then expands and hardens. This is called an erection. After the man is 
done having sex, this extra blood flows out of the penis back into the body. The 
erection goes away. If an erection lasts for a long time (more than 6 hours), it can 
permanently damage your penis. You should call a doctor immediately if you ever 
have  a  prolonged  erection  that  lasts  more  than  4  hours.  Some  conditions  and 
medicines interfere with this natural erection process. The penis cannot fill with 
enough  blood.  The  man  cannot  have  an  erection.  This  is  called  erectile 
dysfunction if it becomes a frequent problem. During sex, your heart works harder. 
Therefore  sexual  activity  may  not  be  advisable  for  people  who  have  heart 
problems. Before you start any treatment for erectile dysfunction, ask your doctor if 
your heart is healthy enough to handle the extra strain of having sex. If you have 
chest pains, dizziness or nausea during sex, stop having sex and immediately tell 
your doctor you have had this problem.  
 
HOW VIAGRA WORKS 
VIAGRA  enables  many  men  with  erectile  dysfunction  to  respond  to  sexual 
stimulation.  When  a  man  is  sexually  excited,  VIAGRA  helps  the  penis  fill  with 
enough blood to cause an erection. After sex is over, the erection goes away. 
 
VIAGRA IS NOT FOR EVERYONE 
As  noted  above  (How  Sex  Affects  the  Body),  ask  your  doctor  if  your  heart  is 
healthy enough for sexual activity. If you take any medicines that contain nitrates – 
either  regularly  or  as  needed  –  you  should  never  take  VIAGRA.  If  you  take 
VIAGRA with any nitrate medicine or recreational drug containing nitrates, your 
blood pressure could suddenly drop to an unsafe level. You could get dizzy, faint, 
or  even  have  a  heart  attack  or  stroke.  Nitrates  are  found  in  many  prescription 
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•   nitroglycerin  (sprays,  ointments,  skin  patches  or  pastes,  and  tablets  that  are 
swallowed 
or dissolved in the mouth) 
 
•   isosorbide  mononitrate  and  isosorbide  dinitrate  (tablets  that  are  swallowed, 
chewed, or 
dissolved in the mouth) 
 
Nitrates  are  also  found  in  recreational  drugs  such  as  amyl  nitrate  or  nitrite 
(“poppers”). If you are not sure if any of your medicines contain nitrates, or if you 
do not understand what nitrates are, ask your doctor or pharmacist. VIAGRA is 
only for patients with erectile dysfunction. VIAGRA is not for newborns, children, or 
women. Do not let anyone else take your VIAGRA. VIAGRA must be used only 
under a doctor’s supervision. 
 
WHAT VIAGRA DOES NOT DO 
•   VIAGRA  does  not  cure  erectile  dysfunction.  It  is  a  treatment  for  erectile 
dysfunction. 
•   VIAGRA does not protect you or your partner from getting sexually transmitted 
diseases, including HIV—the virus that causes AIDS. 
•   VIAGRA is not a hormone or an aphrodisiac. 
 
WHAT TO TELL YOUR DOCTOR BEFORE YOU BEGIN VIAGRA 
Only your doctor can decide if VIAGRA is right for you. VIAGRA can cause mild, 
temporary  lowering  of  your  blood  pressure.  You  will  need  to  have  a  thorough 
medical  exam  to  diagnose  your  erectile  dysfunction  and  to  find  out  if  you  can 
safely  take  VIAGRA  alone  or  with  your  other  medicines.  Your  doctor  should 
determine if your heart is healthy enough to handle the extra strain of having sex. 
 
Be sure to tell your doctor if you: 
•   have ever had any heart problems (e.g., angina, chest pain, heart failure, irregular 
heart 
  beats, heart attack or narrowing of the aortic valve) 
•   have ever had a stroke 
•   have low or high blood pressure 
•   have ever had severe vision loss 
•   have a rare inherited eye disease called retinitis pigmentosa 
•   have ever had any kidney problems 
•   have ever had any liver problems 
•   have ever had any blood problems, including sickle cell anemia or leukemia 
•   are allergic to sildenafil or any of the other ingredients of VIAGRA tablets 
•   have a deformed penis, Peyronie’s disease, or ever had an erection that lasted 
more than 
  4 hours 
•   have stomach ulcers or any types of bleeding problems 
•   are taking any other medicines 
 
VIAGRA AND OTHER MEDICINES 
Some medicines can change the way VIAGRA works. Tell your doctor about any 
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checking  with  your  doctor  or  pharmacist.  This  includes  prescription  and 
nonprescription medicines or remedies: 
 
•   Remember, VIAGRA should never be used with medicines that contain nitrates 
(see VIAGRA Is Not for Everyone). 
•   If you are taking alpha-blocker therapy for the treatment of high blood pressure or 
prostate problems, you should not take a dose of greater than 25 mg of VIAGRA 
at the same time (within 4 hours) as you take your dose of alpha-blocker. 
•   If  you  are  taking  a  protease  inhibitor,  your  dose  may  be  adjusted  (please  see 
Finding the Right Dose for You). 
•   VIAGRA  should  not  be  used  with  any  other  medical  treatments  that  cause 
erections. These treatments include pills, medicines that are injected or inserted 
into the penis, implants or vacuum pumps. 
 
FINDING THE RIGHT DOSE FOR YOU 
VIAGRA comes in different doses (25 mg, 50 mg and 100 mg). If you do not get 
the results you expect, talk with your doctor. You and your doctor can determine 
the dose that works best for you. 
 
•   Do not take more VIAGRA than your doctor prescribes. 
•   If you think you need a larger dose of VIAGRA, check with your doctor. 
•   VIAGRA should not be taken more than once a day. 
 
If you are older than age 65, or have serious liver or kidney problems, your doctor 
may start you at the lowest dose (25 mg) of VIAGRA. If you are taking protease 
inhibitors, such as for the treatment of HIV, your doctor may recommend a 25 mg 
dose and may limit you to a maximum single dose of 25 mg of VIAGRA in a 48 
hour period. If you are taking alpha-blocker therapy, you should not take a dose of 
greater than 25 mg of VIAGRA at the same time (within 4 hours) as your dose of 
alphablocker.  
 
HOW TO TAKE VIAGRA 
Take VIAGRA about one hour before you plan to have sex. Beginning in about 30 
minutes and for up to 4 hours, VIAGRA can help you get an erection if you are 
sexually  excited.  If  you  take  VIAGRA  after  a  high-fat  meal  (such  as  a 
cheeseburger  and  french  fries),  the  medicine  may  take  a  little  longer  to  start 
working. VIAGRA can help you get an erection when you are sexually excited. You 
will not get an erection just by taking the pill. 
 
POSSIBLE SIDE EFFECTS 
Like  all  medicines,  VIAGRA  can  cause  some  side  effects.  These  effects  are 
usually mild to moderate and usually don’t last longer than a few hours. Some of 
these side effects are more likely to occur with higher doses. The most common 
side effects of VIAGRA are headache, flushing of the face, and upset stomach. 
Less common side effects that may occur are temporary changes in color vision 
(such as trouble telling the difference between blue and green objects or having a 
blue color tinge to them), eyes being more sensitive to light, or blurred vision. 
 
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, 
including VIAGRA) reported a sudden decrease or loss of vision in one or both 
eyes. It is not possible to determine whether these events are related directly to 
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combination of these. If you experience sudden decrease or loss of vision, stop 
taking PDE5 inhibitors, including VIAGRA, and call a doctor right away. In rare 
instances, men have reported an erection that lasts many hours. You should call a 
doctor immediately if you ever have an erection that lasts more than 4 hours. If not 
treated right away, permanent damage to your penis could occur (see How Sex 
Affects the Body). 
 
Heart attack, stroke, irregular heart beats, and death have been reported rarely in 
men taking VIAGRA. Most, but not all, of these men had heart problems before 
taking this medicine. It is not possible to determine whether these events were 
directly related to VIAGRA. VIAGRA may cause other side effects besides those 
listed on this sheet. If you want more information or develop any side effects or 
symptoms you are concerned about, call your doctor. 
 
ACCIDENTAL OVERDOSE 
In case of accidental overdose, call your doctor right away. 
 
STORING VIAGRA 
Keep VIAGRA out of the reach of children. Keep VIAGRA in its original container. 
Store  at  25°C  (77°F);  excursions  permitted  to  15-30°C  (59-86°F)  [see  USP 
Controlled Room Temperature]. 
 
FOR MORE INFORMATION ON VIAGRA 
VIAGRA is a prescription medicine used to treat erectile dysfunction. Only your 
doctor can decide if it is right for you. This sheet is only a summary. If you have 
any questions or want more information about VIAGRA, talk with your doctor or 
pharmacist, visit www.viagra.com, or call 1-888-4VIAGRA. 
 
© 2005, Pfizer Inc June 2005 
Distributed by 
LAB-0221-2 Revised June 2005 
Pfizer Labs 
Division of Pfizer Inc, NY, NY 10017 
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6.2.3  Appendix  3:  Medicines  and  Healthcare  products  Regulatory  Agency 
Approval 
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6.2.4  Appendix 4: Local and Regional Ethics Approval 
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6.2.5  Appendix 5: Parent Information Sheet 
VERSION 2 (18/01/2006) 
 
Study  Title:  Does  pre-operative  Sildenafil  protect  against  pulmonary  related 
complications  following  cardiopulmonary  bypass?  A  randomised  trial  in  children 
undergoing cardiac surgical repair. 
 
Lay  Title:  Will  giving  the  drug  Sildenafil  to  children  before  open-heart  surgery 
improve the function of the lungs after surgery? 
 
Invitation paragraph: You and your child are being invited to take part in a research 
study. Before you decide it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following information 
carefully and discuss it with family, medical or nursing staff if you wish. Ask us if 
there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
 
Q1. What is the purpose of the study? 
 
Ans: The purpose of this study is to investigate whether giving the drug Sildenafil 
(Viagra, Pfizer) to children before open-heart surgery improves the function of the 
lungs after surgery. 
 
Q2. Why have I been chosen? 
 
Ans: Participation in this study is being offered to all parents with children aged over 3 
months undergoing heart surgery to correct inborn heart defects that allow increased 
blood flow within the lungs and may be associated with lung related complications 
(pulmonary hypertension) after surgery. 
 
Q3. Do I have to take part? 
 
Ans: NO. It is up to you to decide whether or not you wish your child to take part.  If 
you do decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. If you decide to take part you are still free to withdraw at 
any  time  and  without  giving  a  reason.    A  decision  to  withdraw  at  any  time,  or  a 
decision not to take part, will not affect the standard of care your child receives. 
 
Q4. What will happen to my child, if my child takes part?  
 
Ans: If you decide that you would like your child to take part: 
-  The day immediately before surgery your child will be randomly (like the toss of a 
coin) put into a group that is either given the drug Sildenafil (1/2 teaspoon liquid) or 
Placebo (1/2 teaspoon inactive liquid), 6hrly (4 doses) by the ward nursing staff. 
This will be given in addition to their normal medications. 
-  Otherwise,  your  child’s  surgical  and  medical  care  both  before,  during  and  after 
surgery will follow the normal practice of their consultant heart surgeon. End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 179 of 192 
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-  Your child’s progress before, during and after surgery will be closely monitored.  
 
(e)  Data from ward charts, intensive care charts and routine blood results will be recorded.  
(f)  Images from routine echocardiography used before, during and after surgery to assess 
the heart’s function will be studied on the computer.  
(g)  Any  blood  that  remains  after  routine  investigations  have  been  carried  out  by  the 
laboratory at Yorkhill will be stored and used to measure markers of inflammation / 
infection. No extra blood will be taken from your child specifically for the trial. 
 
-  Your child will remain part of the trial until the day of discharge (usually 5 
days). 
-  You and your child will not need to visit your GP or attend any additional 
clinics. Your child’s GP will however be informed of your child’s participation 
in this trial. 
 
Q5. What do I have to do? 
 
Ans: There are no associated restrictions with taking part in this study. Your child’s 
stay in hospital should follow the normal course.  
 
Q6. What is the drug or procedure that is being tested? 
 
Ans:  The  drug  being  tested  is  called  Sildenafil  (Viagra,  Pfizer).  Some  children 
undergoing heart surgery to correct inborn heart defects that allow increase blood flow 
within  the  lungs  are  prone  to  lung  related  complications  (pulmonary  hypertension) 
after  surgery.  Oral  Sildenafil  liquid  (0.5mg/kg)  is  routinely  used  in  our  pediatric 
intensive care unit after heart surgery to treat these complications. We hope that giving 
4 doses of oral Sildenafil (0.5mg/kg, equivalent to ½ teaspoon liquid per dose) the day 
before surgery will prevent or reduce lung related complications after surgery. 
 
Q7. What are the side effects of any treatment received when taking part? 
 
Ans: Sildenafil is not licensed in the UK for the treatment of pulmonary hypertension. 
Sildenafil is however effectively and regularly used after heart surgery in our pediatric 
intensive  care  unit  to  treat  post-operative  pulmonary  hypertension.  Clinical  trials 
assessing the use of Sildenafil in children undergoing heart surgery are limited but to 
date there are no clinically significant side effects reported in giving oral Sildenafil 
(0.5mg-2mg/kg; 6hrly) to children. This opinion is also supported by our own clinical 
experience. Although some children in the trial will receive 4 doses of Sildenafil the 
day  before  surgery,  after  surgery  Sildenafil  could  be  given  to  any  child  if  that  is 
deemed necessary by the consultant cardiac surgeon and the medical team responsible 
for their care. All clinically significant side effects thought to be related to Sildenafil 
administration in this study will be recorded and reported to the relevant authorities. 
 
Q8. What are the possible disadvantages and risks of taking part? 
 
Ans: The mainstay of your child’s surgical and medical care before, during and after 
surgery will follow the normal clinical practice of their consultant cardiac surgeon. 
Possible disadvantages and risks would therefore be related to taking 4 oral doses of 
Sildenafil liquid (0.5mg/kg) the day before surgery. Side effects including headache, 
flushing, diarrhoea, rash and heartburn have been reported in the literature but we do 
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used in this study. Oral Sildenafil (0.5-2mg/kg/4-6hrs) is routinely used after heart 
surgery in our pediatric intensive care unit without clinically significant side effects. 
 
Q9. What are the possible benefits of taking part? 
 
Ans: We hope that giving 4 doses of the drug Sildenafil before surgery will protect the 
lungs during surgery to improve lung function and reduce related complications after 
surgery. If this is the case it would reduce the overall recovery time and intensive care 
stay  after  surgery.  All  children  undergoing  corrective  heart  surgery  are  closely 
monitored  throughout  their  admission.  Although  this  will  also  be  the  case  for  all 
research participants they will undergo a more detailed echocardiographic assessment 
both before and after surgery, providing additional clinical information that may be 
beneficial to the caring medical team. 
 
Q10. What if new information becomes available? 
 
Ans: All relevant additional information on the function of the heart and lungs found 
during the trial will be made available to the clinical team caring for your child to 
allow them to make the appropriate clinical decisions early. 
 
Q11. What happens when the research study stops? 
 
Ans: The research study stops when your child is discharged from hospital. There is no 
further participation or responsibility.  
 
Q12. What if something goes wrong? 
 
Ans: If taking part in this research project harms your child, there are no special 
compensation arrangements.  If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  Regardless of this, 
if you wish to complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
 
Q13. Will my taking part in this study be kept confidential? 
 
Ans: All information that is collected about your child during the course of the 
research will be kept strictly confidential. Any information about your child, which 
leaves the hospital/surgery, will have his/her name and address removed so that he/she 
cannot be recognised from it. 
 
Q14. What will happen to the results of the research study? 
 
Ans: The principal aim of this study is to improve the management and care of 
children with inborn heart defects that make them prone to developing severe 
pulmonary hypertension after corrective heart surgery. We also plan to publish our 
results in peer reviewed medical journals. Any publications that arise should be 
available to everyone on-line. The information may also be used in presentations to 
local and international congenital heart disease forums as well as local charities and 
parent groups. You will not be specifically identified in any report or publication. 
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Q15. Who is organising and funding the research? 
 
Ans: This study is being funded by successful research grant application to the 
Yorkhill Children’s Foundation. It has been organised by Mr Tony Vassalos (Research 
Fellow, Cardiac Surgery) under the supervision of Mr Mark Danton (Consultant 
Cardiac Surgeon), Professor Fiona Lyall (Professor of Maternal and Fetal Health) and 
key Cardiac Surgery, Cardiology, Intensive Care and Pharmacy collaborators. 
 
Q16. Who has reviewed the study? 
 
Ans: As mentioned above the study is being funded by a successful research grant 
application to the Yorkhill Children’s Foundation. This involved a stringent, 2 phase, 
internal and external review process of the proposed study. The study has also been 
reviewed and approved by the Research Ethics Committee based in the Western 
Infirmary, Glasgow.  
 
Q17. Who can I contact for further information? 
 
Ans: If there is anything you do not understand or feel you would like further 
information on please do not hesitate to contact either of the persons named below 
through the Cardiac Surgery secretaries at Yorkhill Hospital (0141 201 0251) or the 
Cardiac Liaison Sisters who will introduce themselves during your child’s admission: 
- Mr Mark Danton, Consultant Paediatric Cardiac Surgeon, Yorkhill 
- Mr Tony Vassalos, Research Fellow, Department of Cardiac Surgery, Yorkhill 
- Cardiac Liaison Sisters (0141 201 9291) 
 
Q18. With whom can I register any complaints? 
 
- Ans: The standard NHS complaints procedure will be open to you.  
 
 
 
 
Parents of children participating in this trial will be given a copy of the information 
sheet and a signed consent form to keep.  
 
 
Thank you for your co-operation and patience. 
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6.2.6  Appendix 6: Parent Consent Form 
Centre Number: 
Study Number:  
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project: Does pre-operative Sildenafil protect against pulmonary related complications following 
cardiopulmonary bypass? A randomised trial in children undergoing cardiac surgical repair. 
 
 
 
 
Name of Researcher: Mr Tony Vassalos 
 
 
 
 
              Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 18 January 2006    
  (version 2) for the above trial and have had the opportunity to ask questions. 
 
2.  I understand that my child’s participation is voluntary and that I am free to withdraw at      
  any time, without giving any reason, without my child’s medical care or legal rights being affected. 
 
3.  I understand that sections of my child’s medical notes may be looked at by responsible   
  individuals from the Yorkhill Division or from regulatory authorities where it is relevant to my 
child taking part in research.  I give permission for these individuals to have access to   
  my child’s records. 
 
4.  I give permission for my child to take part in the above trial.     
 
 
 
 
 
 
_________________________  ________________  ____________________ 
Name of Parent or Guardian  Date  Signature 
 
 
 
_________________________  ________________  ____________________ 
Researcher  Date  Signature 
 
 
 
 
  1 for parent/guardian;  1 for researcher;  1 to be kept with hospital notes 
 
 
 End Organ Effects of Paediatric Cardiopulmonary Bypass          Page 183 of 192 
 
Tony Vassalos   2010 
 
6.2.7  Appendix 7: Data Entry Proforma 
 
 
  
 
 
 
PATIENT FACTORS 
1.  Age (Months)    5.  BSA (m
2)   
2.  Weight (Kg)    6.  WCC (Preop) 
 …./….   
3.  Height (cm)    7.  Admitted          /         / 
4.  Sex (M/F)    8.  Discharged         /         / 
 
 
 
PREOPERATIVE FACTORS 
  1.  Cardiac Diagnosis 
 
  2.  Non-Cardiac 
Diagnosis 
 
  3.  Cardiac Catheter 
(PAP/AO/PVR 
 PCWP/Qp:Qs)   
  4.  Signs / Symptoms 
(L > R Shunt) 
 
  5.  Medication 
 
6.  Aspirin / Warfarin / 
Sildenafil  
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OPERATIVE FACTORS  
1.  DATE  ….. / ….. / …..  7.  CPB Temp 
(minimum rectal)   
2.  XC time (mins)    8.  UF volume (mls)   
3.  BP time (mins)   
4.  Surgeon & 
Anaesthetist                                               / 
   
5. 
Inotropes 
(coming off)     
6. 
Aprotinin Regimen  L =   P =  M = 
 
 
 
 
RENAL OUTCOMES 
                       Postop Day    PreOp 
Day…  
…/… 
Th 
1
st 
12hrs 
Th 2
nd 
12hrs 
1 
.../... 
2 
…/.. 
3 
…/.. 
4 
…/.. 
5 
…/.. 
6 
…/.. 
7 
…/.. 
1.  SCr (µmol/l) 
(18-40) 
                   
2.  CrCl (54-86) 
(ml/min/1.73m
2)                     
(Normal values in 
parenthesis) 
 
1hr  
 
2hrs 
 
3hrs 
 
4hrs 
 
5hrs 
 
Total Urine 
1
st 24hr 
Diuretics 
(Inf / 
Bolus) 
3.  Urine (mls)           
 
 
4.  Dopamine 
(µg/kg/min)                 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Timing 
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Timing 
 
 
RESPIRATORY OUTCOMES 
  Post 
Intubation 
Post 
CPB 
2 hrs 
Postop 
4hrs 
Postop 
8am 
Day 1 
 
1. 
Oxygenation 
Index (OI)           
2. 
Dynamic Compliance  
(CL) (ml/cmH2O/kg)           
(Hrs)  3.  Mech. Ventilation  
(Days) 
Sildenafil 
(dose/days) 
(Hrs) 
4. 
Period in PICU  
(Days) 
Hospital  
Stay 
(days) 
 
 
 
Oxygenation Index: Mean airway pressure (cmH2O x 100 x FiO2 / PaO2 (mmHg) 
 
 
                 1
st 24Hrs Post-Op         Days Post-Op 
Test 
2hr  4hr  8hr  12 
Hr 
16 
  Hr 
20 
Hr 
24 
Hr  2   
../.. 
 
../.. 
 
../.. 
1.  PVRI  
(WU/m
2)                       
              5.  Lactate 
Base Excess               
       
6.  Inotrope 
Score                       
7.  LA pressure                       
8.  PA 
pressure                       
9. 
Transpulmonary 
Gradient                       
1
0. 
PaO2                       
1
1. 
PCO2                       
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ECHOCARDIOGRAPHIC OUTCOMES 
 
Pre-Op  <1hr post return 
to PICU  Day 1 Post-Op 
1. 
LVEDD (mm) [23 +/- 3]       
LVESD (mm) [14 +/- 2]       
RVEDD (mm) [9-13]       
LV % FC [38.9 +/- 4.1]       
LV EF % [52-65] (1-18yr olds)       
M
-
m
o
d
e
 
[
m
e
a
n
 
+
/
-
 
S
D
]
  VP (cm/sec) [54.6 +/- 14] (2mn – 6yrs)       
2. 
Peak AO (LVOT) (cm/sec)  median 107.0
* [73-141]       
Peak PA (RVOT) (cm/sec) median 84.4
* [63.8-70.5]       
AO annular diameter [11-13mm]       
PA annular diameter [8.4 – 11.6mm] (up to 10kg)       
VTIPA (stroke distance cm) [heart rate] 
       
VTIAO (stroke distance cm) [heart rate] 
       
MV Peak E wave (cm/sec) [79.7 +/- 18.8]       
S
P
E
C
T
R
A
L
 
MV Peak A wave (cm/sec) [65.3 +/- 13.3]       
3. 
MV E/A Ratio [1.24 +/- 0.3]       
4. 
Regurgitation (L + R AV) (Y/N)         
5. 
Sa: Lateral Mitral (5.7 +/- 1.6) [5.3 – 6.1]       
Sa: Lateral Tricuspid (10.2 +/- 5.5) [8.8 – 11.7]             
Sa: Septum (5.4 +/- 1.2) [5.1 – 5.7]       
IVA (cm/sec
2) [248 +/- 35]       
Ea: Lateral Mitral (9.7 +/- 3.3) [8.8 – 10.5]       
Ea: Lateral Tricuspid (13.8 +/- 8.2) [11.7 – 15.9]       
Ea: Septum (8.1 +/- 2.5) [7.5-8.7]       
Aa: Lateral Mitral (5.7 +/- 1.8) [5.3 – 6.2]       
Aa: Lateral Tricuspid (9.8 +/- 2.4) [9.1 - 10.5]       
Aa: Septum (6.1 +/- 1.5) [5.7 – 6.4]       
T
D
I
 
c
m
/
s
e
c
 
 
(
m
e
a
n
 
+
/
-
 
S
D
)
 
 
[
9
5
%
 
C
I
]
  E/Ea Ratio (L AV valve) (8.8 +/- 2.7) [8.1 – 9.5]       
(Normal values in parenthesis) 
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HAEMATOLOGY OUTCOMES 
  1hr  
Post-op 
2hr 
Post-op 
3hr  
Post-op 
4hr 
Post-op 
5hr 
Post-op 
Total 1
st  
24 hrs     
1.  Chest Tube 
Drainage (ml)                 
  Intra-operatively  Post-operatively 
2.  PRC (units/ml)     
3.  FFP (units/ml)     
4.  Platelets  
(units/ml)     
5. 
Other: 
 
 
 
 
 
 
 
 
COMMENTS / COMPLICATIONS: 
- 
- 
- 
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6.2.8  Appendix 8: Adverse Events Record Sheet 
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6.2.9  Appendix 9: Sildenafil Trial Prescription Form 
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6.2.10  Appendix 10: Protocol Registration Receipt 
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6.2.11  Appendix 11: R&D Management Approval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 